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Abstract 
 
Aim:  Inhibition of K+ efflux through voltage-activated K+ channels (Kv) in demyelinated 
nerves can overcome conduction block in axons; hence, this approach should offer 
therapeutic potential for multiple sclerosis (MS). Use of 4-aminopyridine (4-AP), an 
indiscriminate Kv blocker, has proved effective but with adverse epileptogenic effects due 
to off-site actions. Identification of a specific homo-tetrameric Kv1.1 channel in MS 
autopsies (Dolly, unpublished) opened up a promising avenue for pursuing, effective 
therapeutic options. Hence, this study aimed to establish ‘MS like’ features in an animal 
model, so that CNS axonopathy and the role of Kv1 channels in the dysfunction could be 
explored. 
 
Results: Sub-chronic, systemic demyelination in the central nervous system (CNS) was 
induced in young adult mice, by feeding a moderate dose of cuprizone (bis-cyclohexanone 
oxaldihydrazone) (CZ), to establish a model with several features closely related to human 
MS. Robust loss of myelin was produced and clearly documented in anatomically-
identified regions (Corpus callosum and limbic areas). Disruption of myelin membrane 
periodicity was one of the main demyelinating features of optic nerve (ON) axon, 
elucidated by transmission electron microscopic analysis of its ultrastructure. In addition, 
an apparent activation of glial cells and increased levels of hypo-phosphorylated 
neurofilament, were implicated. This type of demeylination was marked by perturbed levels 
of lipophilin like proteolipid protein (PLP) and its variant DM20. A relative decrease in 
their ratio (PLP/DM20) in CNS myelin was observed after CZ treatment. Presence of three 
Kv1 α-subunits - Kv1.1, 1.2 and 1.4 in the ON of both the untreated and treated group was 
confirmed, with Kv1.1 and 1.2 α-subunits forming the major juxtaparanodal (JXP) 
component. Fluorescence microscopic analysis of Kv1 subunits and nodal voltage-gated 
sodium (Nav) channels showed a notable alteration in apposing JXPs adjoining the nodal 
gap. Expression of Kv and Nav channel became ectopic after CZ treatment. Kv channels 
were prevalent in internodal areas of the affected axons, whereas the remaining intact JXPs 
showed decreased content of Kv1.2 relative to 1.1 close to the nodal gap, indicating 
acquisition of atypical role by these two α-subunits. Compound action potentials based 
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pharmacological analysis using K+ channel blockers like 4-AP and tetraethylammonium 
showed an increase in K+ conductance. Application of Kv1.1 and 1.2-specific inhibitors 
namely dendrotoxin-K and tityustoxin-K further indicated an increase in Kv1.1-mediated 
currents, raising the possibility of emergence of oligomers having higher numbers of Kv1.1 
than Kv1.2 α-subunit.  
 
Conclusions: Taken together these results provide explicit evidence for the applicability of 
this murine model of CZ-induced systemic CNS demyelination in MS research. ON was 
demonstrated to have several features similar to MS associated axonopathy, which included 
loss of myelin periodicity, elevated levels of hypo-phosphorylated neurofilament, reduced 
lipophilin ratio (PLP/DM20),  ectopic expression pattern of JXP Kv1 and nodal Nav 
channels leading to a functional deficit largely mediated by Kv1.1 containing α-subunit. 
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CHAPTER 1 
 
GENERAL INTRODUCTION 
 
 
1.1. Axon organization  
 
Axons are slender neuronal processes, which possess molecular specializations for 
generating and propagating nerve impulses; thus these are indispensible units integral for 
the promotion and survival of nervous system (Kandel et al., 1991, Siegel, 2005, Squire et 
al., 2008). These can be myelinated or unmyelinated, depending on the presence or absence 
of myelin, a dielectric (electrically insulating) material (Kandel et al., 1991, Squire et al., 
2008, Waxman, 2005) wrapped along the axon. Myelin sheath is a compacted membrane 
stack of glial cells namely oligodendrocytes or Schwann cells, in the central and peripheral 
nervous systems, respectively. It helps regulate the development, anatomy, and molecular 
differentiation of an axon into node, paranode, juxtaparanode, and internode (Figure   1). 
These structural specializations isolate segments of an axon into electrically defined 
compartments so that a fast mode of impulse propagation known as saltatory conduction 
becomes possible in myelinated axons. Several axons packed densely as an isolated 
structure form a nerve. Myelinated fibers have evolved to provide the body with a rapid and 
efficient transfer of information from peripheral receptors to the central nervous system 
(CNS) (afferent), from the CNS to peripheral effectors (efferent), and between different 
centers within the CNS. Myelin associated trophic support of these axons is derived from 
their interaction with the glial cells (Figure   1, Figure   2B). For example, CNS 
oligodendrocytes synthesize and maintain myelin sheaths for up to 40 neighboring axons, 
whereas one PNS Schwann cell is responsible for myelination of one axon/axonal internode 
segment (Siegel, 2005). These axons can vary in diameter owing to the extent of 
myelination (Squire et al., 2008, Chomiak and Hu, 2009). Such features are of great 
significance as it allows them to maintain their ability to generate and propagate repetitive 
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nerve impulses at a high speed. Thus, CNS coordination largely depends on the myelinated 
axons—a highly complex biological structure, which has been characterized as “. . . the 
most unique cytological feature in the animal kingdom . . .”  (Schnapp and Mugnaini, 1978, 
Waxman, 2005).  
 
1.1.1. Structural sub-domains of an axon and its segregation into compartments  
 
The structure of CNS axons is less well understood relative to PNS myelinated axons, 
though knowledge of the former is vital for analyzing the functional deficits arising due to 
axonal dysfunction in diseases, like multiple sclerosis (MS).  Both types of axons have 
structural similarities and they (motor axons, preganglionic autonomic axons, primary 
sensory axons) course uninterrupted from the CNS to the PNS or vice versa. This 
continuous and efficacious interaction between nerves is vital for fidel functioning in the 
nervous system. The intricate association between neuronal axon and glial myelin are key 
to their maintenance (Waxman, 2005). 
 
Owing to alliance between the two cells, namely myelinating glia and neuron, myelin is a 
specialized compact layer of membranes which segregates the axon into several 
cytoplasmic domains. Electron microscopically, myelin has several alternating electron-
dense and electron-lucent layers. The major dense line (MDL) or period line is formed 
where the cytoplasmic surfaces of the plasma membrane spiraling oligodendrocyte / 
Schwann cell processes appose. The fused outer leaflets facing the extracellular space form 
intraperiod line (IPL), or minor dense line, which is sometimes split. Longitudinally, a 
myelinated axon is also organized into several repetitive segments. Each of these segments 
has domains of unique structure containing molecular complex (es). 
 
1.1.1.1. Myelin (glial membrane stack) 
 
The condensed myelin spiraled around axon, forming an insulation sheath for the 
segmented domains required for saltatory (fast mode) conduction (Figure   2A) (Brazhe et 
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al., 2011, Debanne, 2004, Devaux and Gow, 2008), was earlier viewed as rudimentary 
amorphous stack of lipid bilayers. However, its biophysical properties were later 
recognized as an insulator with high resistance and low capacitance of large diameter fibers 
common to PNS. This notion falls short in accounting for the small myelinated axons that 
are widely distributed in the CNS, specifically optic nerve. The CNS axons face a greater 
constraint in terms of space limitation, energy utilization and information processing. 
Further on, cis- and trans- protein interactions of the myelin membrane are vital for 
maintaining of axon function; which are being noted to be different in CNS and PNS 
(Ogawa et al., 2010, Arroyo et al., 2001). 
 
Owing to axo-myelin interactions, the compact myelin deprives the axoplasm of free access 
to nutrients in the extracellular milieu, except for widely spaced short gaps (nodes of 
Ranvier). The encapsulated axons reside in a milieu conditioned by the glia that can, 
thereby, support axonal energy metabolism. Non-compacted myelin forms a channel 
system that is continuous with the glial cytoplasm and brings metabolites close to the 
periaxonal space. Locally, the Schmidt-Lanterman incisures (SLIs) of non-compacted 
myelin in PNS spiraled around the axon is linked by gap junctions in these stacks. CNS 
oligodendrocytes are also coupled by gap junctions to astrocytes that extend to the blood-
brain barrier. In addition to simple diffusion, cytosolic perfusions attenuate concentration 
differences of metabolites with high axonal turnover. Similar to fast axonal transport, glial 
intercellular transport depends on the tubular tracks and fine architecture of this type of 
channel system. For the postulated transfer of metabolites across the internodal axon, the 
adjacent glial and axonal compartments may function as a counter-current system. This 
axo-glial association is highlighted in disorders wherein metabolite fuelling of 
mitochondria by glia is hampered leading to axonal swellings in oligodendrocyte-specific 
defects, such as multiple sclerosis (MS) (Figure   1, Figure   2B)  (Nave, 2010a, Nave, 
2010b). 
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1.1.1.2. Axolemma (axon membrane)  
 
The axolemmal membrane (8nm thick) on the other hand has proteins organized in clusters 
responsible for flow of ions mainly K+ and Na+ which maintains segregation of ionic 
gradient within the sub-compartments, entailing potential difference. These are known as 
ion channels and transporters. Energy dependent ion transporters or pumps utilize 
adenosine tri-phosphate (ATP) to restore the ionic gradient following generation of an 
action potential (Figure 3).  
1.1.1.3. Axon cytoskeleton  
 
Axon cytoskeleton provides the basic framework for maintenance of neuron cable essential 
for propagation and processing of information. This includes structures like microtubules, 
neurofilaments and microtrabecular matrix. Longitudinally microtubules are 25-nm thick, 
unbranched discontinuous tubes. A major function of microtubules is to provide tracks for 
fast anterograde transport, mediated by kinesin, and fast retrograde transport mediated by 
dynein (Nave, 2010a, Berthold and Rydmark, 1995, Alberts et al., 2002). Neurofilaments (a 
type of intermediate filament) are the major neuron-specific cytoskeletal element, which are 
10nm unbranched stable fibers.  There are 150-300 neurofilaments/µm2 axoplasm 
irrespective of the axon size. Three types of NF protein (NF-L, ~68 kD; NF-M, ~150 kD; 
NF-H, ~200 kD) co-assemble into heteropolymers in vivo. The NF are linked together by 
protein cross-bridges contributing to the tensile strength of an axon and accounting for the 
regular inter-filament spacing (Alberts et al., 2002). Myelination promotes axon radial 
growth by promoting an accumulation of NFs due to induced phosphorylation (Lunn et al., 
2002, Yabe et al., 2000, Waxman, 2005).   
1.1.1.4. Nodes of Ranvier  
 
Successive myelin sheaths are separated by short gaps the ‘nodes of Ranvier’, where the 
axolemma is exposed to the extracellular space over a length (Figure   1, Figure   2A). It 
remains juxtaposed to the astrocytic processes. Nodal axolemma exhibits a distinct Na+ 
channel immuno-reactivity and a high binding of their probe, saxitoxin (Waxman, 2005). 
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The node of Ranvier is characterized by regularly spaced, short gaps in the myelin sheath 
where voltage-dependent Na+ channels (Nav) are clustered at high density. These mediate 
the inward Na+ currents responsible for the depolarization of nodal membrane and 
propagation of the action potential (Hille, 2001, Rasband, 2004).  
1.1.1.5. Paranode 
 
Nodes are flanked by two paranodes, where the myelin lamellae attach to the axolemma. 
Some previous investigators, including Ranvier himself, used the term ‘paranode’ to 
describe a longer part of the myelin sheath, including both the paranodal myelin attachment 
zones and the juxtaparanode. Longitudinally, each myelin lamella terminates as a lateral 
loop (Figure   2B). Here, the MDL splits and forms a membrane-bound drop shaped 
cytoplasmic compartment containing few microtubules, occasional vesicle(s) and varying 
amounts of electron-dense particles. Since each loop occupies a specific length, the 
paranodal axon allows direct apposition of a limited number of loops. Relative to the 
unspecialized internodal part of the axon, the paranodal part is slightly constricted in thin 
fibers. The paranodal junction is not tight in the conventional sense since small tracer 
molecules, but not larger ones, can reach the periaxonal space from the node gap (Waxman, 
2005). The nodal gap and the periaxonal space (space in between the axolemma and myelin 
membrane) seem to be connected by a narrow helical channel. Overall, the paranode has 
been attributed to a variety of functions: a) to anchor myelin lateral loops to the axon, b) to 
form a partial diffusion barrier from the node gap into the periaxonal space, c) to demarcate 
axonal domains by limiting lateral diffusion of membrane components, d) to be a site for 
signaling between axons and myelinating glial cells, and/or to play an active role in the ion 
exchange underlying saltatory conduction (Schnapp and Mugnaini, 1978, Peles and Salzer, 
2000). Thus, these paranodes form the largest junction adhesion complex in vertebrates 
(Waxman, 2005, Rasband, 2004, Rosenbluth, 1995) with several functional attributes. 
1.1.1.6. Juxtaparanode  
 
Finally, just inside the innermost axoglial junction of the paranode is a 5–15µm-long 
domain called the juxtaparanode (JXP), which is characterized by the high-density 
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clustering of voltage-gated K+ channels (Kv), specifically Kv1 subtype (Figure   2A) (Chiu 
and Ritchie, 1980, Wang et al., 1993, Rasband, 2004). In a thick myelinated PNS axon, this 
region extends some 35µm in an abnodal direction from the paranodes (Waxman, 2005). 
Their restricted and concealed localization underneath the myelin membrane is vital for 
action potential propagation. This is essentially due to the high density of Kv1 channels that 
aggregate in proximity to the node, on the axolemmal surface of JXP. This together with 
the nodal Nav form small structural units spaced at regular intervals along the axon, which 
are vital for action potential propagation. These axolemmal proteins lodged in segregated 
compartments work in co-ordination to ensure effective information propagation (Figure   
2). 
1.1.1.7. Internode  
 
The segment of a myelinated axon extending between the JXPs is known as internode. 
However, this term is more appropriately used to define the entire myelin sheath covered 
stretch of an axon (Figure   1, Figure   2). These segments are sometimes referred as 
unspecialized sections of an axon. They have CNS myelin sheath separated from the 
axolemma by a space, namely the intra-myelinic periaxonal space of at least 12nm. In 
myelinated PNS axons, the inner aspect includes a thin cytoplasmic lamella terminating in a 
small inner loop that is part of the inner mesaxon. Whereas in the oligodendroglia 
cytoplasm is associated with the outer aspect of internodal segment of myelin sheath, and 
limited to a small outer tongue and the outer mesaxon of thin myelinated CNS axons 
(Hirano and Llena, 1995).  
 
1.1.2. Functional organization of an axon   
 
The described structural organization of a myelinated axon is vital for coordinated 
functioning of the nervous system. An axon is a cable like structure with segregated ionic 
sub-compartments containing molecularly differentiated domains (Waxman, 2005). Patho-
mechanisms perturb these structural elements which are reflective of hindered electrotonic 
properties affecting the spread of electric current generated by ionic changes (Rash, 2010). 
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In MS such functional deficits produce symptoms early on, but the structural co-relate 
remains undetected due to the inability to discriminate using currently available diagnostic 
tools (Compston and Coles, 2002). In unmyelinated axon, which lack such defined 
compartments, the conduction is slow and energy consumption less relative to the 
myelinated axons (Figure   2, Figure   5, Figure   6). Axo-myelinic associations in a 
myelinated axon of the nervous system allow segregation of potassium (K+) and sodium 
(Na+) along an axon (Figure   1,  Figure   6). The reliable expression of axolemmal 
proteins like ion channels: voltage-gated K+ channel (Kv) and voltage gated Na+ channels 
(Nav), and sodium-potassium transporters: Na+/K+ pump known as Na+/K+ ATPase, allow 
the generation of potential difference due to the ionic gradient across the membrane length 
(Figure 3, Figure   4, Figure   5). Synchronous and energy-dependent activity of these 
structural elements is the basis of information propagation along an axon in the form of 
action potentials. Myelin wrap produce the requisite insulation against leak of ions, 
between the axon sub-compartment or amongst the adjoining axons (ephaphtic cross-talk).  
 
These facts emphasize that axolemma and myelin are equal contributors towards the 
conduction of information. The daunting task of conducting nerve impulses is achieved by 
the axon owing to a constant delivery of organelles of their respective site of functioning 
and turnover of metabolites. Thus major consumption of ATP is entailed. Owing to this 
energy demand by myelinated axons, recent studies have advocated the transport, 
distribution and function of axonal mitochondria as a part and parcel of its functioning  
(Kiryu-Seo et al., 2010). Additionally, energy demand is also levied on the insulating 
myelin membranes in fast conducting axons. These features indicate that myelin assisted 
trophic support is essential for long-term axon survival, specifically when axon performs 
with an increased velocity or frequency of conduction (Trapp and Nave, 2008).  
 
1.2. Action potential propagation and ion channels  
 
Action potential was first demonstrated by Alan Hodgkin and Andrew Huxley in squid 
axons in 1939 when they showed that they are electrically polarized at a resting phase. The 
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membrane exhibits a resting potential of -60mV inside versus outside. Generation of action 
potential involves removal of the polarized state of the membrane (referred as 
depolarization) and a rapid swing toward, and even past -0mV. Depolarization is followed 
by another rapid swing the repolarization of membrane potential to more negative values, a 
process referred to as hyperpolarization. The membrane potential following an action 
potential typically becomes more negative than the original value of  -60mV and this period 
of increased polarization is referred to as the after-hyperpolarization (AHP) or the 
undershoot (Squire et al., 2008) (Figure   4).  
 
For a human neuron, the resting potential is -70mV. Action potential generation involves a 
co-ordinated sequence of events:  
 
1. First response to a stimulus leads Nav channels of the node to be activated and Na+ 
flows inside the cell. If the inflow of Na+ is sufficient to drive the interior potential 
from -70mV up to -55mV, then action threshold is achieved 
2. Action threshold allows more Nav channels to open and Na+ influx drives the 
interior of the cell membrane up to about +30mV leading to depolarization. This 
stimulates deactivation of already activated Nav channels. 
3. Gradually all the inactivated Nav channels close and Kv channels open in response to 
depolarization in order to repolarize the membrane.  Since the Kv channels are much 
slower to open (slow activating) the depolarization peak is achieved and both Nav 
and Kv channels remain open in response to these ionic influx. This synchronized 
activity of both the channels drives the system towards neutrality. 
4. Gradually as the Kv channels remain open, the membrane begins to repolarize back 
towards its resting potential.  
5. This repolarization typically overshoots the resting potential even up to -90mV in 
many cases. Even though this hyperpolarization would seem to be counter 
productive, it is actually important in the transmission of information. 
Hyperpolarization prevents the neuron from receiving another stimulus during this 
time, or at least raises the threshold for any new stimulus. Part of the importance of 
hyperpolarization is in preventing any stimulus already sent up an axon triggering 
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another action potential in the opposite direction. In other words, hyperpolarization 
assures that the signal proceeds in one direction.  
6. After hyperpolarization, the Na+/K+ATPase pump eventually brings the membrane 
back to its rest state of -70mV. For every 3 Na+ pumped out 2 K+ is pumped into the 
neuron and an ATP is hydrolysed and this equals to 2/3 energy expenditure in a 
neuron (Figure 3) (Charand, 2012) (http://hyperphysics.phy- 
astr.gsu.edu/hbase/biology/actpot.html) accessed on 1st May 2012.  
Thus, the two principal mechanisms which allow K+ to cross the axolemma involve 
transporters and ion channels, which work in conjunction with several enzymes, cell 
adhesion molecules and myelin membrane proteins. For K+ to be transported against its 
electrochemical gradient the expenditure of energy is supplemented by the ATP hydrolysis 
or from the electrochemical gradient of another ion. The Na+/K+ATPase pump achieves this 
transport of K+ at a lower rate in order to maintain the resting concentration gradient across 
the neuron membrane. Ion channels on the other hand permit ions to flow across the 
membrane at a much higher rate and can thus affect the membrane potential of the cell 
rapidly. Ion channels do not permit the flow of ions when they are not activated, i.e., when 
they are in the resting condition. Instead they need to receive a physical or chemical 
activating stimulus to change the conformation of their pore region to permit ion flow 
(Squire et al., 2008).  
        
With such operations in place and special ionic buffering, owing to the presence of myelin 
membrane and astrocyte (a glial cell type), they maintain precise internal concentrations of 
Na+, K+, Cl-, and Ca2+ (Figure 3). At a membrane potential, when there is no net flow of K+ 
(the same number of K+ enters and leave the cell per unit time) these ions are said to be in 
equilibrium (Ek) and is referred as equilibrium potential. The equilibrium potential is 
determined by: 
1) concentration of ion inside and outside the cell, 
2) temperature of the solution, 
3) valence of the ion, and  
4) amount of work required to separate a given quantity of charge.  
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The equation that describes the equilibrium potential was formulated by a German physical 
chemist Walter Nernst in 1888. According to Nernst equilibrium potential 
 
                                        Eion = RT/zF.In([ion]o/[ion]i) 
Here,   
Eion = membrane potential at which the ion species is at equilibrium, 
R = gas constant (8.315J per Kelvin per mole (JK-1mol-1), 
T = temperature in Kelvin (Tkelvin-273.16+Tcelcius),  
F = Faraday’s constant [96,485 coulombs per mole (Cmole-1)] 
z = the valence of the ion 
[ion]o= concentration of ion outside the cell 
[ion]i = concentration of ion inside the cell 
 
The concentration of [K+]o and [K+]i in mammalian neurons and glial cells is 3.1mM and 
140mM respectively, hence the equilibrium constant at the body temperature T = 37ºC is 
                                    
                                         Ek= 61.5 log10 (3.1/140) = -102mV 
 
At membrane potentials positive to -102mV, K+ flow across the membrane (i.e., increasing 
the conductance of the membrane to K+ (gK) causes the membrane potential to become 
negative, or hyperpolarized, due to the exit of positively charged ions from inside the cell. 
At membrane potentials negative to -102mV, K+ tend to flow into the cell; increasing the 
gK causing the membrane to become more positive, or depolarized, due to the flow of 
positive charge into the cell. The specific membrane potential at which net current “flips” 
direction is referred as reverse potential (Squire et al., 2008).  
 
Global functioning of the nervous system is dependent on the synchronized activity of ion 
channels and action potentials which serve a very different function in neuronal cell bodies, 
where they encode information in their frequency and pattern, than in axons, where they 
serve primarily to rapidly propagate signals over distance. So, the precise location of these 
ion channels with different functional attribute is vital for the fine tuning of a neuron, which 
 29 
is an important aspect of neuro-modulation. Most neuronal cell bodies (in both vertebrate 
and invertebrates) can fire over a far wider range of frequencies and can respond to small 
changes in input currents with significant changes in firing frequency. This richer firing 
behavior depends on the expression of more types of voltage-dependent ion channels. 
There has been a gradual realization of just how many distinct voltage-dependent 
conductances are expressed by individual neurons in the mammalian brain — commonly 
including 
 
 2 or 3 types of Na+ current,  
 4 or 5 different voltage-dependent calcium (Ca2+) currents, 
 at least 4 or 5 different voltage-activated K+ currents,  
 at least 2 to 3 types of calcium-activated K+ currents, 
 the hyperpolarization-activated current Ih, and others 
 
Because of this complexity, our understanding of how different conductances interact to 
form the action potentials of even the best-studied central neurons is still incomplete 
(Debanne, 2004). Such synchronized activity of several factors lead to appropriate 
functioning of a nerve and any breach owing to the emergence of an ectopic component 
leads to disruption of a well established neural code. In diseases like MS where 
demeylination occurs which, in turn affects various aspects of the neural network, rift of 
normative function(s) is eminent. As nerves are made of several thousands of axons, 
enwrapped in layers of connective tissue, the algebraic sum of their action potentials is 
referred as compound action potential (Patten et al., 1999). Each nerve has a characteristic 
CAP feature and demyelination affects it variously (Gordon et al., 1988). Optic nerve is the 
most susceptible target in MS associated demeylination (Soderstrom, 2001).  
 
1.3. Compound action potential  
 
Action potentials propagate along an axon; they produce electric potentials that can be 
recorded from the surface of nerve. When a nerve bundle is stimulated many axons produce 
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potentials synchronously. The resulting electric responses recorded from the surface of the 
nerve are called compound action potentials to distinguish from action potentials generated 
by individual axons (Patten et al., 1999).   
 
CAP is measured using stimulus electrodes applied to one end of the nerve and recording 
electrode located along the nerve. Upon application of sufficient current pulse the action 
potentials produced in fibers propagate towards the recording electrodes. The aggregate 
effect of many action potentials is an extracellular potential, moving along the surface of 
the nerve. If the recording electrodes are widely spaced, the wave of negative potential 
produces a negative pulse recorded as voltage.  
 
1.4. Kv1 channel: Background, Structure and function  
 
As described above, the flow of K+ across the plasma membrane is critical for all neuronal 
tissue. Stimulus induced ion channel activation and its conformational changes lead to 
depolarization of membrane and permit ion flow.  For the Kv1 channels, the direction in 
which K+ will flow is normally from inside the cell to outside tending to oppose 
depolarization that evoked their flow. This K+ efflux tends to reduce the amplitude of the 
depolarization. One channel molecule could perform various functions in different neurons 
if the resting voltages of the neurons differ (Pinto and Klumpp, 1998, Kandel et al., 1991). 
 
Kv1 channels are also known as ‘Shaker channels’ because of its origin which stems in to 
the Shaker locus of Drosophila melanogaster mutants which provided the first tools for 
cloning and characterization of these membrane proteins.  Shaker flies exhibited a peculiar 
phenotype under ether based anesthesia marked by shaking of their legs, wings and 
abdomen.  Voltage clamp experiments with these flies revealed defects in the transient K+ 
current associated with each of their different Shaker alleles. This locus appeared to encode 
the affected voltage gated K+ channel. Later chromosome walking strategies by several 
groups allowed cloning of cDNAs and molecular characterization of these clones. These 
studies revealed that they were closely related and were products of alternatively spliced 
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mRNAs (Judge and Bever, 2006, Papazian et al., 1987, Kamb et al., 1987). Sequence 
determination of one of these clones revealed a predicted protein with several putative 
transmembrane (TM) helices (Tempel et al., 1988). Thus combined molecular and 
electrophysiological, approaches brought forth an unexpected and vast diversity of Kv 
channels.  
  
1.5.  Kv channel subfamilies and nomenclature 
 
In mammals distinct genes encode the molecular structure of each type K+ channel subunit. 
Many voltage-activated Kv channels have been cloned and sequenced from several tissues 
in different species, including human (Pongs, 1992, Pongs et al., 1988, Wulff et al., 2009) 
(IUPHAR Compendium of Voltage-Gated Ion Channels, 2002; http://www.iuphar-
db.org/iuphar-ic/). Four subfamilies of distinct Kv genes were originally identified in 
Drosophila. The initial cloning of members of the Shaker (Sh) subfamily of Kv channels 
(Kamb et al., 1987, Papazian et al., 1987, Pongs et al., 1988, Tempel et al., 1988, Wulff et 
al., 2009) was quickly followed by isolation of the Shab (Sb), Shaw (Sw), and Shal (Sl) 
subfamily genes (Wulff et al., 2009). Homologous subfamilies of vertebrate genes were 
subsequently found in Xenopus, mouse, rat, and man and were commonly referred as  (Sh) 
‘‘Kv1’’, (Sb) ‘‘Kv2’’, (Sw) ‘‘Kv3’’, and (Sl) ‘‘Kv4’’ which formed part of an original 
standardized nomenclature (Judge and Bever, 2006, Gutman et al., 2005) for Kv channels 
with a description of 6 subfamilies (‘‘Kv1’’–‘‘Kv6’’). This system was proposed as a means 
of simplifying the burgeoning list of human Kv gene names and their species homologues. 
Later a supposedly simpler nomenclature was introduced based on the ‘‘sequence 
homology’’ of their genes (channels sharing 65% sequence identity being classified as a 
single subfamily). This was quickly expanded to include standardized nomenclatures for  
Ca2+-activated (KCa) and inwardly rectifying (Kir) K+ channels prior to the successful 
sequencing of the human genome, which initially identified 67 human K+ channel proteins 
under the International Human Genome Mapping Consortium (Venter et al., 2001). The 
human genome organization (HUGO) developed and introduced new guidelines for naming 
human genes in 1997 (White et al., 1997). Although the original standardized nomenclature 
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needed updating, the HUGO KCN (K+ channel nomenclature) only introduced renewed 
confusion by removing all intuitive identifiers and failing to logically classify channel 
genes based on the molecular relationships between ion channel proteins. As a result, the 
use of the HUGO KCN nomenclature has been more often parenthetic. Subsequently, The 
International Union of Pharmacology (IUPHAR) together with the American Society for 
Pharmacology and Experimental Therapeutics (ASPET) convened multiple subcommittees 
to resolve these prevailing confusions and introduced a comprehensive and rational 
nomenclature that reinserted fundamental intuitive identifiers; classification based on 
molecular relatedness, and is presently meeting with wide acceptance within the ion 
channel field. To date, 12 subfamilies of Kv channel genes have been identified (Gutman et 
al., 2005, Gutman et al., 2003) (Figure   7, Figure   8).  
 
The phylogenetic tree of all K+ channel genes, as identified by protein sequence 
comparisons, divides first into 4 structural classes based on whether the pore forming 
structure or α-subunits comprising a given K+ channel contain 2 [2TM; i.e., inward 
rectifiers and ATP-regulated K+ channels (Kir)], 4 [4TM; i.e., background, leak, or tandem 
2-pore K+ channels (K2P)], 6 [6TM; i.e., delayed rectifiers, rapidly inactivating (A-type), 
and small/intermediate conductance voltage and calcium-activated K+ channels (KCa)], or 
7 [7TM; i.e., large conductance Ca2+ activated K+ channels (KCa)] TM domains. The 
family of Kv channels belongs to the 6TM structural class. Originally, the 6TM structural 
class was comprised of 6 K+ channel families including Kv, KQT-type, cyclic nucleotide-
gated Ca2+-activated (CNG), ether-a-go-go-related (eag, erg, or elk), small/intermediate 
conductance Ca2+-activated (SK/IK), and large conductance Ca2+-activated (slo, maxi KCa, 
or BK) K+ channels (Judge and Bever, 2006, Hille, 2001). The formerly separate families 
of KQT and CNG K+ channels have been reclassified as members of the Kv family, 
whereas the family of large conductance Ca+-activated K+ channels is now recognized as a 
separate structural class (7TM); channel subunits contain a 7TM segment due to the 
extracellular location of the N-terminus as opposed to its intracellular location in 6TM K+ 
channels (Gutman et al., 2003, Gutman et al., 2005, Judge and Bever, 2006) (Figure   9A). 
 
 
 33 
1.5.2. α-and β-subunits of Kv1 channels 
 
1.5.2.1. α-Subunits 
 
All mammalian Kv1 channels are large (Mr ~ 400 kDa) sialoglycoprotein complexes 
(Parcej et al., 1992) composed of 4 pore-forming α-subunits (Kv1.1-1.6) and 4 auxiliary, 
cytoplasmically associated β-subunits (Figure   9B) (Orlova et al., 2003, Dolly and Parcej, 
1996, Parcej et al., 1992, Rettig et al., 1994, Scott et al., 1994a). Kv1 channels are 
tetrameric surface proteins. Each subunit of a tetramer has six conserved integral membrane 
spanning segments, namely S1-S6 which is connected by intracellular and extracellular 
loops or linkers and both the N- and C-termini being located intra-cellularly. A functional 
channel consists of 4 α-subunits arranged around a central axis forming the ion conduction 
pathway. S1-4 of an α-subunit are responsible for voltage sensing, and wrap around the 
pore of the adjacent subunit   The S4 helix contains a positively charged amino acid 
(arginine) at every third residue, interspersed with hydrophobic residues, and is generally 
thought to function as the main voltage-sensor  (Jan and Jan, 1992). The ion conduction 
pore consists of S5, the S5-S6 loop and S6 (Long et al., 2005b). The S5-S6 loop contains a 
conserved sequence which acts as a K+ selectivity filter  (Li et al., 2006). The S4-S5 linker 
connects the pore and voltage sensing components of α subunits (Figure   9, Figure   10) 
(Long et al., 2005a).  
 
1.5.2.2. T1 domain 
 
The N-terminus preceding S1, the first membrane spanning helix of an α-subunit, forms a 
T1 or tetramerization domain (within the cell). These domains (1 from each α-subunit) 
form a tetrameric complex at the intracellular membrane providing a docking platform for 
β-subunits (Figure   10A, B, Figure   13) (Long et al., 2005a). The T1-S1 linker maintains 
separation between the pore of these channel and the intracellular regions. A wide space 
between the T1 domain and pore is achieved by the radial direction of the linkers, allowing 
the inner pore helices to undergo large movements during pore opening without 
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interference. This also results in diffusion pathways, called side portals, between the 
cytoplasm and pore entrance which provide a means for communication and allows the 
flow of K+. The 4 side portals of a complete channel attract cations due to negatively 
charged amino acids on their rims and surface. They also have a role in inactivation (Long 
et al., 2005a). 
 
1.5.2.3. β Subunits 
 
The β-subunits are non-glycosylated, hydrophilic proteins with 367 (β2) or ~ 400 (β1, β3) 
residues. There are three types of β-subunits identified, namely β1, β2, and β3.  The 
inactivation rate is greatly accelerated for several K+ channels by the cytoplasmic 
association of β-subunits, via binding of a ball formed from the N terminus of the α-
subunit, to the central cavity and the inner mouth of the pore (Figure   10). The main role 
of β2 is to act as a chaperone to increase the expression of Kv1 channels at the plasma 
membrane (Orlova et al., 2003, Shi et al., 1996)  
 
1.6. Molecular determinants of Kv channel function 
 
1.6.1. N- type and C- type inactivation  
 
Ionic gradient and resulting potential difference across the axolemma creates an electric 
field. This induces structural rearrangements in Kv channel TM which allows the opening 
of its translocation pore. Such a change renders the channel to be either conducting 
(Hoopengardner et al., 2003) or non-conducting (closed or inactivated). In response to 
appropriate changes in the TM electric field, the non-conducting channel undergoes 
conformational rearrangements, which open (activation) or close (deactivation) the ion 
translocation pore (McCormack et al., 2002) (Figure   10E). There are two mechanisms 
which take effect for the inactivation of a channel. If the pore is occluded due to the binding 
of a hydrophobic N-terminal “ball” to the cytoplasmic vestibule of the pore and this is 
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called rapid or N-type inactivation (Isacoff et al., 1990). This is common for rapidly 
inactivating channels. The latency is dependent on the length of the N-terminal chain and is 
typically in milliseconds. After a period of binding, the inactivation ‘‘ball’’ releases in a 
process called ‘recovery from inactivation’. Multiple inactivation domains have been 
identified in the amino terminal ‘ball and chain’ region of the Kv1.4 α-subunit 
(Ruppersberg et al., 1991). In addition, solution structures have also been determined for 
the N- terminal inactivation domain as well as the Kvβ subunits which confer rapid 
inactivation or non-inactivation or slow inactivation of K+ channels (Wissmann et al., 2003, 
Gulbis et al., 2000, Judge and Bever, 2006). A second form of inactivation, termed ‘C-type 
inactivation’, also emerges with prolonged depolarization leading to decreased current flow 
due to structural changes that constrict the extracellular end of the ion translocation pore 
(Yellen et al., 1994).  
 
Detailed models (Bezanilla et al., 1991, Bezanilla, 2008, Elinder et al., 2007) 
mathematically describe the steady/open state probability and their kinetic transitions 
taking place during activation and conformational changes in Kv channels (Figure   10C, F, 
G, H). Such models are based on the ability to measure gating currents that reflect, not the 
movement of charged ions (ionic currents) through the pore, but the intramolecular 
movement of charges or dipoles (gating currents) within the subunits of the channel protein 
itself (voltage-dependent action of the channel voltage sensor thought to be the S4 TM 
segment in Kv) (Bezanilla et al., 1991, Bezanilla, 2000, Bezanilla, 2006).  
 
1.6.2. Voltage sensing models and conformational changes 
 
How the voltage-sensing region translates TM voltage changes into structural 
conformational changes that leads to the opening or closing of the ion translocation pore 
remains unresolved and controversial but it entered an exciting era in 2003 with the first 
crystallization of a Kv channel. Using X-ray crystallography techniques, the MacKinnon 
laboratory crystallized the bacterial Kv channel from Aeropyrum pernix (KvAP;(Jiang et al., 
2003b, Jiang et al., 2003a). Their results reinvigorated research in this area by yielding an 
unexpected visualization of the voltage sensing region that conflicted with prevailing views 
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on the structure and movement of the voltage-sensing S4 segment in a Kv channel. It was 
the tertiary structure (not the primary or secondary structures) in KvAP that came as a 
surprise. Unlike the long-standing and experimentally supported view that each of the S1–
S4 segments spanned the TM region, the C terminus half of S3 and the S4 segment in 
KvAP appeared to form a ‘‘paddle-like’’ structure lying alongside the intracellular surface 
of the membrane ‘‘translocating’’ charge through the membrane while S1 and S2 were 
approximately parallel to the surface of the membrane encircling the pore-forming S5–P–
S6 domain (Figure   10, Figure   11)  (Judge and Bever, 2006, Elinder et al., 2007).  
 
In contrast, the voltage-sensing S1–S4 region of the recently determined Kv1.2 crystal 
structure has the anticipated TM topology with a tertiary structure very similar to that of the 
second KvAP crystal structure of an isolated voltage-sensing domain. The MacKinnon lab 
(Jiang et al., 2003b) recognized that the voltage-sensing domain of the full-length KvAP 
crystal structure is distorted from its native conformation, as a probable result of the 
antibodies used in the purification and crystallization process and/or the fact that the 
detergent solubilized protein does not exist in its native bilayer. Kv1.2 crystal structure 
confirms early proposals that the S4–S5 linker forms an amphipathic α-helix that lies 
parallel to the cytoplasmic surface of the membrane. Numerous models have been proposed 
for the voltage sensing mechanism of activation gating. The best known of these are the 
‘helical screw’, the ‘gating pore’, the ‘transporter’, and the ‘paddle’ (Jiang et al., 2003b, 
Jiang et al., 2003a) (Figure   10F, G, H) (Judge and Bever, 2006, Elinder et al., 2007).  
 
1.6.3. Ion and gating currents  
 
Voltage-gated ion channels largely depend on membrane voltage. This voltage dependence 
suggests that around 12 elementary charges are required to move through the membrane 
electric field to open the channel (Keynes and Elinder, 1999, Swartz, 2004). Thus, there are 
three charges per subunit in the tetramer. When these charges are moving, they should 
cause a tiny gating current. This was realized already by Hodgkin and Huxley in their 
classical studies from 1952. However, due to its smallness and the consequent 
contamination by ion currents it withstood measurements for a long time. The first 
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measurements were possible only after development of efficient signal averaging 
techniques and were published 30 years ago. With the development better techniques it has 
now been demonstrated that even though there is no channel opening at -40mV potential 
difference across the axolemma, there is a large gating current. Larger voltage steps (-20 
mV) move more charges and open the channel. The major gating current component 
precedes the opening of the channel. Still higher voltage steps (0 mV) speeds the movement 
but do not increase the total gating charge. The integrated gating current vs. voltage, Q(V) 
curve is typically to the left of the G(V) curve (conductance vs. voltage) (Figure   11 C, D). 
This means that the voltage sensors have to move before the channel can open (Keynes and 
Elinder, 1999). 
1.6.4. The voltage-sensor movement 
 
1.6.4.1 Early helical-screw and helical-twist models 
 
The first model to describe the S4 movement was the helical-screw model. As depicted in   
Figure   10 the positive charges are lined up in a spiral around S4. They are supposed to 
pair with conserved negative counter charges in S2 and S3. Upon activation, S4 moves to 
new stable positions by rotating 60° and translating 4.5 Å per step. Three steps, thus a 
rotation by 180° and a translational movement of 13.5 Å, are required to transfer three 
charges per subunit to open the channel (Keynes and Elinder, 1999). This relatively large 
scale movement of S4 was almost generally accepted as charge transfer mechanism in 
voltage-gated channels, until it was challenged by the helical-twist model, involving a 
much smaller movement, as shown in (Figure   10G) — a 180° rotation with no 
translational movement. Narrow, water-filled crevices make it possible to transfer the 
charges during gating.  
1.6.4.2. Electrostatic interactions suggest a novel helical-screw model 
 
The location of S4 within the channel has also been a matter of debate. Most investigators 
have placed S4 buried in the channel protein, in direct contact with the pore-forming 
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domain, and shielded from the lipid bilayer by surrounding S1 to S3. In contrast when it 
occupied a lipid facing position in the periphery of the channel the  charge on the 
extracellular surface of the channel, close to S4, would electro statically interfere with the 
movement of the positively charged S4 —a position close to S4 would have a larger effect 
than a charge further away. A positive charge would decrease and a negative charge would 
increase the outward movement. 
 
Introduction of extra charge on the channel surface at different distances from S4 allows 
measurement of the effect induced on the G (V) curve. A position at the extracellular end of 
S5 (residue 419) showed the largest effect on the G(V) curve compared to the other 
investigated positions, shifting the curve to ±8.2 mV. This study showed positioning of the 
charges of S4 8 Å outside S5 — not in the crevice between two adjacent subunits as 
previously assumed. The other segments, S1–S3, were placed to satisfy electrostatic 
interactions and to fill in structural gaps in the molecule. With this arrangement charges of 
S4 face S1–S3 and the hydrophobic side of S4 face the lipid bilayer. Thus it was suggested 
that such an unorthodox solution allows large-scale movements of S4 with little friction 
from the fluid lipid bilayers (Elinder et al., 2007). 
 
The magnitude of the S4 movement was also measured using an electrostatic strategy. It 
was reasoned that a voltage sensor close to our mutated residue would attract negatively 
charged reagents, and increase the rate of reaction, while it would repel positively charged 
reagents, and decrease the rate of reaction. Depending on the position of S4 in open and 
closed states we would expect different reaction rates. This study found that S4 increased 
the local potential with 35 mV at the extracellular end of S5 when the channel was in open 
state. The top charge (residue 362) alone contributed 19 mV. Electrostatic calculations 
suggested that the top of S4 moved from a distant position (N20 Å) to a position close to S5 
(8 Å) upon activation. Thus, they reasoned that it is compatible with a helical- screw 
motion with the helix located as suggested in Figure   10F. It is apparent that in diseases 
like MS where demeylination is most predominant feature and membrane protein-lipid 
dynamic is distorted, the axolemmal ion channels are also variously affected (Elinder et al., 
2007). 
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1.7. Brief overview of multiple sclerosis (MS) and demyelination   
 
Multiple sclerosis (MS) is a chronic, disabling disease that affects 2 million people 
worldwide, especially young adults in industrialized societies. It is typically diagnosed 
between 20 and 40 years of age. A study on European MS epidemiology found an overall 
estimated prevalence of 83 per 100,000 with higher rates in northern countries (Pugliatti et 
al., 2006). MS is an inflammatory demyelinating (loss of myelin) disease of the CNS 
(Martin et al., 1992) and a leading cause of nontraumatic neurological disability (Trapp and 
Nave, 2008, Compston and Coles, 2002, Dutta and Trapp, 2010). 
 
MS derived its name because the patients have multiple attacks separated both in time and 
location, affecting different parts of the CNS. The disease often displays a relapsing–
remitting pattern of demyelination associated symptoms early in its course, and then 
recovers during remissions. There is cumulative acquisition of neurological deficits in some 
patients either at a later stage (secondary progressive MS), or at the beginning of disease 
onset (primary progressive MS) which do not remit (Bitsch et al., 2000, Waxman, 2006). 
Demyelination involves CNS glial cell; namely, the oligodendrocyte as a principal target. 
Effects of unfavorable conditions during disease progression and associated mechanisms 
alter its interaction(s) with neurons and initiate symptoms (Lassmann et al., 2007, Smith, 
2011, Smith and Hall, 2001, Smith and McDonald, 1999) due to CNS lesions. MS lesions 
denote loss/damage of oligodendrocyte coupled with axon degeneration  (Dutta and Trapp, 
2010, Prineas and Wright, 1978, Kuhlmann et al., 2002). Progressive axonal loss is the 
major cause of prolonged neurological disability (Dutta and Trapp, 2010, Bitsch et al., 
2000). Morphological analysis of brain tissue (Trapp and Nave, 2008, Campbell et al., 
2011, Lassmann et al., 2001) has further established this fact (Dutta and Trapp, 2011, Trapp 
and Stys, 2009). Alteration or disruption of axonal cyto-architecture impacts axonal 
functioning which in turn leads to  conduction blocks of varying degrees due to differential 
levels of neuro-degeneration (Haider et al., 2011, Prineas and Wright, 1978, Lassmann et 
al., 2001).  
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1.8. Etiology and clinical symptoms of MS 
 
The actual cause of MS remains unexplained and is a debatable issue. It is attributed to 
various causes like virus, toxin, genetic or environment induced leading to CNS 
inflammatory response followed by demyelination. Demyelination and axon loss begins 
right at the onset, which continues leading to chronic effects on axon and gliosis while the 
disease progresses as the inflammatory phase wanes off in due course (Figure   12). Focal 
CNS plaques of primary demyelination with a variable degree of impact on the axon and 
neuron are a characteristic feature of disease progression (Lassmann et al., 2007).  
Clinically T2-weighted magnetic resonance imaging (MRI) scan is used to detect the total 
number of lesions (lesion load) and disease burden. These are hyper-intense lesions, which 
appear as bright spots on the MRI image. The T2-weighted scan is part of conventional 
MRI technology which is used to monitor and diagnose MS, usually in conjunction with a 
T1-weighted scan and with gadolinium enhancement. 
 
About 50-70% of patients present themselves with a clinically isolated syndrome (CIS) 
(i.e., a single relapse of the sort seen in MS). They are affected within the optic nerve, brain 
stem, or spinal cord which readily disseminates into the cerebral white matter lesions and is 
very typical of MS. Most of such individuals later develop clinically definite MS with 
follow-ups. MS patients display phenotypic heterogeneity, some may present with atypical 
clinical patterns, while others could be asymptomatic. But as the disease progresses and 
demyelination sets in individuals exhibit characteristic tiring during physical and cognitive 
tasks, taking longer to recover. 
 
Demyelination can initially results in the expression of “negative” symptoms, namely loss 
of function resulting in deficits such as blindness, paralysis, and numbness. During the next 
few weeks the axon adapts to its demyelinated state, resulting in a gradual increase in 
excitability and then, if conditions are favorable, conduction through the demyelinated 
lesion(s) may be restored. Where this occurs, it contributes to clinical recovery and the 
remission of the negative symptoms – remitting relapsing phase of MS (RRPMS), although 
conduction remains insecure and some residual deficits may persist. Some axons may 
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become hyperexcitable, resulting in the expression of “positive” symptoms such as tingling 
sensation or pain (Waxman, 2005).  
 
1.9. Factors leading to axonal conduction block 
 
Axonal conduction block is an outcome of demeylination associated disruption of its 
function owing to the structural changes. Several elements of this change contribute 
differently leading to a perturbed homeostasis as the disease progresses. Briefly structural 
changes in an axon account for the following conditions.  
 
1.9.1. Segmental demyelination involving complete loss of myelin over a single internode 
which is more than sufficient to block conduction completely.  
 
1.9.2. Nodal widening: Sometimes demyelination does not involve the whole internode, 
but only the paranodes, resulting in widening of the nodal gap. In agreement with 
predictions made by computer modeling (Chiu and Ritchie, 1981, Koles and Rasminsky, 
1972), nodal widening is also sufficient to block conduction (Waxman, 2005).   
 
1.9.3. “g” ratio/myelin index: It is a measure of myelin thinning. The ratio of the inner 
axonal diameter to the total outer diameter or ‘g’ ratio is widely utilized as a functional and 
structural index of optimal axon myelination.  Rushton was the first to derive an optimal 
theoretical ‘g’ ratio of 0.6 (Rushton, 1937). In this classic study, the calculation was based 
on the speed of fiber conduction. ‘g’ ratio=di/do (Rushton, 1951, Chomiak and Hu, 2009), 
and myelin index = do/di (Nashmi and Fehlings, 2001). 
 
1.9.4. Soluble factors: There is an inevitable dysregulation of the composition of 
extracellular fluid bathing axons, including the appearance of other agents of various 
origins. 
 
 Nitric oxide (NO):  is a reactive agent that can have direct or indirect effects on Na+ 
channels (Smith, 2007) and K+ channels (Yang et al., 2007c); it also causes 
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membrane depolarization and inhibits mitochondrial metabolism. Any of these 
mechanisms would be expected to impair conduction. 
 QYNAD/endocaine: An endogenous pentapeptide Gln-Tyr-Asn-Ala-Asp 
(QYNAD), which acts like a local anesthetic lidocaine and is found at 14-fold 
higher levels in CSF, producing Nav channel blocking effects.  
 Cytokines: like TNF-α and γ-interferon act indirectly. 
 Antibodies: anti-GM1 etc.(Smith and Hall, 2001). 
1.10. Compensatory mechanisms in demyelination, a structure function co-relate  
 
Although conduction might be initially blocked by segmental demyelination, the block is 
not necessarily permanent. The loss of the myelin triggers a series of adaptive responses in 
the axon. These might be kicking in of several compensatory mechanisms that lead to 
restoration of axon conduction in the presence or absence of myelin loss. There are two 
most widely known facts:  
 
1.10.1. Altered distribution and expression of ion channels 
 
Atypical expression of ion channels, and their expression in different proportions and 
locations, can be expected to contribute to the complex neurological manifestations of 
demyelinating diseases. Although at present our understanding of the roles of individual 
types of channel is limited, increased knowledge is anticipated from studies conducted on 
several types of animal models including transgenic knock-outs of particular ion channels 
(Smith and Hall, 2001) Changes in the ion channel population along the demyelinated 
membrane is an adaptive response. Experimental allergic encephalomyelitis (EAE) optic 
neuritis induces dispersion of Na+ channels into paranode and internode region, and the 
timings of this altered distribution correlates with the symptoms produced. Functional 
studies on dorsal root ganglion (DRG) and sciatic nerve also support this view. On the 
other hand, diffuse paranodal and JXP expression of Kv channels owing to destabilization 
of these structures in demeylination or hypomyelination (Rasband et al., 1999b) or lack of 
galactolipids is known. Axotomised DRGs show reduced immunoreactivity to Kv1.1, 1.2 
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.1.3 and 2.1. In MS and EAE demyelinated axons may express channels Ca2+ (Kornek et 
al., 2001) and Nav (Smith, 2007, Waxman, 2006) that are not normally present (Smith and 
Hall, 2001).  
 
The restoration of conduction to demyelinated axons involves substantial remodeling of 
demyelinated axolemma at the molecular level. The nature of these changes is becoming 
clearer with the advent of suitable antibodies for immuno-histochemistry (IHC), and it is 
now possible, to view the exquisite precision with which Nav1.6 sodium channels are 
segregated at nodes of Ranvier (Arroyo and Scherer, 2000, Black et al., 2002) or Kv1 
channel at the JXP (Rasband, 2004). Earlier morphological evidence that Nav density can 
increase in demyelinated axons (Kazarinova-Noyes and Shrager, 2002) has been 
augmented by the discovery that two different isoforms of voltage-sensitive Na+ channels, 
Nav1.2 and Nav1.6, become expressed along demyelinated axons (Craner et al., 2004). On 
the other hand, nothing is known about any kind of Kv channel subunit changes in 
demyelination.  
 
1.10.2. Microsaltatory conduction 
 
This is a property involving restoration of conduction to demyelinated axons in the 
presence of remyelination. Conduction in lysolecithin-induced demyelinated axons proceed 
in a discontinuous manner, by adopting a microsaltatory mode of conduction, perhaps 
reflecting the organization of Na+ channels into new node-like foci, termed phi-nodes or 
reformation of shorter internodes. Thus, conduction may be possible even in “open” MS 
lesions, where there is a paucity of glial processes and a greatly expanded extracellular 
space. The presence of conduction in demyelinated axons can also explain the observation 
that large, but clinically “silent” (i.e., asymptomatic) demyelinating lesions can occur in 
patients in pathways where symptoms may have been expected (Waxman, 2005). 
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1.11. Persistence of conduction block and failure of regulatory mechanisms  
 
Why these mechanisms fail and lead to persistence of conduction block?  Does it involve 
modulation? There could be several answers to it. Although conduction can be restored to 
demyelinated axons, conduction block remains a common feature of such axons. Whether 
conduction is restored in practice depends on a number of factors; those favoring the 
persistence of conduction block include: 
  
1. large axon diameter (Bostock et al., 1978);  
2. long internode preceding the demyelinated region (especially if the internode is 
partially demyelinated);  
3. long overall length of demyelination (e.g., many internodes lost); 
4. dysregulation of extracellular fluid composition, for example due to the failure of 
blood-brain barrier; the presence of factors deleterious for conduction such as nitric 
oxide and other factors associated with inflammation; 
5. absence of any glial ensheathment; 
6. short period of time elapsed since the occurrence of demyelination;  
7. recent (seconds/minutes) history of sustained impulse conduction (see later);  
8. an inopportune composition of ion channels and pumps along the demyelinated 
axolemma, perhaps theoretically influenced by genetic background; and  
9. warm body temperature (Ulthof’s phenomenon) (Section 1.13.4). 
 
Some of these points deserve further comment, and with regard to axon diameter, it is 
known that conduction can occur in demyelinated axons as large as 5.5 mm in diameter. As 
most demyelinated axons are smaller than this, especially in the CNS, it is likely that most 
peripheral and central demyelinated axons are capable of conduction if conditions are 
optimal. Also with regard to the preceding list, a long internode before the demyelinated 
region impedes the depolarization of the demyelinated axolemma by reducing the local 
current available at this site due to capacitative and resistive loss over the internode 
(Waxman, 2005).  
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1.12. Safety factor for conduction  
 
The concept of safety factor is useful in the pathophysiology of demyelination. It is defined 
as the “current available to depolarize the axolemma, divided by the current necessary to do 
so” (Rushton, 1937, Waxman, 2005) .  
 In normal myelinated axons, the action potential at an individual node generates 
approximately three to seven times more current than is actually required to fire the 
next node along the axon (Tasaki, 1953, Waxman, 2005), giving a safety factor of 3 
to 7.  
 In demyelinated axons, however, several factors conspire to reduce the safety factor 
and in some axons it falls to around unity. This is a critical level, because if the 
safety factor is fractionally higher than 1, the axon will conduct and the patient will 
have few symptoms; but if the safety factor is fractionally lower, conduction will be 
blocked and a neurological deficit may ensue.  
 
Some patients have many axons with a safety factor near unity, can result in noticeable, 
quite sudden changes in the severity of symptoms, because the safety factor is not 
absolutely fixed for any particular axon and it can be modulated slightly by small changes 
in the environment of the axons, especially temperature. In fact, even subtle changes in 
temperature can have dramatic effects on the success of conduction and, thereby on the 
expression of symptoms. Thus, the low safety factor of demyelinated axon means that 
conduction along the axon is not only particularly sensitive to changes in temperature but 
also vulnerable to chemical factors that may impair conduction 
An increased nodal gap can block conduction because the loss of the myelin means that the 
local current generated by the driving node (i.e., the last intact node before the 
demyelinated region) is now dispersed across a much wider area of axonal membrane than 
normal and, in particular, the nodal capacitance is greatly increased. Cell membranes, like 
axolemma, have a significant amount of capacitance and as they are very thin, and this 
capacitance has to be discharged as the axon is depolarized. The nodal capacitance is 
effectively determined by the area of the denuded axolemma, so demyelination can 
dramatically increase nodal capacitance, thereby, increasing the amount of local current 
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required for depolarizing the membrane to its firing threshold. The dispersal of the current 
and the increase in capacitance both serve to reduce the safety factor for conduction. Even 
myelin thinning along the internode can be sufficient to cause conduction failure, and 
failure is especially likely if an equivalent quantity of myelin is lost from the paranodes, 
resulting in widening of the nodal gap (Waxman, 2005). 
 
1.13. Collative functional impact on axon  
 
1.13.1. Slow conduction - impedance mismatch.  Why? 
Although demyelinated axons can sometimes conduct impulses successfully, they never 
conduct as well as the normal axons. Conduction remains much slower and less secure than 
normal (McDonald and Sears, 1970, Bostock et al., 1978). It has proven to be particularly 
valuable clinically, assisting in the diagnosis of demyelinating disease because of delays in 
the latency of the sensory or motor compound action potentials in patients with peripheral 
neuropathy, or in delays in the latency of the visual, somatosensory, or auditory-evoked 
potentials in patients with MS. 
 
1.13.2. Refractory period of transmission (RPT) or conduction of pairs of impulses 
The slow conduction along demyelinated axolemma inevitably limits the ability of the 
axons to transmit pairs (and trains) of impulses because the second action potential of a 
pair, traveling close behind the first, will run into the relative and absolute refractory 
periods of the first impulse as this is slowed at the site of demyelination. McDonald and 
Sears (McDonald and Sears, 1970) coined this deficit the refractory period of transmission 
(RPT), defining the RPT as the maximum interval between two conducted impulses such 
that the second impulse fails to be conducted successfully through the lesion. In a 
subsequent study of central axons proven to be segmentally demyelinated, the refractory 
period of the normal portion of the axon was always in the range 0.5 to 1.4 m/sec, but this 
was prolonged to 1.0 to 6.0 m/sec if the site of demyelination was included in the 
conduction pathway (Waxman, 2005).  
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1.13.3. Conduction of trains of impulses  
The problems associated with conducting pairs of impulses are magnified when considering 
the conduction of trains of impulses. One consideration is that the RPT of the second and 
later impulses is longer than that of the first (McDonald and Sears, 1970, Waxman, 2005), 
slightly increasing with increasing numbers of impulses until a plateau is reached. This 
effect is due, in part, to the fact that the second impulse conducts across the demyelinated 
region in the relative refractory period of the first, and so conducts a little more slowly, and 
so on. The maximum frequency of transmission therefore slowly declines over time. These 
latter frequencies are within the physiological range, and so the phenomenon raises the 
likelihood of impairing normal sensation and motor function, contributing to the reduced 
flicker fusion frequency in some patients, to the “fading” or blurring of vision upon 
prolonged fixation of gaze, and to the progressive weakness experienced by some patients 
upon walking only a short distance (Waxman, 2005) (Figure   15 B,C).  
 
1.13.4. Uhthoff’s phenomenon or temporary exacerbation caused by warming 
The security of conduction in demyelinated axons is markedly affected by temperature, and 
this effect can readily be demonstrated in the laboratory in both central (Smith et al., 2000) 
and peripheral experimentally-demyelinated axons. The effects can be sufficiently strong 
that even subtle changes in body temperature can have a profound effect on the expression 
of symptoms by patients with MS. 
 
Indeed, many patients with MS exhibit a worsening of some symptoms upon body 
warming, and the worsening is sufficiently robust and reproducible that at one time the 
phenomenon was used in the diagnosis of MS in the form of the “hot bath test”. The effect 
was first described in 1890 by Uhthoff, and the phenomenon now bears his name. Uhthoff-
like phenomena can be provoked by a hot shower, sunbathing, exercise, or even by the 
normal circadian change in body temperature. Just as warming can be deleterious to 
function, so cooling can be beneficial and can sometimes be realized after a cool bath or 
simply after drinking cold water. Indeed, improvement in vision has been documented after 
drinking iced water, and these functional improvements are accompanied by an increase in 
the amplitude of the visual-evoked potential (Waxman, 2005).  
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1.14. Consequences of sustained impulse activity  
 
1.14.1. Activity dependent conduction block 
Axonal activity failure is also caused by axonal hyperpolarization resulting from activity of 
electrogenic Na+/K+ ATPase. Pump activity is prompted by the raised intra-axonal Na+ 
concentration as a result of preceding impulse activity. Hyperpolarization can effectively 
and abruptly turn demyelinated axons ‘off’ for a period (e.g., 0.2-2s) and its intermittent 
appearance can cause a continuous train of impulses to be divided into short bursts 
separated by silent periods. The phenomenon has now been demonstrated in normal human 
axons and human axons affected by chronic demyelination (Smith and Hall, 2001). 
 
1.14.2. Hyperexcitability and ephaphtic transmission 
Apart from the negative symptoms in MS (e.g., paralysis, blindness, numbness) positive 
symptoms (tingling sensation) are also known. Such symptoms are believed to arise 
primarily from spontaneous impulse activity, which is generated by axons rendered 
hyperexcitable by their response to demyelination. What leads to hyperexcitability is an 
open debate (Smith and Hall, 2001), but one consequence of it is the possibility of 
ephaphtic transmission, namely the excitation of neurons/axons by activity in neighboring 
neurons/axons, at a site other than a synapse (Walz, 2000). 
 
1.15. Inhibition of Kv1 channels and challenges  
 
After protein kinases and G-protein coupled receptors (GPCRs), voltage-gated ion channels 
(VGICs) constitute the third largest group of signaling molecules encoded by the human 
genome. Even though about 40 Kv channels encoded by the human genome have been 
cloned and their biophysical properties characterized, it often remains a challenge to 
determine precisely which channel underlies the K+ current in a native tissue. This is 
because within subfamilies, such as the Kv1 or Kv7 families, the α-subunits can 
heteromultimerize relatively freely, resulting in a wide range of possible channels tetramers 
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with different biophysical and pharmacological properties (Wulff et al., 2009, Gutman et 
al., 2005). Kv channel-interacting proteins (Long et al., 2005b, Long et al., 2005a, Wulff et 
al., 2009) enhance the surface expression (McKeown et al., 2008) and alter the function of 
Kv4 channel α-subunits (Gutman et al., 2005). In addition to this ‘mixing and matching’ of 
α- and β-subunits of Kv channel leads to properties that can be further modified by 
phosphorylation, dephosphorylation (Singer-Lahat et al., 1999, Yang et al., 2007a, Park et 
al., 2008), ubiquitination (Manganas et al., 2001), sumoylation (Plant et al., 2011, Dai et al., 
2009) and palmitoylation (Gubitosi-Klug et al., 2005). In terms of drug discovery, this 
molecular diversity creates a challenge. However, it also provides an opportunity to achieve 
selectivity by designing modulators that discriminate between homotetramers and 
heteromultimers or that binds to tissue specific β-subunits (Wulff et al., 2009). The non-
canonical (nonconductive) properties of Kv channels are increasingly found to be of 
importance. For instance Kv channels also play an important part in Ca2+ signaling, volume 
regulation; secretion proliferation (Wickenden, 2002, Chittajallu et al., 2002) and migration 
(Coma et al., 2003). Although no Kv channels have been found to have direct intrinsic 
catalytic functions, they induce indirect effect, since they are often a part of large 
supramolecular complexes. The behavior of these complexes can be influenced by the 
channel in the absence of ion flow. Thus inhibiting Kv channels by a certain blocking 
strategy remains a major challenge in drug discovery (Wulff et al., 2009).  
 
1.16. Channel modulation strategies and pharmacological targeting 
Agents that modulate Kv channels can be broadly divided into three chemical categories: 
metal ions, organic small molecules (molecular weight 200–500 dalton) and venom 
peptides (molecular weight 3–6 kD). These substances affect Kv channel function by 
blocking the ion-conducting pore from the external or internal side, or modifying channel 
gating through binding to the voltage sensor domain or auxiliary subunits. Similar to other 
proteins expressed on the cell surface, Kv channels can be targeted with antibodies 
(molecular weight 150 kD) which can inhibit channel function, lead to channel 
internalization or deplete channel-expressing cells by complement or cell-mediated 
cytotoxicity. Antibodies and toxins can also be engineered to serve as carriers for the 
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delivery of active compounds to channel-expressing cells, or can be conjugated to cytotoxic 
drugs, isotopes or other molecules (Figure   13) (Wulff et al., 2009).  
  
In terms of channel inhibition, one study has reported the development of monoclonal 
antibodies (specific for Kv10.1); polyclonal antibodies have been obtained in several cases 
using extracellular parts of the pore loop as antigen. Peptide toxins typically bind either to 
the outer vestibule or the voltage sensor of Kv channels. By contrast, small molecules — as 
exemplified by the hydrophobic cations like tetrabutylammonium, d-tubocurarine and 
verapamil — block Kv channels by physically occluding the inner pore and inserting their 
ammonium group into the ion permeation pathway (Wulff et al., 2009). 
  
The inner pore of Kv channels can also be targeted by nucleophilic molecules such as the 
Kv1 channel blocker correolide, which fits neatly into the hydrophobic surface of the S6 
helix with its lipophilic domain and chelates a permeating K+ with its polar acetyl groups. 
Typical blockers of Kv11.1 enter the channel from the intracellular side and seem to reside 
in a pocket in the inner mouth, where they interact mostly with two aromatic residues. The 
wide range of drugs that this pocket can accommodate might be due to the lack of a cluster 
of proline residues, which induces a kink in the intracellular channel pore opening of Kv 
channels, in contrast to other K+ channel families. This produces a broader opening in 
Kv11.1 that allows entry of a wide range of molecules of varying sizes and shapes (Wulff et 
al., 2009). 
 
In addition to the inner pore, small molecules can also bind to the ‘gating hinges’. This 
occurs in the case of the Kv7 channel activator retigabine, which has been found by 
mutagenesis to bind to a putative hydrophobic pocket that is formed following channel 
opening between the cytoplasmic parts of S5 and S6. Another interesting mechanism of 
action for channels with α-subunits is the so-called disinactivators that disrupt the 
interaction between α- and β-subunits and, thereby, modify channel behavior (Wulff et al., 
2009, Lu et al., 2008).  
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As evident several strategies can be adopted for Kv channel modulation; therefore, typically 
a blocking molecule is usually identified through high-throughput screening (Wacker et al., 
2012) or serendipity, and then optimized through classical medicinal chemistry. Lead 
identification is usually achieved by ion flux assays (mostly using isotopes and/or atomic 
absorption spectroscopy) or fluorescent dye assays. More recently, it has been achieved 
through automated electrophysiological measurements, which can offer quality levels 
comparable to that of manual patch clamp assays and has a reasonable throughput. Detailed 
studies on functional drug–target interactions can be achieved through patch clamping, 
which allows the behavior of a single ion channel to be studied on the microsecond 
timescale. Subsequently, the identified compound can be pipelined for pre-clinical animal 
studies (Wulff et al., 2009).  
 
1.17. Principal goals of this study 
 
Several years back a biochemical analysis (unpublished results) conducted by Prof. J.O. 
Dolly’s laboratory on human brain autopsy tissue of  MS patient from a brain bank based in 
London, UK, indicated the appearance of an intriguing and conserved diagnostic form of 
Kv1 channel. This observation emphasized greater significance of Kv1.1 subunit 
compositions and their stoichiometry in functional tetrameric organization of Kv1 channels. 
This form of Kv1.1 channel(s) has been hypothesized as a likely therapeutic target, which 
could contribute to the underlying cause of benefits rendered by 4-AP like drugs. Even 
though benefits of 4-AP like drug in demyelinated axon is known for a long time (Sherratt 
et al., 1980), its clinical application remains restricted due to its off-site action and 
subsequent epileptogenic side-effects (Judge and Bever, 2006). 
 
A great deal of progress has been achieved in the lab to decipher the biophysical profiles of 
Kv1.1 oligomeric forms (Shamotienko et al., 1999, Shamotienko et al., 1997, Wang et al., 
1999) and identify an appropriate pharmacological inhibitor, i.e., a molecule, which can 
effectively block the K+ flow through Kv1 channels  (Al-Sabi et al., 2010) in order to 
restore the conduction in demyelinated axons. This has to be achieved by inhibiting the K+ 
efflux from a demyelinated axon allowing improvement of toxic-to-therapeutic ratio. This 
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work has been specifically designed to explore the features of Kv1.1 channel in an animal 
model mimicking MS.   
 
It could be anticipated that several demyelinating axon features are associated with subunit 
composition and specialized sub-cellular distribution of Kv1 channels which contribute to 
the functional diversity. Exploring such features in a demyelinating CNS nerve is 
contemplated to contribute towards eventually improving the specificity of Kv1 blocking 
agent. Hence, the aim of this research project is to establish the features of MS in an animal 
model, followed by elucidation of Kv1.1-containing channels in disease state, such that it 
can be used as an established model for in vivo screening of pharmacophore that is being 
currently developed under our research program.  
 
1.18. Animal models for multiple sclerosis 
 
MS is a complex disease and hence involves several aspects of research. In vitro studies 
have addressed issues specific to mechanisms like T-cell activation by a myelin epitope, 
migration across the blood-brain barrier and demyelination whereas in vivo models have 
mostly encompassed approaches based on experimental allergic encephalomyelitis (EAE), 
as well as transgenic and mutant strains (Altmann and Boyton, 2004, Schmandt et al., 
2006). Various types of demyelinating models have been developed and used to address 
specific issues of research interest (Merrill, 2009).  
 
EAE models require immunization using CNS tissue in adjuvant to produce inflammatory 
disease in species of animals like mouse, rats, macaques, marmosets and rhesus monkeys. 
This approach has been instrumental in basic discoveries about the nature of disease. It has 
also been affected for pre-clinical testing of monoclonal antibody based therapies targeted 
against p40 receptor of interleukin IL-12 and IL-23 and against CD40. However, these 
models suffer major limitations with respect to translational MS research, one being that 
disease is not spontaneous; hence, investigation of interactions between environmental 
factors and their susceptibility is not possible. Furthermore, most therapies are tested in 
 53 
EAE by giving the treatment at the time of disease induction, an unrealistic test compared 
with the clinical context of requirement to treat a patient in the midst of an ongoing and 
potentially irreversible pathogenic process of unknown duration (Altmann and Boyton, 
2004). EAE induces a highly inflammatory multifocal CNS disorder with a largely 
unpredictable distribution pattern of the lesion and, hence, has proved less appealing 
compared to demyelination or dysmyelination models (Schmandt et al., 2006). Virus 
(Theiler and Semliki Forest Virus) induced models are also used which is argued to induce 
pathological patterns of MS (the III and IV lesions) (Lucchinetti et al., 2000) and has been 
instrumental in identifying some of the steps involved in T-cell migration to the CNS.  
 
On the other hand mutant models have shed light on some forms of dysfunctional or 
damaged myelin sheath by spontaneous or experimentally conducted mutation of genes 
specific for CNS constituents.  Although it is not widely believed that a key component of 
susceptibility to MS resides in genetic malformation of myelin, the notion of some form of 
highlighted glial vulnerability to inflammatory damage has been plausible.  Some of these 
models include, Shiverer mice (MBP deletion) which fail to develop compact myelin and 
die by 22 weeks of age, Jimpy mouse (PLP mutation) result in hypomyelination and 
oligodendrocyte death, Twitcher mice have deficiency of galactosyl-ceramidase b-
galactosidase resulting in distended ‘globoid’ macrophages, impaired myelin formation and 
myelin breakdown (Altmann and Boyton, 2004).  MAG mutants show hypomyelination 
(50% unmyelinated axons in optic nerve) (Schmandt et al., 2006) and double knockout 
mice of MAG and the non-receptor src-type tyrosine kinase Fyn show higher levels of 
hypomyelination as compared to the single mutant (Schmandt et al., 2006).  
 
Models of chemical demeylination use gliotoxic/neurotoxic agents like ethidium bromide 
(Guazzo, 2005), lysolecithin or cuprizone (Matsushima and Morell, 2001).  Affinity and 
DNA chelating properties of ethidium bromide not only destroys oligodendrocytes but also 
their progenitors and astrocytes. Cuprizone (CZ) feeding leads to systemic defects 
representing an intermediate model where it leads to oligodendrocyte death and subsequent 
demeylination. It interferes with mitochondrial function and has been shown to affect the 
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expression of myelin genes and to cause apoptosis of oligodendrocytes (Schmandt et al., 
2006). 
 
In vivo models are important for defining “whole animal” aspects of disease with respect to 
immune system or CNS interactions, which are vital for designing and testing new 
therapies (Altmann and Boyton, 2004). Depending on the specific patho-mechanism or 
disease component to be targeted, different animal models offer distinct advantages for 
probing experimental therapies. It is generally believed that the immunological mechanisms 
responsible for inflammation in MS are similar to those in EAE, an experimental paradigm 
of Th1-mediated autoimmune disease, and immuno-modulatory therapeutic strategies that 
work in EAE should also be beneficial in MS. Unfortunately, in many instances this 
approach has been disappointing (Lassmann et al., 2001). The inflammatory models induce 
brain inflammation, mediated by T cells and local activation of hematogenous macrophages 
or microglia which in turn impairs the blood–brain barrier. That allows circulating 
demyelinating antibodies and complement components to enter the CNS and destroy 
myelin, either by complement activation or an antibody-dependent cellular cytotoxicity 
reaction. The pathological hallmark of such lesions is the local precipitation of the lytic 
terminal complement complex on the surface of myelin sheaths and oligodendrocytes. 
However, other mechanisms that have been identified could induce myelin damage during 
the course of an inflammatory process in the CNS. Thus, the major challenge for future 
research, is to define which of these mechanisms operate in demyelinating MS plaques 
(Groebe et al., 2009, Norkute et al., 2009, Soderstrom, 2001), so that a successful 
therapeutic strategy can be worked.  
 
1.18.1. Developing animal model for in vivo screening of Kv channel blocker 
 
MS is distinguished from that of other inflammatory diseases of the nervous system by the 
presence of large, multifocal, and chronic demyelinated plaques with reactive glial scar 
formation (Lassmann et al., 2001). The existing data regarding myelin status in chronic 
injury is incomplete and its correlation between rodent and human studies appalling 
(Lasiene  et al., 2008). In order to develop a CNS demyelinating model, it is imperative to 
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contemplate the basic fact that myelin sheaths not only ensure successful propagation of 
action potentials but also participate in axonal maturation, transport and survival (Lasiene  
et al., 2008). So, an understanding of the state of axons during disease progression is of 
prime importance in order to develop the most appropriate therapeutic strategies. 
1.18.2. Chronic demyelination 
 
Although myelin sheaths are primarily targeted during MS disease progression, neurons 
their axons and astrocytes are also affected though to a lesser extent. Initially, 
demyelination was thought to be caused by necrosis of oligodendrocytes; however, it is 
unclear what causes prolonged oligodendrocyte death weeks and months after injury. Acute 
axonal injury is frequent in demyelinating MS lesions and this leads to 50–70% reduction 
in neurite density in chronic plaques (Lassmann et al., 2001). The concept of chronically 
demyelinated axons is based on anatomical, pharmacological and cell based studies 
(Lasiene  et al., 2008) and it has remained difficult to establish the lesion pattern in the 
most popular EAE model of demyelination (Altmann and Boyton, 2004, Schmandt et al., 
2006). MS lesions are classified under three categories: 
 
1. Type I (Acute): With numerous T cells (CD3+ cells) and macrophages (CD68+ 
cells) throughout. These can be of two subtypes 
 With macrophages 
 Without macrophages 
2. Type II (Active chronic): Centre of the lesion contains few macrophages and T cells 
but there are more of these cells at the border between demyelinated and normally 
myelinated tracts  
3. Type III (Chronic): Few or no macrophages and T cells in the centre or periphery of 
the lesion (Ferguson et al., 1997) but with oligodendrocyte apoptosis.  
1.18.3. Cuprizone induced demeylination and multiple sclerosis 
 
Oral administration of Cuprizone (CZ) or biscyclohexanone oxaldihydrazone is known to 
produce status spongiosus and demyelination in the CNS plus hepatic lesions (Suzuki and 
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Kikkawa, 1969); induction in young adult mice is synchronous and consistent. Loss of 
myelin occurs in lesion sites large enough to allow detection of changes in the relevant 
cellular, molecular, biochemical and morphological parameters (Hiremath et al., 1998, 
Matsushima and Morell, 2001) and has been used to investigate demyelination as well as 
remyelination processes (Matsushima and Morell, 2001, Kipp et al., 2009, Crawford et al., 
2009). The action of CZ involves copper chelation, which produces the same effects as 
chronic copper deficiency (Benetti et al., 2010).  Copper being a co-factor of mitochondrial 
cytochrome-C oxidase, its deprivation by presence of CZ is assumed to cause strong 
impairment of energy production, neuron viability and their proliferation. However, CZ is 
not a neurotoxic molecule capable of directly acting on CNS neurons. Degeneration of 
oligodendrocytes precedes disruption of the myelin sheath (Pasquini et al., 2007). It leads to 
early observable myelin loss, without damage to other cell types in the CNS. This is 
evidently due to disturbance of energy metabolism marked by decrease in the activities of 
the various respiratory chain complexes, indicating a disruption of mitochondrial function 
resulting in demyelinating lesions (Pasquini et al., 2007).  
 
Why oligodendroglia is preferentially susceptible to copper deficit is not known, although 
an obvious and most plausible hypothesis is that the perikaryon of this cell type has to 
maintain a vast expanse of myelin and this extraordinary metabolic demand (Waxman, 
2005) places it in jeopardy if the demand cannot be met (Stidworthy et al., 2003, Binder 
and Steinhauser, 2006, Matsushima and Morell, 2001).  CZ challenge for oligodendrocytes 
mimics a form of demeylination where oligodendrocyte apoptosis predominates, and 
resembles the so-called type III lesions of MS (Franklin and Ffrench-Constant, 2008, 
Lassmann et al., 2001, Kipp et al., 2009, Hiremath et al., 1998). Hence, this model 
facilitates testing of several strategies in an easily inducible, very predictable and consistent 
manner in C57BL/6J strain of mice. The use of this particular strain is advantageous as it 
bestows an easy comparative analysis with other mouse models for demyelination, such as 
the twitcher mouse that also has the same genetic background. Thus, similar hypotheses can 
be tested and corroborated in several models of demyelination, and that should lend 
credence to any discovery (ies) and, perhaps, provide insights in to broad implications of 
any finding(s). Additionally, there are many genetically altered mice are of the C57BL/6J 
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genetic background; therefore, comparison of demyelination in these mutant mice to the 
wild type may further implicate roles for additional effector molecules (Hiremath et al., 
1998).  
 
1.18.4. Optic nerve and clinical relevance  
 
Although demyelination has profound effects on axonal function, in most lesions the initial 
occurrence of demyelination has no detectable consequences for the patient because the 
lesions may occur in clinically “silent” areas (Lassmann et al., 2001, Waxman, 2005) of the 
brain where even the local complete destruction of nerve tissue does not produce symptoms 
and remain asymptomatic. However, optic nerve (ON) lesion always has major 
consequences for the patient, causing profound neurological deficits (Waxman, 2005, 
Edgar et al., 2004, Fairless et al., 2012). Development of a lesion in such a neural pathway 
can produce a clinical relapse. The form of the relapse (e.g., whether it is sensory or motor) 
and the modality or body part affected are determined directly by the location of the lesion 
and, thus, by the axons affected. The occurrence of even large lesions with similar 
pathology in silent areas of the brain would be overlooked by both patient and physician 
during the life-time, in absence of diagnostic imaging.  
 
ON is one such clinically symptomatic tissue and has always been used for visually evoked 
potential (VEP) based diagnosis in delineating demyelination-associated features of a 
suspected patient, before they are identified as clinically defined MS (CDMS) (Figure   
15). ON or second cranial nerve is sensory in nature which projects from the eye and is a 
well-studied, characterized system. Here in this study, it is considered as one of the most 
appropriate tissues for analyzing Kv1 channels of demyelinating axon due to the reasons 
below: 
 
a) Structurally, it is a CNS nerve fiber exhibiting axon and oligodendrocyte interaction; its 
axonal conduction is sensitive to 4-AP, a general blocking agent for Kv1 (Kocsis et al., 
1986, Smith et al., 2000).  
b) A relatively homogenous population of axonal Kv1 channels can be analyzed there. 
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c) Demyelination can be reproducibly induced. 
 
Anatomically, the eye is protected from mechanical injury by being enclosed in a socket or 
orbit, derived from several skull bones. These together form a four-sided pyramid like 
structure, the apex of which points back into the head. The orbit floor comprises parts of 
maxilla, zygomatic and palatine bones, while the roof is made up of the orbital plate of 
frontal bone with the sphenoid behind it. Optic foramen forms the opening of the optic 
canal. The superior surface of the sphenoid bone is bound behind by a ridge, which forms 
the anterior border of a narrow, transverse groove, the chiasmatic or optic groove. Above 
and behind it lies the optic chiasm. The groove ends on both side of an optic foramen, from 
which the ON and ophthalmic artery emerge into the orbital cavity. The ON is ensheathed 
by the three meningeal layers (dura-meter, arachnoid and pia-meter) rather than 
epineurium, perineurium and endoneurium of peripheral origin. Since the fiber tracks of 
CNS (as opposed to peripheral nerves) are incapable of regeneration, and nerve damage 
readily exhibit vision associated symptoms. These features further strengthen its clinical 
relevance. 
 
To summarize, the set goal under this PhD project entailed experiments designed to achieve 
them in four major steps. This involved 
 
 Establishment of a murine model with MS like demyelinating features,  
 Verification of CNS axon demyelination in ON 
 Identification of changes in Kv1 channel expression of the myelinated axon and  
 Elucidation of induced functional deficit (s). 
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Figure   1: Axo-glial associations and structure of myelin membrane. 
 
Oligodendrocyte (purple) and astrocyte (brown) processes form a cytosolic perfusion 
network by coupling of gap junctions in between the cells. This network terminates by 
adhering to the blood - brain barrier (Nave, 2010b), which form the essential metabolite 
transport system (shown by black arrows) (Adopted from Nave 2010b).  
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Figure   2: Axo-glial associations for conduction. 
 
A. Myelin enables the axon with saltatory conduction such that the action potentials travel 
from one node to the other (dashed line) which is staggered and interrupted due to 
demyelination and becomes discontinuous. Discrete location of juxtaparanodal Kv1 
(orange color) and nodal Nav (shaded region) on the axons plays a vital role for this mode 
of conduction, which are adversely affected (dashed orange lines) in demyelination.  B. 
Diagrammatic representation of an oligodendrocyte process which forms myelin sheath. It 
is formed by thick dense stacked layers of membranes  (Meister and Berry, 1999) which 
surround the axon.   Myelin membranes face each other on apposed extracellular surfaces 
at the intraperiod line (thin black line) in compact myelin. Cytosolic surfaces adhere at the 
major dense line (red line) which is mediated by MBP. The paranodal outer and inner 
loops contain glial cytosol. The radial component consists of a series of tight junctions and 
contains actin, and tubulin.  
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Figure 3: Electrochemical gradient, ion channels and transporters of a neuronal 
membrane. 
Distribution of ions inside and outside the plasma membrane of neurons and neuronal 
processes, showing ionic channels for Na+, K+, Cl-, and Ca2+, as well as an electrogenic 
Na+-K+ ionic pump. Concentrations (in millimoles except that for intracellular Ca2+) of the 
ions are given in parentheses; their equilibrium potentials (ENa, Ek, ECl, ECa) for a typical 
mammalian neuron are indicated (Charand, 2012) http://hyperphysics.phy- 
astr.gsu.edu/hbase/biology/actpot.html) accessed on 1st May 2012.   
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Figure   4: Electrochemical gradient and involvement of ion channels and 
transporters in action potential generation. 
Action potential generation and the role of Kv and Nav ion channels in depolarization  (1 & 
2) repolarization (3 & 4) and hyperpolarization (5 & 6) phases (Charand, 2012) 
http://hyperphysics.phy- astr.gsu.edu/hbase/biology/actpot.html) accessed on 1st May 2012. 
This involves several steps 1-6 as shown in the schematic representation. 
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Figure   5: Action potential propagation in an unmyelinated axon. 
 
Synchronised and sequential activation of Nav and Kv channels lead to propagation of 
action potentials. The axon has been represented at two time points (t1 and t2) to 
demonstrate the upstream (point A) and downstream (point B, C) effects of a stimulus. The 
inactivation of upstream Nav channels ensures unidirectional propagation of action 
potential. Top panel shows the generation of action potential in response to a stimulus, 
which opens Nav channels, and the bottom panel show the opening of neighbouring Nav 
channels due to local depolarization. These events lead to the propagation of action 
potential (Fleming, 2012) http://www.arts.uwaterloo.ca/~bfleming/psych261/lec4se21, 
accessed on 1st May 2012.  
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Figure   6: Myelination of axon is a specialization for saltatory conduction. 
 
Synchronised activity of Nav channels at the node (point A, B and C) and JXP Kv channels 
(red gradient along the axoplasm) lead to action potential propagation from one node to 
another node, thus allowing a fast movement in such axons. Note from Fig. 3, where the 
distance travelled by the action potential is less within the same time as compared to this 
case when the axon is myelinated (t1, t1.5 and t2 represent the time points). This  highlights 
the benefits of sub-compartmentalised structure of this type of axon (Fleming, 2012) 
http://www.arts.uwaterloo.ca/~bfleming/psych261/lec4se21, accessed on 1st May 2012. 
.  
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Figure   7: Phylogenetic tree of Kv1–9 channel families. 
 
Classification of human Kv channels on the basis of amino acid sequence alignments 
represented as trees comprising the Kv1-Kv6 and Kv8-Kv9 families. IUPHAR and HGNC 
names are shown together with the genes’ chromosomal localization and other commonly 
used names (Gutman et al., 2005).  
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Figure   8: Phylogenetic tree of Kv10–12 channel families. 
 
The IUPHAR and HGNC names are shown together with the genes’ chromosomal 
localization and other commonly used names (Gutman et al., 2005). 
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Figure   9: Structural classes of Kv channels. 
 
Four major classes of Kv channels based on the number of TM spanning units and their 
functional relevance. 
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Figure   10: Schematic presentation of Kv channel in various conformations and TM 
voltage sensing models. 
 
A. Kva-subunit has a 6TM structure (S1-S6), with a P-loop in between S5 and S6. The N- 
and C-terminus are intracellular. B.Octomeric Kv channel has 4a-subunits and 4β-subunits 
and a T1 domain where N- terminus of each subunit tetramerize to acquire this 
conformation (Orlova et al., 2003). C. Schematic view of closed, non-conducting channel, 
and D. Open, conducting channel in which the voltage sensor region (lined by +ve 
charges) has moved up and out so that the critical S4 charges are accessible from the 
extracellular surface (Fig. 9A-C). E1. Open, non-conducting channel following N-type 
inactivation in which the channel is occluded by the binding of the N-terminus ‘ball’ in a 
rapidly inactivating K+ channel, at the intracellular mouth of the pore. E2. Open, non-
conducting channel in which the process of C-type inactivation has produced a molecular 
rearrangement closing the selectivity filter (Fig. 9B, C) (Judge and Bever, 2006). Three 
molecular models for location and movement of S4 voltage sensor (F, G, H) after 
activation of the channel namely helical screw (F), helical twist (G) and paddle (H).  
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Figure   11: Conformational and structural changes of Kv channels regulate their 
kinetics and functional properties. 
 
A. Topology of a-subunit in a 6TMchannel, showing voltage sensing domain and the pore 
domain. Left to right are S1 to S6 TM segments. Four such subunits make an octomeric ion 
channel. B. Structural working hypothesis of voltage-gated 6TM ion channels in closed and 
open configurations. Pore domain of a closed (KcsA), and open channel Methanobacterium 
thermoautotrophicum (MthK). For clarity only two subunits are shown in the side view 
(upper part). Views from the extracellular side (lower part). C. Ion currents (thin line) and 
gating currents (thick line) at the voltages indicated. Voltage-clamp technique based study 
in Xenopus oocyte at a holding potential (-100mV) show ion currents measured from wild-
type Kv channels and gating currents measured from non-conducting mutant Kv channels. 
D. Integrated gating current vs. voltage, Q (V), and conductance vs. voltage, G (V) (Elinder 
et al., 2007). 
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Figure   12: MS pathogenesis, course of neurological disability and therapeutic 
intervention(s). 
A. MS pathogenesis during the clinical phases of relapsing remitting and secondary 
progressive phase involve loss of myelin or demyelination (left corner). Disease onset (a) 
involves frequent inflammation (yellow bars), along with demyelination (purple plateau 
region), axonal transaction plasticity and remyelination. Subsequent phase is marked by 
continued inflammation and persistent demyelination (b) but, in the last progressive phase 
is featured by gradual waning of inflammation, accompanied with axon degeneration and 
gliosis (c). Clinical threshold (dashed line) when immuno-therapeutic interventions are 
used to contain the disease progression is limited until the onset it reaches the progressive 
phase. Early events of axon loss at the onset continue till the late phase leading to loss of 
brain volume (red line). B. Even though axonal loss (purple) begins very early on, it is 
diagnosed at a much later phase when brain atrophy (green line) and disability levels (red 
line) of the patient are very high. This is demonstrated in the T2 lesion load (blue line) of 
clinical diagnosed based on MRI. Active lesions labelled on the X axis of (B) indicate the 
patient age at disease onset (20-40 yrs) till the terminal time point reflecting prolonged 
disabling survival phase of the patient (Compston and Coles, 2002) 
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Figure   13: Kv channel blocking strategies.  
 
Structural illustration of Kv1.2 channel highlighting domains and sites of action for various 
types of blockers (Eunson et al., 2000). S5–P–S6 regions are shown in green the voltage 
sensor domain (S1–S4) light grey, tetramerization (T1) domain in orange and the 
intracellular Kvβ2 subunit in magenta. Outer- and inner- pore, blocking toxins obstruct the 
pore domains, gating modifiers interact with S1-S4 segments, and disinactivators disrupt 
αβ association.  For clarity, only two of the four subunits are shown (Wulff et al., 2009). In 
the bottom panel (left) an open, non-conducting channel in which 4-AP molecule has 
gained access to its intracellular binding site thereby occludes the channel. An open non-
conducting channel gets blocked due to toxin binding at the extracellular pore surface 
(bottom middle panel). Bottom right panel shows a condition when closed, non-conducting 
channel in which a voltage-sensor-modifying toxin molecule has partitioned into the 
membrane lipid bilayer binds to the voltage sensor region (at the S3 segment) inducing 
closure of the channel (Judge and Bever, 2006).  
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Figure   14: Kv channel blocking and restoration of conduction. 
 
Blocking of Kv channels in demyelination has restorative effect has been identified much 
early on nearly two and half decades back. Effect of 4-AP (dashed line) on CAP in rat 
dorsal root ganglion, can distinguish the myelinated and unmyelinated components (top left 
and middle). It does not have any effect on a myelinated axon (top left). The unmyelinated 
and demyelinated (top middle and right panel) axons exhibit broadening of the CAP base 
indicating the presence of exposed Kv channels. (Sherratt et al., 1980)Bottom panel 
demonstrates the effect of 4-AP on membrane currents of two consecutive nodes 1mm apart 
in control and demyelinated axon. Solid lines and dashed lines represent before and after 
4-AP application. Note the emergence of second hump, which disappears upon application 
of 4-AP (Sherratt et al., 1980).    
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Figure   15: Anatomy of eye and clinical relevance of ON. 
 
 A.  Organisation of eye showing various chambers, lens, retina, origin of ON and muscles 
involved in the visual process. B. Difference in latency is depicted in VEP recordings due 
to onset of demeylination in MS. A comparison of P100 wave or trace from the recording 
demonstrates increase in latency from 107msec of a normal case to 134msec in abnormal 
or affected individual (C).  Adopted and accessed from University of Utah, School of 
Medicine, website on 30th November 2011, Webpage, Visual Evoked Potentials in a Patient 
with Multiple Sclerosis, John Rose, M.D.   
http://library.med.utah.edu/kw/ms/mml/ms_vep.html  
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CHAPTER 2 
 
 
MATERIALS AND METHODS 
 
2.1. Animal husbandry, mouse strain and cuprizone treatment 
Male C57BL/6J mice (8 weeks old) were acquired under import license from Harlan, UK. 
They were kept under controlled housing conditions (ambient temperature 27-28ºC, 
humidity 36%, lights on from 6.00am to 6.00pm) in certified Bio-Resource Unit (BRU) at 
Dublin City University and handled by trained animal technicians. The mice were provided 
with ad libitum access to water and food. The technique for oral administration of CZ was 
approved by the Department of Health and Children in Ireland and conformed to relevant 
EU regulations. The designed experiments were peer reviewed by the University’s REC 
(Review Ethics Committee) and supervised by a consultant veterinary surgeon. These were 
in compliance with the European Communities Council Directive of 24th November 1986 
(86/609/EEC), under the license number BE100/3609. Prior to the introduction of feeding 
protocol, they were ensured their health and absence of any obvious abnormality. They 
were acclimatized for 3-4 days under normal housing conditions at BRU facility and then 
grouped as 4/cage for each experimental and control conditions. The treated (T) and normal 
control (UT) populations were housed in separate cages. Daily monitoring sheets were 
maintained to record the details of their weight, feeding and drinking pattern.  
 
Groups under treatment received Modified LabDiet® (Laboratory Rodent Diet) 5001 with 
CZ (5TBI – 1810588, ½” pellet). This special feed was prepared by IPS Product Supplies 
Limited, London, UK, by including 0.2% CZ (bis-cyclohexanone oxaldihydrazone; Sigma-
Aldrich Inc., St. Louis, MO) in normal laboratory rodent diet 5001. The feed was stored at 
4ºC before opening the bags and once opened they were stocked in airtight containers to 
avoid oxidation of the added compound. All opened bags were consumed within 4 months. 
Each lot of mice were administered this special diet for 8 weeks following which the 
experiments were conducted or samples prepared and saved at appropriate temperature 
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(4ºC, -20ºC) until used. All efforts were made to minimize animal suffering and reduce 
their number. 
 
2.2. Determination of brain myelin content and demyelination 
 
Homogenization of CNS tissue in a solution of low ionic strength peels off myelin from the 
axons and reforms vesicles of size range equivalent to the nuclei and mitochondria. Due to 
the high lipid content, these myelin vesicles have a low intrinsic density relative to any 
membrane fraction. Myelin from mouse forebrain was purified and quantitated based on 
this principle, employing sucrose density gradient centrifugation (Norton and Poduslo, 
1973). In brief, a lethal dose of sodium pentobarbital (Euthatal, 200mg/kg. i.p.,) was used 
and irreversible anesthesia was invoked in these mice. Their body weight was recorded. 
Then the brain was quickly removed, frozen in liquid nitrogen and saved at -80ºC till used. 
Brain tissue was gradually thawed on ice weighed in tared dry tubes to confirm the wet 
weight. Then the forebrain was defined by a coronal cut bordering the anterior end of the 
cerebellum and posterior end of the olfactory lobe. The posterior end was extended to 
include the entire cerebellum and used for total brain myelin content. The weighed tissue 
was homogenized in 0.25M sucrose, and centrifuged for 10 min at 500 x g, 4°C. The 
supernatant was then centrifuged for 10 min at 10000 x g, 4°C, and the resulting pellet 
resuspended in 10 volumes (relative to the supernatant) of 0.25 M sucrose. The same 
volume of 0.88M sucrose was added delicately below, and centrifuged for 3hrs at 100000 x 
g, 4°C. Myelin was collected from the interface of the two sucrose layers and resedimented 
at 15000 x g for 30min at 4°C. Further on, residual amounts of sucrose were removed from 
the myelin pellet by employing osmotic shock. For this, the pellet was resuspended in 10 
volumes of ice-cold deionized water and recentrifuged at 15000 x g for 30min at 4°C. This 
step was repeated 4 times to get rid of contaminating sucrose. The final pellet was dried and 
weighed (Perrot et al., 2007, Sperber et al., 2001).  
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2.3. Transcardial perfusion of mice and tissue fixation 
In order to perform transcardial perfusion, the mice were irrevocably anaesthetized 
(Section 2.2), to immobilize them, so that they were non-responsive to toe pinch anesthesia 
It was then placed on the surgical platform immediately without any delay and a cautious 
superficial cut was made along the ventral skin below the zyphoid process. The skin was 
pulled to expose the thoracic and peritoneal membranes. They were then cut below the 
zyphoid process to expose the diaphragm and visceral organs taking care not to lacerate any 
vasculature. Then both lateral aspects of the rib cage were carefully cut in a caudal to 
rostral direction up to 2nd rib avoiding damage to the lung, heart and mammary arteries. The 
thoracic organs were exposed. Dissection-pan was then oriented so that the apex of heart 
was at 6 o’clock and the aortic outflow at 12 o’clock position. Using thumb forcep, the 
right ventricular free-wall was visualized delineating the darker, blood-filled-coloration of 
right ventricle and the redder, muscular-coloration of left ventricle. Right atrial-chamber 
was lacerated with scissors and carefully (but quickly) inserted with 25 gauge hypodermic 
needle attached to the perfusion set. The needle was angled at 2 o’clock position. Slowly 
the forcep grasp was released from the right ventricular free-wall to begin perfusion by 
setting the pump at a rate of 1 drop (50µl) per minute. Blood and phosphate buffered saline 
(PBS) (0.01 M PBS containing 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 2 mM 
KH2PO4, pH7.4) effluent flow from the right atria laceration was allowed to drip into the 
dissection pan. As the perfusion takes place, the heart and liver get blanched due to blood 
being replaced with buffer. Upon completion of saline perfusion, the motor was switched 
off and buffer replaced with the fixative.  
2.3.1. Fixation, cryopreservation and sectioning  
Freshly prepared 4% PBS buffered paraformaldehyde (PFA) was used for tissue fixation.  
During perfusion visualization of extremities for evidence of tremors resulting from the 
aldehyde-crosslinking within the nervous tissue and muscle indicated appropriate perfusion 
within the circulatory system and, thus, a good fixation was ensured. Following perfusion-
fixation, the brain along with ON was isolated and the brain was allowed to be further fixed 
in the same fixative for 12-24 hrs at 4ºC, whereas the ON was fixed for another 45 minutes 
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only (room temperature). Thus overfixing of axons was avoided. The tissue was then 
cryoprotected by transferring into 30% sucrose and allowed to sink. It was then embedded 
in cryomatrix (Tissue-Tek), mounted on Leica cryostat platform and 10 or 30µm ON/brain 
sections in the requisite plane was obtained. They were placed on superfrost charged slides 
(VWR # J1800AMNZ / FisherBrand) or suspended in PBS as per the experimental 
requirement. The sections placed on super-frost charged slides were allowed to dry and 
then stored at -70ºC until used. 
2.3.2. ON preparation for transmission electron microscopy (TEM) 
 
In case of TEM samples, the transcardial perfusion was performed as described above 
(Section 2.3), but 0.1M Sorensen’s sodium phosphate buffer (0.1M Na2HPO4.2H2O + 0.1M 
NaH2PO4.2H2O, pH7.2) containing 1.5% glutaraldehyde was used for draining the blood 
and care was taken to maintain the temperatures at 37ºC during the entire process. This 
buffer was perfused for 2-3 minutes at a rate of 3 drops (100-150µl) per minute. Then it 
was replaced by a freshly prepared fixative solution (2% PFA + 2% glutaraldehyde made in 
0.1M Sorensen’s phosphate buffer). These buffers were prepared in 13 mega ohm deionised 
water. A volume of 125ml fixative was perfused to drain out the blood completely which 
ensured adequate and ideal fixation as it was evident by the stiffening of the entire animal. 
Then the ON was dissected and saved in the same fixative at 4ºC until it was sent to 
University College of Dublin, Electron Microscopy facility, for further processing and 
TEM.  
 
2.4. Brain histology  
 
2.4.1: Luxol fast blue (LFB) staining.  
 
The cryosections were rehydrated in PBS and cryomatrix was washed thoroughly. The 
sections were then passed through a series of ethanol: 70%, 90%, and 100%. Dehydrated 
tissue was then processed for a de-fat step by keeping it immersed in chloroform: ethanol 
(1:1) overnight. This was followed by a wash in 95% ethanol, and transferred in 0.1% luxol 
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fast blue (LFB) stain in 95% acidic ethanol (100 ml 95% ethanol + 5 ml glacial acetic acid) 
at 50-60ºC temperature. Time required for the stain to develop was manually monitored 
under light microscope to acquire the desired intensity. Excess stain was washed in 95% 
ethanol. Then the stain was cleared in, 0.05% lithium carbonate followed by final 
dehydration in 95% and 100% ethanol. Before mounting the sections with DPX mounting 
medium, they were dipped in xylene and allowed to dry. LFB is a sulfonated copper 
phthyalcyanine type of dye. It is a popularly used histo-pathological stain for demonstrating 
normal myelin. This dye is insoluble in water and hence, used as solutions of alcohol or 
other moderately polar liquids. It stains phospholipids, and the hydrophobic domains of 
protein molecules. Cryosections (30µm) were processed for LFB histology. A minimum of 
five animals from each T and UT group were analyzed. Mid-saggital sections were 
processed from a collection of serial sections. The myelinated tracts or portions after 
staining appear blue which can be easily distinguished under the microscope. The staining 
solution was applied long enough so that almost everything in the section became colored 
followed by a differentiation step. This “background” coloring was removed by subsequent 
washing in lithium carbonate. This is a preferred way of performing LFB histology, as 
inclusion of the “differentiation” step leaves the stain only in the myelin sheath and rules 
out any kind of false staining. Further care was taken to avoid any kind of discrepancy that 
may arise in different lots due to the processing procedure; and hence, all the sections were 
handled simultaneously under the same conditions. 
 
2.4.2. Cresyl violet staining.  
For cresyl violet (CV) staining the fixed tissue samples which were saved on superfrost 
slides were rehydrated in distilled water to get rid of the cryomatrix. They were then placed 
in 0.1% CV counterstain. A few drops of glacial acetic acid were added to the stain just 
before use and filtered on whatman paper to get rid of the crystallized precipitates. The 
stain was manually monitored under the microscope. When the desired intensity was 
achieved, it was dehydrated by passing on to ethanol series followed by a clearing step in 
xylene. This preparation was then mounted using DPX mounting medium. The slides were 
allowed to dry appropriately, cleaned with xylene and used for bright field microscopy.  
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2.4.3. Toluidine blue staining and TEM processing.  
The PFA fixed nerve was further fixed in 1% osmium tetroxide for 2hr, and dehydrated. It 
was then stained with 1% toluidine blue made in 2% borate solution. The quality of fixation 
and gross morphology of ON was assessed on these 15μm cross-section preparations. Rest 
of the tissue was processed in graded ethanol, dehydrated and embedded in Epon resin. 
Ultra-thin sections (70nm) were cut in an ultra-microtome (Ultramicrotome, Leica 
Microsystems, Ireland) and contrasted with uranyl acetate and lead citrate, placed on grid, 
and imaged with an FEI Tecnai-12 electron microscope (Tecnai FEI, Oregon, USA). This 
was done under arrangements made for a service provided by University College of Dublin, 
Electron Microscopy Facility, Dublin, Ireland.   
2.5. Double immunohistochemistry  
 
In general double immunohistochemistry (IHC) involved: rehydration, washing off the 
cryomatrix, permeabilization and blocking followed by primary antibody incubation and 
then development of signals with flurophore-tagged secondary antibodies. When signal 
amplification was required, an intermediate step was included after the labeling with 
primary antibody wherein the samples were incubated with biotinylated secondary antibody 
followed by streptavidin-tagged fluorophore tertiary antibody. Alexa fluor® dyes -488, -
568 or -594 (Molecular Probes, Invitrogen, Ireland) were used to develop the fluorescent 
signals in green or red. Permeabilization step involved incubation with the requisite 
concentration of Triton- X100 in PBS (PBST) or blocking buffer. Usually the blocking and 
washing contained 0.1% PBST, but in case of Nav/Kv1.2 staining 0.3% PBST was used. 
Blocking was always maintained for at least an hour and, if longer blocking was required, 
the permeabilization was conducted as a separate step. The antibodies were usually diluted 
in the blocking buffer unless mentioned otherwise. A combination of monoclonal (mAb) 
and polyclonal antibody was used for double labeling. Usually the mAb was incubated 
ahead of polyclonal antibody. The primary antibodies were always incubated for 4-5 hrs at 
room temperature or overnight at 4ºC depending on each experiment. When the samples 
needed to be incubated simultaneously, for both primaries they were mixed and applied. If 
sequential development was required, as in case of signal amplification, the first primary 
 93 
was incubated for 4-5 hrs at room temperature developed by the flurophore and then kept in 
second primary overnight at 4ºC. The secondary and tertiaries were never incubated for 
more than 45 min to minimize non-specific binding. Along with this appropriate negative 
control were also processed. This required omission of primary/secondary/tertiary antibody 
depending on the experimental requirement/ design(s). Washes were 3 x 5min in between 
each antibody incubation step. Finally, Vectashield (Vector Labs, Peterborough, UK) was 
used for mounting the tissue samples and ProLong® Gold antifade reagent (Cat. no 
P36930, from Molecular Probes, Invitrogen, supplied by Bio-Sciences, Dun Laoghaire, 
Dublin, Ireland) was used to mount the ON axon preparation. The details of antibody 
dilution used in this study are provided in Table 2. For quantitative analysis, the samples 
under T and UT conditions were simultaneously processed.  
2.6. Microscopy and imaging   
This study involved three types of imaging as described below. During imaging the 
exposure time was kept the same for each sample in all experiments.  
Light microscopy: Bright field microscopy (Axioskop, Zeiss Germany fitted with a digital 
camera) was used to obtain DIC images. A single chip color CCD camera DP72 (Olympus) 
and Cell^F imaging software were used to analyze images and show loss of myelin 
following 8 weeks of CZ treatment. This entailed using the same exposure time and frame 
size for anterior commissure, corpus callosum and fornix imaging from LFB stained 
sections.  
Confocal microscopy: Micrographs were obtained by EC Plan-Neofluar 10X/0.30, EC 
Plan-Neofluar 20X/0.50 and EC Plan-Neofluar 40X/1.30 Oil objectives, using a laser 
scanning microscope (AxioObserverZ1, LSM710, Carl Zeiss, Germany). Field micrographs 
were obtained (10 or 20X objective) in epifluorescence mode (pinhole wide open). For 
confocal images, the pinhole was set to 1AU and for Z-stack images the section thickness 
was defined and a laser scan set up accordingly. Argon and Helium/Neon lasers provided 
the 488 and 568nm lines for excitation; the emitted signals were sampled in a frame mode 
at spatial resolution of 30 nm per pixel with 1.5 μs dwell time. An appropriate and standard 
excitation-emission spectrum was set up, using the “smart set up” option for the Alexa dyes 
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from Molecular Probes used herein. Alexa® 488, 568 and 594 had their excitation set at 
499, 579 and 591nm, with their corresponding emissions at 519, 603 and 618 nm. Usually 
images of the same pixel resolution and size were obtained in comparable frame for each 
experiment. 8 bit images were obtained from Zen 2008, Zeiss ObserverZ1, LSM 710. For 
intensity profiles, several selection tools were used to define the regions of interest (ROI). 
For instance “closed bezier” tool or any other appropriate tool as per the requirement was 
used to obtain the raw data.  
Transmission Electron Microscopy: FEI Tecnai-12 electron microscope (Tecnai FEI, 
Oregon, USA) was used at UCD EM Facility to obtain high resolution images; 16 bit 
images obtained were saved with the requisite scale bar.  
2.7. Scoring of demyelination  
 
Evaluation of demyelination status for brain regions employed blinded scoring by neutral 
observers. Images of the same magnification were obtained and the cerebellar nuclei 
(located in the cerebellar marrow) i.e., the lateral cerebellar nucleus (LCN), medial 
cerebellar nucleus (MCN), and interpositos nucleus (IN), or hippocampus or corpus 
callosum, were numbered and 5 to 10 independent and blinded readers scored these regions 
of interest (ROIs) against the UT sample which was processed simultaneously (Groebe et 
al., 2009). Five UT and CZ-treated mice samples were included with three sections (30μm) 
per animal. The blind observers were asked to score the LFB staining intensity in between 
0-5. This scoring allowed identification of demyelination. A score of five is equates to the 
myelin status of a mouse not treated with CZ, whereas zero is equivalent to full 
demyelination. So, a score of one or two meets 1/5th (~ 20%) or 2/5th (~40%) of fiber 
myelination. 
2.8. Densitometric mapping of images and analysis 
 
LFB-stained images were first converted into gray scale black and white format and then 
analyzed. Parallel images (30µm) corresponding to the same regions from both UT and T 
group were traced to define the ROIs and the intensity was measured using Zen 2008, Carl 
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Zeiss software. The background for each image was obtained by multiple sampling from 
the regions which were devoid of tissue boundary. This particular software returned the 
intensity signals as high numerical values for the blank regions. Lower numerical values 
were obtained for the defined ROI.  Three such images from each sample were analyzed to 
get an average value. The raw data obtained was normalized for the sampled background. A 
comparison of absolute value obtained from both groups has been used for data 
interpretation here. LFB and MBP stained tissue sections were analyzed in this manner. 
Fluorescence images for MBP produced direct signal read outs after the threshold cut-off, 
unlike the bright filed images for LFB. Zen 2008 software, histogram view function 
displayed the distribution of pixel intensities of defined ROI in addition to the summary of 
values in a tabular form. Co-localization data were also obtained from this software and the 
values obtained as Pearson’s correlation coefficient. This selection provided the 
information of intensity distribution within the co-localizing region. Scattergram was used 
to define the threshold for co-localization analysis.  
 
Alternatively, Image J (NIH) software was employed for densitometric analysis and is 
specified in the subsequent section. The TEM images were analyzed using the standard 
methods of this software. The scale was set by following the steps “Image menu-scale-
define the length”. Any measurement made after this adjustment generates the result in a 
separate window which was copied and saved on an Excel sheet for further analysis. Free 
hand line and polygon tools were used here to define the ROI. This works in such a manner 
that larger values were obtained for high intensity signals and the background was lower 
relative to signal. So, it provided a direct read out of the visual impact of an image, whereas 
it was reverse in case of ZEN software for bright field images. 
 
Length and area measurements were collected using either of the two softwares from pre-
scaled images.  
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2.9. Affinity chromatographic purification of antibodies specific for Kv1 α and β 
subunits 
 
Polyclonal Kv1α- and β subunit antibodies (Scott et al., 1994a, Scott et al., 1994b) were 
affinity purified on a 1ml column of protein A/G-sepharose fast flow (Sigma). A 1 ml 
column was prepared. The column bed was calibrated in methanol, washed with purified 
water several times (5ml volume) and then equilibrated using 20mM sodium phosphate 
buffer pH 7.4. The buffer was allowed to stand for 10-15 min taking care that no air bubble 
was trapped within. It was again washed with 5ml sodium phosphate buffer. 500µl of 
Kv1.1, 1.5 and 1.2 (RCK (rat cortex K+ channel) 1, 2 & 5) or Kvβ antibodies to be purified 
was applied on to a column. The crude serum and Sepharose beads were mixed properly 
before allowing it to stand. It was then, allowed to settle for 10min and washed with 
sodium phosphate till the optical density for a 280nm fraction was less than 0.05. After re-
equilibration of the column, the antibodies were eluted with 0.1M glycine pH 3. 1ml 
fractions were collected in each tube containing 100µl of 1M Tris HCl, pH 9 for 
neutralization. Absorbance was read at 280nm. Fractions containing antibody were pooled 
and dialyzed for 24 hours against 5 liters of PBS. The column was re-equilibrated after use 
with PBS. Purified antibodies Kv1.1 and Kv1.6 produced non-specific bands whereas RCK 
5 / (mAb5) / (Kv1.2) (McNamara et al., 1993, Muniz et al., 1992) and guinea-pig β subunit 
antibodies showed excellent reactivity in Western blots (Lab data, C. Sidera’s  Thesis, 
1999). 
2.10. Extraction of proteins from ON  
 
Tissue homogenization and protein extract: Mice were anaesthetized (Section 2.2) and 
the ON dissected out. A T 10 basic ULTRA-TURRAX® homogenizer was used to 
homogenize the nerve in 500µl of homogenizing buffer. This contained 0.32M sucrose, 
20mM Tris-HCl, 2mM ethylenediamintetracetic acid (EDTA), 0.5mM ethylene glycol bis 
(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA), 1mM Sodium orthovanadate, 
50mM Sodium pyrophosphate decahydrate, 1mM Phenylmethylsulfonyl fluoride (PMSF), 
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50mM sodium fluoride, and 1X protease inhibitor  cocktail (Sigma# Catalogue no: S8830).  
The resultant homogenate was centrifuged at 1000 x g for 10 min to remove nuclei and 
debris. The supernatant was then recentrifuged at 45,000 x g for 1hour to pellet the crude 
membranes.  
 The resultant membrane obtained was resuspended in a solublization buffer 
containing 20mM Tris-HCl, 2mM EDTA, 0.5mM EGTA, 1mM sodium 
orthovanadate, 50mM sodium pyrophosphate decahydrate, 1mM PMSF, 50mM 
sodium fluoride, 1X protease inhibitor  and 1% Triton X-100 (Utsunomiya et al., 
2008). 
 For obtaining total protein, the first step was excluded and the pellet obtained after 
homogenization was solubilized by including 1% Triton-X 100 in the buffer.   
 For the preparation of cytoskeletal protein which mostly remains in the insoluble 
fraction of the homogenate the dissected ON nerve was placed in a BUST buffer 
(Xu et al., 1996), containing 25mM phosphate buffer pH 7.2 , 1mM EGTA, 1% 
SDS, and 1mM PMSF and homogenized. The homogenate was allowed to stand for 
10-15 min at room temperature, subjected to high speed centrifugation and the clear 
supernatant was used for protein quantification.  
 
All these protein preparations were performed as per the experimental requirement and 
aliquots saved at -70ºC until used. A separate aliquot was saved for BCA protein 
quantification. BCA assay (Pierce kit) was performed as per given protocol of the 
manufacturer. Absorbance (562nm) was obtained using a plate reader. A representative 
standard curve for BCA is shown in Figure   16.  Regression values for all the preparations 
were maintained above 0.9.  
 
2.11. SDS-PAGE and western blotting   
 
SDS-PAGE and protein transfer: Solubilised ON membrane was resolved by SDS-
PAGE, using precast 12% or 4-12% NuPAGE® Novex® Bis-Tris gels from Invitrogen. 
Samples were prepared in NuPAGE®LDS (Lithium dodecyl sulfate) sample buffer by 
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heating at 95-100ºC for 5 min. The gels were run in MOPS buffer (50 mM MOPS, 50 mM 
Tris base, 0.1% SDS, 1 mM EDTA, pH 7.7) at 90 mV till the protein migrated into the gel, 
following which it was allowed to run at higher voltage (120 mV), maintaining the entire 
process at 4ºC. In general, the resolved proteins from the gels were then transferred onto 
polyvinylidine difluoride (PVDF; Millipore) membrane for 45 min at 19V in a trans-Blot 
SD cell (Bio-Rad).  25 mM Tris, 192 mM glycine, 10% methanol was used for transfer 
buffer. Use of 10% methanol provided good transfer for mid-range protein, whereas for 
lower kD protein, a better transfer was achieved by using 20% methanol. For 
immunoprecipitation experiments 60mM Dithiothreitol (DTT) was included in the sample 
buffer.  
 
Blocking and antibody treatment: The PVDF membranes were blocked with 2-5% non-
fat marvel milk in TBST for an hour.  The membrane was cut out according to the loaded 
sample and incubated in separate tubes containing the requisite IgG overnight at 4ºC or 2-4 
hrs at room temperature. After antibody treatment, the blots were subjected to TBST 
washes (15 x 3 min). 
 
Detection of immuno-reactive bands: Proteins of interest were detected using anti-mouse 
secondary antibodies conjugated with horse-radish peroxidase (1:10,000; Jackson 
Laboratories), in combination with enhanced chemiluminescence (ECL) detection 
(Millipore) system. Due to the known presence of avidin in milk, 2-5% BSA fractionV 
blocking in TBST (0.2M NaCl, 50mM Tris-HCl, 0.5% Tween 20, pH 7.4) was used when 
signal amplification with biotinylated secondary was employed. After blocking with BSA 
these blots were treated with biotinylated secondary antibody, washed (15 x 3 min) and 
followed by treatment with high sensitivity streptavidin conjugated to horse-radish 
peroxidase (1: 80,000, Pierce Protein Research Products) for 30 minutes. Incubation with 
secondary and tertiary antibodies never exceeded 45-60 min in order to minimize non-
specific binding. After this the blots were washed (15 x 3 min) in TBST, exposed to the 
ECL reagent (Millipore) for 30 seconds only and imaged in the G-box attached with a CCD 
camera.  
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Use of UC Davis/ NIH NeuroMab Facility monoclonal antibodies, in conjunction with 
biotinylated secondary for signal amplification produced some background. Hence the 
stringency of washing buffer (TBST) was increased by raising the concentration of NaCl 
from 100 mM to 500 mM in the washing buffer. In order to confirm the specificity of the 
IgGs, a preadsorption control was set up by incubating the antibody solution with excess of 
the peptide used for its generation. The pre-adsorbed antibody did not produce any signal. 
In this case rat brain, membrane preparations were used as positive control. Collectively 
this allowed identification and elimination of non-specific bands. Thus only specific bands 
within the predicted protein size range were ensured to be included for quantitation. Cases 
where a non-specific band was obtained due to the use of biotinylated secondary and their 
size coincided with the protein of interest, no primary negative control was included in each 
experiment to eliminate such ambiguity. Further precaution was maintained by considering 
the protein bands only within a linear loading range for quantification. The experimental 
proteins were normalized against α-tubulin, wherever suitable. Densitometric analysis was 
performed using ImageJ software (NIH). The molecular weights of the protein bands 
obtained from Western blot (below) were calculated by semi-log plot analysis or GeneTool 
Software from Syngene, Cambridge, UK.  
 
2.12. Immunoprecipitation (IP), co-IP and sequential-IP 
 
Immunoprecipitation experiments were employed to demonstrate α-subunit interaction(s) 
and it involved co-IP and sequential-IP from solubilized protein preparations. Kv1 
polyclonal antibody (1µg antibody / 3µg of protein) for the α-subunit of interest was 
incubated with 45μg of solubilized ON homogenate so that the antibody bound the protein 
in solution. Incubation was maintained at 4ºC for 4 hrs or overnight under gentle agitation. 
The antibody/antigen complex was then pulled out of the sample using protein A coupled 
agarose beads. This physically isolated the Kv1 protein from the rest of the sample. The 
specificity of these antibodies was determined by setting up a preadsorption control with 
1µg antibody / 3µg of glutathione- S- transferase (GST) fusion protein against which the 
antibody was developed.   
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In order to prepare the slurry, protein-A Sepharose® 4B, Fast flow beads from 
Staphylococcus aureus, aqueous ethanol suspension (from Sigma) was added to 1ml PBS 
for one hour and rinsed in PBS twice before use. The supernatant was removed and 400 μl 
of PBS with protease inhibitors was added. This slurry was stored at 4°C until used for few 
days. For longer storage, the beads were saved in PBS with 0.02% sodium azide at 4ºC. 
When precipitating, the protein complex was mixed with the slurry (70-100 μl of the beads) 
and maintained on ice for centrifugation at 1000 rpm, for 15 min at 4ºC. The supernatant 
was removed and beads washed in PBS buffer three times (each time centrifuging at 4°C). 
Finally, 25-50μl of 4X LDS loading buffer supplemented with 60mM DTT was added to 
these beads and boiled at 95-100°C for 5 minutes to denature the protein and separate it 
from the protein-A Sepharose. Supernatant from these IP-experiments were also included 
for western blot analysis. In cases where SDS-PAGE analysis was not performed 
immediately, samples were frozen (-20ºC) at this stage. 
2.13. Quantification of Kv1 channels from ON membrane extract by immuno-
fluorometric titration 
 
Quantification of Kv1 protein using Western blot analysis remained woeful largely owing to 
two facts. Firstly, a large quantity (at least 15µg per well) was required for detection of Kv1 
on Western blots, but the protein yield from an ON was miniscule. Secondly, individual 
response associated with variability in CZ treated mice had to be ruled out.  Hence an 
immuno-fluorometric titration assay, employing chemiluminescence detection was devised 
to overcome these issues. Serial dilutions of GST fusion tagged peptide for Kv1.1, 1.2, 1.4 
were used to generate a linear standard plot with regression values above 0.9; and the ON 
protein samples from treated and untreated conditions were quantitated against the standard 
value. For each experiment conducted triplicate samples were included and the averages 
considered for quantification. The linear range was also considered by setting up an initial 
experiment using varying concentrations of the analyte (ON membrane extract). The 
precision and accuracy of the assay was established for specificity in terms of the nature of 
the analyte and concentration to be measured.  
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Briefly, the free antigen (solubilized ON protein from treated and untreated mice) and Kv1 
antibody were incubated overnight at 4ºC to form antigen-antibody complex and then these 
complexes were allowed to bind the antigen-coated surface (solubilized ON protein) in the 
assay plate. The unbound antibody-antigen complex was washed off before adding enzyme-
linked (alkaline phosphatase) secondary antibody against the rabbit polyclonal primary 
antibody.  CSPD (Disodium 3-(4-methoxyspiro 1,2-dioxetane-3,2'-(5'- 
chloro)tricyclo[3.3.1.13,7] decan-4-yl) phenyl phosphate) substrate was then added and 
antigen concentration determined by the signal strength elicited due to enzyme-substrate 
reaction as relative luminescence units (RLU) per second, by comparing it against the 
known values obtained using a standard. These readings were obtained by Gen5 software 
from BioTek (Bedfordshire, UK). A standard optical sensitivity and filter setting 
recommended by the software was used to measure the RLU. The background was 
eliminated by subtracting values obtained from the wells which went through all stages of 
washings and incubation and were devoid of samples.  
 
Protocol details: 
 
1. Opaque white walled 96 well plates were used to perform this luminescence assay. 
2. ON homogenate (0.1µg protein/ml) diluted in PBS was used to coat the plate, overnight 
at 4ºC before washing (3 x 10 min) with PBS (200µl). 
3. Then it was blocked with 2% skimmed milk in PBST (0.1% Tween, filtered) 
4. Preincubated overnight peptide with antibody (3µg peptide/µg antibody, Kv1.1, 1.2 and 
1.4) was serial diluted, 0.02, 0.04, 0.09, 0.18, 0.37, 0.75, 1.5, and 3µg and plated in 
duplicate wells to generate a standard curve (100 µl volume)  
5. Correspondingly 3µg of unknown protein from ON was incubated with rabbit polyclonal 
Kv1.1, 1.2 or 1.4 antibodies overnight. The antigen-antibody complex was serial diluted and 
plated in duplicate wells besides the standard.  
7. This was allowed to stand for 3-4 hrs at room temperature. 
8. It was then washed PBST (3 x 10min) before incubation with goat anti-rabbit alkaline 
phosphatase antibody (1:10,000, Sigma-aldrich, A9919) for 1 hr at room temperature. 
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9. Washed with PBST (3 x 10 min). 
10. Washed with buffer (Tropix, Aalto Bio Reagents, Dublin 14, Ireland) 
11. CSPD (50µl/well) with Sapphire Substrate (Tropix reagent, Aalto Bio Reagents, Dublin 
14, Ireland) was added and the luminescence checked. 
The enzymatic dephosphorylation of CSPD by alkaline phosphatase leads to the metastable 
phenolate anion which decomposes and emits light at a maximum wave length of 477nm. 
The luminescent light emission was recorded using Gen 5 software attached to BioTek 
Luminometer, as described earlier, and the signals obtained. Six such experiments were 
averaged and a graphical representation from all these is presented.  
2.14. Proximity Ligation Assay (PLA)  
 
Duolink® in situ PLA™ Assay from Olink Bioscience, Sewden, is a PCR amplification 
based technique for detection, visualization and quantification of individual protein, protein 
modifications and protein interactions in tissue or cell samples prepared for microscopy. 
The target is detected using one or two primary antibodies. When two primary antibodies 
are used, they must have been raised in different species or modified with different haptens.  
In principle a pair of oligonucleotide labeled secondary antibodies (PLA probes) is 
expected to generate a signal only when the two PLA probes have bound to close proximity 
(approx. 40 nm (Yang et al., 2007b, Shafey et al., 2010) after the application of ligase 
enzyme. The sample locations where ligation could be achieved were further amplified by 
application of polymerase enzyme and then the signal from each such spot was detected by 
a fluorescent signal. Microscopic visualization of each fluorescent dot indicated the 
presence of protein interaction. In order to identify Kv1.1 interacting subunits a 
combination of the following antibodies were used: 
a) Kv1.1 containing subunits:  Polyclonal (rabbit) Kv1.1 raised against cytoplasmic or 
intracellular epitope and mAb Kv1.1 for extracellular epitope developed in mouse 
b) Kv1.1-1.2 interaction:  mAb Kv1.1 extracellular epitope (raised in mouse) and rabbit 
polyclonal Kv1.2 against cytoplasmic or intracellular epitope  
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Epitope No. of 
residues 
Peptide sequence 
Kv1.1 
(extracellular) 
191-208 ELKDDKDFTGTIHRIDNTC 
Kv1.1 
(intracellular 
C-terminus) 
416-495 HRETEGEEQAQLLHVSSPNLASDSDLSRRSSSTISK
SEYMEIEEDMNNSIAHYRQANIRTGNCTTADQNC
VNKSKLLTDV 
Kv1.2 
(intracellular 
C-terminus) 
417-499 YHRETEGEEQAQYLQVTSCPKIPSSPDLKKSRSAS
TISKSDYMEIQEGVNNSNEDFREENLKTANCTLAN
TNYVNITKMLTDV 
Kv1.4 
(intracellular 
C-terminus) 
589-655 PYLPSNLLKKFRSSTSSSLGDKSEYLEMEEGVKES
LCGKEEKCQGKGDDSETDKNNCSNAKAVETDV 
 
Table 1: Epitope sequences of Kv1.1, 1.2 and Kv1.4 antibodies used in PLA and 
fluorometric titration 
 
Briefly, the method involved sample (placed and fixed on superfrost slide, Section 2.3.1) 
incubation with primary antibodies that bind to the protein(s) to be detected. Incubation 
timings were same as used for IHC experiments. Hybridization of PLA probes, i.e., 
secondary antibodies conjugated with oligonucleotide required their addition and 
incubation at room temperature. PLA probes MINUS and PLUS used here at this stage 
indicated the complementary oligonucleotide sequence which was expected to anneal in the 
presence of hybridization buffer if they were in close proximity. Ligation of these two 
nucleotides was achieved using a ligase reaction. The ligation solution contained ligase 
which was added next for the two hybridized oligonucleotides to form a closed circle. Then 
these protein interactions were subjected to amplification. This was done by addition of a 
solution, consisting of nucleotides followed by polymerase treatment. The oligonucleotide 
arm of one of the PLA probes acts as a template,  for a rolling-circle amplification (RCA) 
reaction using the ligated circle as a template, generating a concatemeric (repeated 
sequence) product. The final step required detection, and for this a solution, consisting of 
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fluorescently labeled oligonucleotides, was added and the labeled oligonucleotides 
hybridized to the RCA product. The signal obtained is easily visible as a distinct 
fluorescent dot (excitation 598 nm /emission 634 nm) and it was analyzed by microscopy. 
For these experiments a negative control was used by omitting one of the primary 
antibodies, here to estimate the amount of background signal. A positive control using the 
standard specimen provided by the company was included to establish the validity of the 
technique employed. 
2.16. Neuronal Culture as an in vitro system for analyzing Kv1 expression 
2.16.1. Neuronal cultures  
Two types of primary neurons, namely cerebellar granule neuron and hippocampal neuron 
were cultured. Conditioned media from astroglial primary cultures and OLN 93 cell line 
(Section 2.16.3) was tested on hippocampal neurons. This required dissection of timed 
pregnant mice to obtain E18 embryos which were further dissected to isolate the brain and 
hippocampus, and cultured on poly-D Lysine coated coverslips. Cerebellar granule cell 
culture was performed on (postnatal day 1) P1 pups.  
  
2.16.2 Dissection of timed pregnant mice to obtain E18 embryos 
Pregnant mice (18 days) were anesthetized (Section 2.2), the abdomen was wiped off with 
70% ethanol and then cut open by grabbing the skin with curved forceps and cutting along 
the midline with scissors. Two cuts were made onto the sides and both horns of the uterus 
pulled out.  These uteri were then placed on to a 10 cm dish containing hanks buffered salt 
solution (HBSS). Using the tip of a scissors the embryos (E18) were removed, decapitated, 
and the heads placed in a fresh dish containing HBSS. Subsequent dissection was 
performed under a dissecting microscope (Vicario-Abejón, 2004), as described in Figure   
17. 
 
The dissected hippocampus of E18 pups was pooled (3 of them in this case) and minced 
using a fine scissor. It was then dissociated in 100µl trypsin. This was achieved by placing 
the trypsin containing tube was placed at 37ºC for 4 minutes in water bath and allowed to 
dissociate on its own. The tube content was then resuspended in dissociation medium 
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[(BME (B1522, Invitrogen) /MEM) with 10% fetal calf serum, 0.5% glucose, 1mM sodium 
pyruvate, 25mM glutamate, 1% penicillin-streptomycin solution (Sigma # P4333, 10,000 
units penicillin and 10 mg streptomycin/ml)]  and an even suspension containing cells was 
obtained. These evenly suspended cells were placed in 15 ml tube each containing 5 ml of 
dissociation medium, centrifuged at a speed of 1000 rpm at 22ºC for 5 min. The 
supernatant was discarded and the cells were re-suspended in another 5 ml of dissociation 
medium centrifuged as described above and discarded. These cells were then plated on the 
desired coated surface. Following 8-10 hrs of culture in dissociation medium, it was 
replaced with serum free media described as neuronal culture medium (Neurobasal with 
B27 supplement 0.5mM glutamax and penicillin streptomycin.), which had been 
conditioned with OLN-93 or astroglial culture for 24 hours. These were cultured for the 
requisite days in vitro (DIV) and then analyzed for the presence of Kv1 ion channels Figure   
18 employing immunohistochemical staining for Kv1 and neuronal marker β-tubulin III. 
For cortical neuron culture, the same procedure was employed except that tissue from 
cortex was used for seeding the cells.  
 
2.16.3. Culturing of OLN 93 cell line  
OLN-93 cell line is a rat oligodendrocyte precursor cell line received from, Department of 
Pediatric Neurology, University Children’s Hospital Carl Gustav Carus, University of 
Technology Dresden, 01307 Dresden, Germany. Growth medium consisted of high glucose 
DMEM medium, 5-10 % fetal bovine serum, and 1% (v/v) antibiotica/antimycotica, 5% 
CO2, 95% relative humidity and 37°C temperature. It required sub-culturing every ~ three 
days with trypsin/EDTA (3-4 min). The cells have a doubling time of 16-18 hours Figure   
19. 
 
2.17. CAP recordings and pharmacological analysis  
Mice were decapitated under deep anesthesia (Section 2.2). Brain with attached ON was 
extracted and immersed for 5 min in bubbled (95% O2, 5% CO2) ice-cold solution 
containing (in mM): sucrose, 75; NaCl, 85; KCl, 2.5; NaH2PO4, 1.25; NaHCO3, 25; CaCl2, 
0.5; MgCl2 4; glucose, 25, pH 7.3. The meninges of ON were carefully removed and the 
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brain was transferred and secured with tissue glue (with ON facing up) in the recording 
chamber attached to the stage of the upright Olympus BX51WI microscope of the rig. The 
distal end of the nerve was drawn into the suction electrode for stimulation (100 s pulse). 
Recordings of CAPs were made with low-impedance glass pipettes (10 μm tip diameter, 1-
3 MΩ input resistance) filled with artificial cerebrospinal fluid (ACSF) which was carefully 
inserted into the ON at close proximity to the chiasm under stimulation (1.0-1.5 
mA/0.03Hz). Recordings were made under continuous perfusion with bubbled (95% O2, 
5% CO2) ACSF containing (in mM): NaCl, 125; KCl, 3; NaH2PO4, 1.25; NaHCO3, 25; 
CaCl2, 2; MgCl2, 2; glucose, 25; pH 7.3 after at least 1h equilibration at 32°C. Analog 
signals were acquired continuously and amplified with EPC-10 USB amplifier controlled 
by Patchmaster 2.20 software (HEKA Instruments), digitized at 5-10 kHz and stored for 
off-line analysis (Clampfit 10.0; Molecular Devices, CA). For measurements of the 
refractory period, paired stimuli were applied at various inter-pulse intervals, and the 
maximum amplitude of the second response was plotted as a function of the inter-pulse 
interval. Peptide blockers stored at -20°C were thawed and added to the perfusion medium 
before use. 
2.18. Reagent suppliers   
DTXK was purified in-house; TsTX-K was obtained from Peptide International. Duolink® 
in situ PLA™ Assay Kit was purchased from Olink Bioscience, Sewden. Antibodies used 
were sourced from different vendors listed below (Section 2.20). All other reagents were 
obtained form Sigma-Aldrich, Ireland.  
 
2.19. Data and statistical analyses 
 
All the data were calculated and graph generated using Microsoft Excel software and 
presented as means ± S.E. or S.E.M. Student’s t-test was used to evaluate significance of 
changes and expressed as ‘ns’ p>0.05 (not significant), ‘*’ p<0.05, ‘**’ p<0.01, ‘***’ p< 
0.001, ‘***’ p< 0.0001.  
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2.20. List of antibodies  
 
 
Primary antibodies 
and Cat. No. 
 
Monoclonal (mAb) or 
polyclonal (poly) 
 
                Vendor 
 
IF 
Dilution 
 
WB 
Dilution 
     
Kv1.1  
Cat. No.73-007 
mAb (K20/78)  NeuroMab  1:10 1:10 
Kv1.2  
Cat. No. 73-008 
mAb (K14/16) NeuroMab 1:10 1:10 
Kv1.3  
Cat. No. 73-009 
mAb (L23/27) NeuroMab  1:10 1:10 
Kv1.4  
Cat. No. 73-010 
mAb (K13/31) NeuroMab  1:10 1:10 
Kv1.5  
Cat. No. 73-011 
mAb (K7/45) NeuroMab  1:10 1:10 
Kv1.6  
Cat. No. 73-012 
mAb (K19/36) NeuroMab  1:10 1:10 
Kvβ 1.1  
Cat. No. 73-018 
mAb (K9/40) NeuroMab  1:10 1:10 
Kvβ 1.2  
Cat. No 73-019 
mAb (K47/42) NeuroMab  1:10 1:10 
Kv1.1 extracellular 
Cat. No 73-105 
mAb (K36/15) NeuroMab  1:10 1:10 
Kv1.1  
Cat. No. APC 009  
 poly Alomone Labs  1 : 200 1 : 200 
Kv1.2  
Cat. No. APC 010  
mAb  Alomone Labs  1 : 200 1 : 200 
Kv1.4  
Cat. No. APC 007 
poly Alomone Labs 1 : 200 1 : 200 
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Pan Nav (SP19) 
S6936 
 poly Sigma-Aldrich  1 : 50 NA 
PLP 
Cat. No ab28486 
 poly Abcam 1 : 1000 1 : 1000 
CNPase  
Cat. No. C5922 
mAb   Sigma-Aldrich  1 : 1000 1 : 1000 
MBP (SMI -99P) mAb   Abcam 1 : 1000 1 : 1000 
β-tubulin III 
 Cat. No. T2200  
 poly Sigma-Aldrich  1 : 50 1 : 1000 
GFAP Clone G-A-5, 
G3893  
 poly Sigma-Aldrich  1 : 400 NA  
GFAP  
Cat. No. G9269 
 poly Sigma-Aldrich  1 : 100 1 : 1000 
Anti- APC 
 Cat. No.(Ab-7) 
mAb   Millipore  1:100 1:50 
Neurofilament 200 
Cat. No. N5389 
mAb   Sigma-Aldrich  1 : 400 1 : 500 
Phosphorylated 
neurofilament 
 (SMI 31) 
mAb   Abcam 1 : 1000 1 : 1000 
Dephosphorylated 
neurofilament  
(SMI 32) 
mAb   Abcam 1 : 1000 1 : 1000 
α- tubulin 
 Cat. No.ab8227-50 
 poly Abcam 1 : 1000 1 : 1000 
 
 
 
NeuroMab -- NeuroMab Facility, UC Davis/NIH 
Sigma -- Sigma-Aldrich Ireland Limited, Wicklow, Ireland 
Abcam -- Abcam, Cambridge, UK 
Alomone -- Alomone Labs, Ltd, Jerusalem, Israel 
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Millipore -- Millipore, Cork, Ireland 
mAb – Monoclonal antibody 
Poly – Polyclonal antibody 
 
Table 2: List of antibodies their suppliers and indicated dilutions used in this study. 
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Figure   16: Representative elution profile and Bicinchoninic acid (BCA) standard 
curve. 
 
A. Protein A affinity chromatography eluate showing peak fractions that contain purified 
RCKs represented in the elution profile. B. Graph representing a typical standard curve 
obtained for BCA assay and the regression formula used to calculate the protein quantity.  
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Figure   17: Method for dissection of E18 mice embryos and isolation of hippocampus. 
 
A. A pair of Dumont forceps was used to grasp the embryo head firmly to remove the skin 
and skull with another pair of forceps. The skull was removed beginning from the lambda 
and continuing forward to bregma. The tissue surrounding the head (arrowheads) was also 
removed. B. Caudal parts of the CNS, such as the cerebellum, pons, and cervical portions 
of the spinal cord, was then removed. With the ventral aspect of the brain facing up, the 
two hemispheres could be separated by moving the forceps through the midline. C. The 
septum and diencephalic tissue (thalamus and hypothalamus) of one hemisphere is 
removed (arrows) in the next step. The olfactory bulb (ob) is indicated. D. The 
hippocampus is visible as a slightly thicker portion lining the curved medial edge of the 
cortex (arrows). E. The hippocampus was dissected out by making a longitudinal cut 
through the border and the cortex. This could be done from either the ventral or dorsal 
side. Finally, the meninges and choroid plexus surrounding the hippocampus were 
carefully removed [Adopted from (Vicario-Abejón, 2004)].  
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Figure   18: Demonstration of absence of Kv1.1 and 1.2 channels from 8 DIV 
hippocampal neurons. 
 
Hippocampal neurons at 2, 4, 6 and 8 days DIV immunostained with β-tubulin III (green) 
and Kv1.1 or Kv1.2(red) to show the absence of these two channels until 9 DIV in culture. 
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Figure   19: Microscopic illustration of cells in culture. 
 
 
A. OLN 93 cells after 8 days in culture. The undifferentiated cells have a small cell body. 
When they get differentiated, the cell body becomes large as seen in the centre of the image 
(white arrow). The scale bar is 50µm. B. Cerebellar grannule cell and C. cortical neuron 
culture. Left hand image shows cerebellar granule neuron cultured and stained red for a 
neuron specific protein β-tubulin III (scale bar 20µm). Right hand image represents a 
bright filed image of cortical neurons in culture (scale bar 50µm). 
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CHAPTER 3 
 
CZ INDUCED CNS MYELIN LOSS, AND ITS RELEVANCE 
TO MS 
 
3.1. Introduction 
 
CZ-induced demeylination impairs oligodendrocyte-axon association. A substantial extent 
of variation in myelin loss can exist within CNS regions owing to different levels of 
susceptibilities. Similar clinical and paraclinical heterogeneity in MS pathology is also 
identified because of the polygenic and multifarious nature of this disease. Such diversities 
are considered as manifestations of time for clinical presentation and therapeutic responses 
(Lassmann et al., 2001, Lucchinetti et al., 2000, Gilmore et al., 2009). MS induction is 
complex which stems in several factors, individual responses, and differences in 
demyelinating pattern between subgroups. Furthermore, there could be indiscriminate 
amplifying factors for myelin loss. For instance, autoimmune antibody directed against the 
surface components of myelin or factors that impair metabolism of myelin-supporting 
oligodendrocytes.  Even though as a dogma demyelination is considered as loss of myelin 
from white matter tracts, but studies in past few years have shown that grey matter (GM) 
demyelination is not excluded in MS (Vercellino et al., 2009, Geurts and Barkhof, 2008). 
Gilmore et al., estimated significantly high levels of myelin loss from GM rather than WM 
in several anatomical sites (Gilmore et al., 2009). Additional complexity can arise owing to 
the nature of lesions which could be large, multifocal and with reactive glial scar formation 
(Lassmann et al., 2001). Irrespective of such facts, loss of myelin invariably affects 
myelinated axons, responsible for efficient saltatory conduction and important in neural co-
ordination.   
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Inclusion of CZ in mouse diet induces CNS demyelination within weeks (Blakemore, 1973) 
and  its withdrawal can produce nearly complete remyelination (Ludwin, 1980, Crawford et 
al., 2009). Even though the background for this model stems from studies of the toxic 
effects of this compound (Suzuki, 1969, Suzuki and Kikkawa, 1969, Venturini, 1973), in 
the past few years, this model has gained wide acceptance for studying demyelination and 
remyelination (Matsushima and Morell, 2001, Hoffmann et al., 2008, Koutsoudaki et al., 
2009, Crawford et al., 2009). CZ leads to loss of myelin within 5-6 weeks of oral 
administration, but it is possible to study the chronic phase by continued feeding (12-13 
weeks at 0.2% dose) in C57BL/6 mice (Mason et al., 2001, Hoffmann et al., 2008). The 
characteristics induced parallels type-III lesion features (Stidworthy et al., 2003) of MS. 
Mice treated with higher doses 0.5- 0.6% exhibit diffuse status spongiosus of the brain stem 
and midbrain (Suzuki and Kikkawa, 1969). CZ induces GM and WM (Koutsoudaki et al., 
2009) lesions similar to MS characterized by degeneration of oligodendrocytes  rather than  
by a direct  attack on myelin sheet (Kipp et al., 2009).  
 
CNS myelin loss in MS leads to sensory and motor incapacitation. Several types of studies 
on MS therapeutic strategies highlight a marked difference between CNS and PNS axonal 
features, creating a sizeable void in the present understanding (Smith et al., 2000), which 
continues to grow (Chomiak and Hu, 2009, Sperber et al., 2001). Even though pioneering 
studies (Moran and Mateu, 1983) in this field were based on peripheral nerves (Brismar and 
Schwarz, 1985, Sobko et al., 1998, Vabnick et al., 1999) and has significantly contributed 
to the understanding of mechanisms underlying demyelination, (Arroyo et al., 2001), it is 
imperative that CNS axon features need to be explored. A mere glimpse of the two systems 
provides sufficient reasoning for the existing gap. 
 
 For instance, the distance between successive repeats of myelin membranes (i.e., 
between the midpoints of two consecutive MDLs differ in these two systems. 
Additionally, CNS and PNS myelin shrinks differentially during EM sample 
preparation (Hildebrand, 1974, Waxman, 2005). These differences seem to reflect 
varied effects of organic solvents, preservatives and fixatives on the lipid content of 
myelin, highlighting their compositional diversity (Siegel, 2005). This in turn could 
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relate to differences in the membrane dynamics owing to characteristics associated 
with lipid rafts which are vital for the maintenance of membrane protein topology.  
 Structurally, myelinated CNS fibers lack a delimiting basal lamina. In cross 
sections, the string-shaped cytoplasmic domains of myelin sheath appear as inner 
and outer loops. In thin myelinated fibers, both loops are very small; but in large 
fibers, and all PNS fibers, the outer loop may include the myelinating glial cell 
soma.  
 The paranodal loops which represent expansions of MDL at the nodal end of each 
myelin lamella, attach to the axon. These dense lines in internodal parts of the 
myelin sheath are stacked in sequence one on top of the other (Figure   2B), which 
forms incisures of Schmidt and Lanterman in PNS but is usually found to be lacking 
in CNS axons (Waxman, 2005).   
 
The main objective of this study was to develop an in vivo model of MS with CNS 
demyelination features for evaluation of concurrent changes in axonal Kv1 channels. This 
chapter is focused in providing a description of the induction of myelin loss from the brain, 
detailing specific patterns of WM and GM. Histochemical techniques like LFB/CV or 
toluidine blue staining, in conjunction with sucrose density gradient ultracentrifugation 
analysis, IHC and Brightfield or confocal (Chapter 2) were employed to elucidate 
biochemical and morphometric features.  
 
3.2. Mild dose of 0.2% (w/w) CZ is suitable in terms of morbidity, weight loss and 
general behavior of mouse  
 
The protocol for inducing demeylination involved 8 weeks oral administration of CZ by its 
inclusion in chow feed (rodent diet) (Section 2.1) to effectively produce early ‘chronic 
phase-like’ features of the disease. In this study 8 week old young adult C57BL/6 male 
mice were fed 0.2% CZ (w/w) diet under the experimental condition (T); the controls (UT) 
received the same diet devoid of this additive (Section 2.1).  
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3.2.1. CZ feeding did not introduce any behavioral abnormality 
 
CZ-fed mice did not display any kind of gait abnormality, like splayed hind-limb or ataxia. 
No apparent vision associated defect could be observed.  Habituation behavior was   
normal.  However, after 3-5 weeks the group which received CZ-diet showed increased 
climbing activity. Occasional aggression during 4th week of induction was seen in both 
groups. Since no actual cause accountable to such a behavior could be traced, it was 
assumed to be a normal aggressive demeanor of C57BL/6 mice. Furthermore, no visual 
sign for anxiety was noticed, except as reported by Franco- Pons et al., 2007, which 
indicated reduced anxiousness owing to lower rates of defecation in the treated group. In 
essence no major behavioral change or morbidity, mortality or motor co-ordination defect 
(visual assessment) appeared during the course of 8 week treatment.  
 
3.2.2. Food intake is normal in CZ treated animals 
 
Even though ad lib food and water were provided, the respective food intake for the control 
and CZ-treated group was 3.65 ± 0.8 and 2.7 ± 0.2 g/day (data is represented as SD). In 
spite of lower intake by the experimental group, differences were never significant (p=0.10, 
n=4) during the entire course of treatment. Minimum and maximum intake was recorded as 
0.4g, and 8g in the both case. Since the average intake was within accepted limits, this 
could not be interpreted as loss of appetite (anorexia) due to CZ. Individual feeding pattern 
varied a lot displaying peak differences at the fourth week. The disparity in food intake did 
not exceed 2.2g. However, this difference gradually waned off in the following weeks and 
both of the groups displayed a similar feeding pattern.  
 
3.2.3. Concurrent body and brain weight gain during CZ-feeding 
 
During 8 weeks of treatment mice from both groups gained an average 10g body weight, 
and the increase was proportional to their feeding pattern. As described in earlier section, a 
corresponding discrepancy was noticed between 3rd -4th week of CZ feeding. They 
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exhibited a lower weight gain (5-7%) in between 2nd to 5th week with an increased disparity 
of (7-10%) during last three weeks. After 8 weeks (T1) of CZ treatment (end-point) body 
weight was 9.2 ±0.3 % lesser in the treated group relative to controls (n = 20). An 
additional week of CZ administration i.e., 9 weeks (T2) resulted in further increase in this 
disparity (13±0.23%). They differed significantly for T2 (p>0.01) but not for T1 (p= 0.31) 
Figure   20A). This discrepancy accounted for 50% and 30% weight gain following 8 
weeks in the normal and CZ-fed mice. Overall, the experimental group exhibited lower 
weight gain at the end of treatment. 
 
Does this mean that brain weight is also affected? In order to assess this briefly the wet 
weight of a dissected brain was recorded and compared to the corresponding body weight 
of that particular animal. Even though brain weight of treated group exhibited a decrease 
(Figure   20B), after normalizing them to the body weight, it revealed a non-significant (8.4 
± 0.01% g, n=8, p=0.40) difference. These brain weights were further co-related to myelin 
loss induced by CZ (described in a later section, Section 3.3).   
3.2.4. Increased variation in body weight gain response in post 8 week CZ treatment 
 
Variability of weight gain depends on the severity of demyelinating changes present in an 
individual mouse undergoing CZ treatment (Suzuki and Kikkawa, 1969, Stidworthy et al., 
2003). Collectively, if the individual responses exhibit high variability their suitability for 
experimental use would be low. Body and brain weight scatter plot analysis provided an 
insight into such a deciding factor before commencing further analysis. The body wt. vs. 
brain wt. data points cluster closely (Figure   20C) for 8 week treated group (T1) indicating 
low variability. Extending the treatment to a longer period (T2, 9 week) exhibited an 
obvious lower clustering and reduced overlap in this analysis. This was reflected by an 
equal co-relation (R2) values for the control groups after 8 or 9 weeks, but CZ-fed groups 
showed higher 0.21 co-relation  at 8 week relative to 9 week 0.11 (n=20), indicating 
increased variation. On the basis of these confirming observations during the course of 
treatment, T1/8 week CZ-feeding was considered an appropriate time point for establishing 
the demyelinating features. 
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3.2.5. Seizure is induced during anaesthetization in the treated group 
 
Throughout this study even though no overt behavioral symptom was exhibited during the 
entire course of CZ-feeding (Section 3.2.1), a mild seizure activity (Supplementary, 
movies) was noticed after the administration of commonly used anesthesia drugs namely, 
Ketamine (80-120mg/kg) / Xylazine (100mg/kg) or pentobarbital (Euthatal 200mg/kg). 
Most of the experimental CZ-fed mice, 15 out of 20 (~ 75%) showed an induced seizure 
activity. Interestingly, some (2 out of 10) mice exhibited greater extent of seizure, than the 
recorded video presented here. The control group which did not receive CZ had no such 
effect during anaesthetization. Apart from this no activity was noticed in response to startle-
induced stimulations like handling, opening of the cage lid, or flashes of light. This was 
interesting as Hoffman group, noticed clinical seizure employing EEG/video after 12 weeks 
CZ-feeding and a chronic demeylination response to different types of startle-induced 
stimulations was concluded. The earliest response noted by that group was starting 9 weeks 
(0.2% CZ diet) (Hoffmann et al., 2008).  Unlike Hoffman, in this study, a seizure activity 
was noticed after 8 weeks CZ (0.2%) feeding in spite of no obvious sign demarcating 
neurological deficit.  
 
3.3. Loss of brain myelin content is eminent after 8 weeks of CZ treatment  
 
CZ fed mice was expected to have induced CNS demeylination; hence, brain myelin loss 
was evaluated. Even though this can be measured in several ways, herein standard method 
of differential sucrose density gradient ultracentrifugation (Norton and Poduslo, 1973) was 
employed to obtain total myelin content and examine the myelin dry weight (Sperber et al., 
2001) as a first step towards estimating the myelin loss. Mice from both groups were 
anesthetized, their brain dissected, and forebrain and total brain defined by coronal cuts 
(Section 2.2, Figure   20D) and weighed. Parts excluding the olfactory bulb and distal to 
the cerebellum was considered as total brain and forebrain defined by excluding the entire 
cerebellum. Myelin obtained from the interface of sucrose gradient was used for 
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quantification. Significant loss of myelin was observed in the treated group. The myelin 
content was normalized against the brain weight of each animal. This corresponded to 
75.55 ± 6.76% and 55.78 ± 2.4% (p= 0.02, 0.02 n=3,) for total brain and forebrain in CZ 
treated group, when the control was expressed as 100 (mg dry wt)/ (wet brain wt) (Figure   
20F). This reflects a notable reduction of 24.45± 6.7 and 44.22± 2.4% in these two parts of 
the brain. As is evident here, forebrain alone contributes to a larger amount of myelin loss 
accounting for CNS demyelination.  
 
Biochemically, demyelinating changes may involve altered forms of protein (Kim et al., 
2003), lipid (Wheeler et al., 2008, Saher et al., 2005) and carbohydrate moieties 
(glycolipid) (Tomlinson and Gardiner, 2008) which, in turn, would affect protein 
complexing/association with other protein(s). For instance, the myelinoid bodies reflect 
catabolic turnover resembling degraded myelin fragments formed during wallerian 
degeneration (Waxman, 2005) due to the acid phosphatase activity of surrounding 
astrocytes and microglia.  Participating calpains of the degrading myelin proteins during 
degeneration, might be present in the floating fraction (FF) of the myelin (Section 2.2) 
obtained by sucrose density gradient ultracentrifugation. FF is highly enriched in myelinoid 
bodies, which can be obtained from the CNS pathological tissue (Waxman, 2005). 
Interestingly, similar FF was noticed in myelin preparations from CZ-treated samples. Mass 
spectrophotometer analysis of such fractions could be revealing but it remained beyond the 
scope of present interest. It had been impossible to extract the myelin content of an ON at 
sucrose interface, owing to its very small dimension relative to total brain. However, 
following observations on myelin membrane features of ON axons (Chapter 4, Section 
4.3), it was of interest to analyze the myelin content in subsequent section 4.6, hence, 10 
ONs were pooled together for such extraction. Efforts to analyze the myelin loss from 
cerebellum also remained unsuccessful. 
3.4. Anatomically CNS demyelination features regional variation in myelin loss  
 
The distribution, nature and extent of CZ-induced myelin loss is anatomically variable 
(Groebe et al., 2009, Koutsoudaki et al., 2009) as in human (Lassmann et al., 2001, 
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Lucchinetti et al., 2000). Hence, in order to validate the model for MS associated 
demeylination it was imperative to (Section 1.17 and 1.18) ensure a consistent and 
reproducible demyelinating pattern (Altmann and Boyton, 2004, Schmandt et al., 2006) of 
axon rich CNS tracts. Even though several morphological assays for estimating the 
myelination status in discrete brain regions exists, here in order to identify anatomical 
myelin loss Luxol Fast Blue stain (LFB) histology (Deloire-Grassin et al., 2000, Merrill, 
2009) which works via an acid-base reaction was used. This allows semi-quantitative 
evaluation of myelin status by subjective (but observer blinded) scale. Cresyl violet (CV) 
and LFB stain were collectively used to define the ROIs (Figure   20E). Mid-saggital 
sections (30µm) from the brain of both groups were used. Additionally, MBP 
immunohistochemistry (IHC) was included to estimate GM demeylination of hippocampus. 
Even though these techniques suffer from several limitations due to the fact that lipid debris 
from degraded myelin gave a positive signal, these microscopic methods along with 
myelination (histological) scoring (Groebe et al., 2009) and densitometric profiling have 
provided ample evidence to establish CNS demeylination in cerebellum, hippocampus and 
corpus callosum (CC). However, the analysis of ON axo-myelin pattern had to be 
established using ultrastructural TEM analysis (Chapter 4).  
 
3.4.1 Deep cerebellar nuclei is severely demyelinated by CZ treatment  
 
Total brain myelin content exhibited lower loss relative to the forebrain, indicating a 
differential impact on parts of the brain. Cerebellum is well known to be a part of the 
pathological processes associated with demyelination in MS (Gilmore et al., 2009, 
Kutzelnigg et al., 2007) and animal models as well (Crawford et al., 2009, Groebe et al., 
2009, Shields et al., 2012). So in order to gain an insight into the effect at a cellular level 
myelin loss in cerebellum after 8 weeks of CZ-treatment was evaluated. The rostro-caudal 
and medio-lateral peduncle of cerebellum identified in CV stained mid-saggital sections 
(Figure   21A, B) and parallel LFB staining were used to analyze the effect on WM and 
GM regions. The molecular layer (ML), granular layer (GL), pyramidal layer (PL), and 
WM layers of the cerebellar cortex (CCx) as well as the cerebellar marrow (CM) could be 
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distinguished. CM of the cerebellar peduncle containing the three deep cerebellar nuclei 
(DCN) namely, lateral (LCN), medial (MCN), and interpositus nucleus (IN) were assessed. 
The WM which is rich in myelinated axonal tracts appeared brownish red; whereas the GM 
with larger cellular population in ML, GL, and PL were purple in CV stained preparations 
(Figure   21A, B). LFB stained myelinated tracts were prominently blue colored structures 
of CM and WM tracts of the CCx folia across the entire cerebellum including the anterior 
to posterior lobe (Figure   21C, D). CZ-treatment for 8 weeks resulted in a massive and 
evident loss of myelin from the CM as LFB stained fibers diminished in these samples.  
Entire DCN in the cerebellar peduncle region and its three nuclei namely, LCN, MCN, and 
IN cease to stain blue due to myelin deprivation (Figure   21 C, D, E, F, double black 
arrow) in the treated group. Interestingly, the surrounding area of the cerebellar nuclei was 
not much affected. The myelin sheets in the CCx and distinct cellular layers the ML, GL 
and PL did not reveal any change in myelination (Figure   21 C, D red arrow).  Blinded 
quantitative histological scoring of LFB stain intensity in the entire cerebellum on a scale of 
1-5 was performed by 10 neutral observers. According to this assessment, the myelin status 
in the entire cerebellum was significantly reduced (Figure   20G) (p>0.001, n=10). 
 
Densitometric profiling of the above-described ROIs within the cerebellum was adopted to 
investigate the difference between WM and GM subdomains. The average data obtained 
from 5 ROIs defined in 3 images of each brain sample was normalized for the background 
(density of regions without tissue) (Section 2.8). This approach provided evidence of 
highly significant (p>0.001, n=3) loss of myelin in the deep cerebellar nucleus only (Figure   
20H). Rest of the regions namely the WM of CCx (foliar structure), and GM of ML and GL 
also showed a minor, non-significant decrease in myelin. Thus, it is concluded that post 8 
week CZ-treatment, CCx of the cerebellar folia remains resistant to WM or GM 
demeylination. The GL and ML are not susceptible to myelin loss as per this method, but 
there is a drastic deprivation of myelin from the CM depleting it from the entire DCN.  
 
Differential demyelinating effect on the rostral or caudal cerebellar cortex of CZ mice 
(Stidworthy et al., 2003) may lead to varied symptoms as found in human (Gilmore et al., 
2009).  Herein, demeylination was assessed for the entire cerebellum. Saggital sections at 
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an interval of 500µm from the medial longitudinal fissure until the lateral edge i.e., 3mm 
away were analyzed. No difference in the pattern extending from the medial to lateral 
position was observed in the treated group. It is therefore, concluded that after 8 weeks of 
CZ feeding, entire cerebellar peduncle extending from i.e., latero-central to the rostro-
caudal end is uniformly demyelinated.  
 
These results established, cerebellar demeylination pattern in CZ fed animals at 8 week 
time point. Disparity between the WM of cerebellar folia and peduncle is similar to 5-6 
week pattern (Groebe et al., 2009). GM layers like ML and GL remains unaffected as per 
this method of assessment. The DCN of cerebellar peduncle was extensively demyelinated. 
This also explains the inability to detect myelin from cerebellum, using sucrose density 
gradient method, possibly due to the low yield of myelin content expected from the 
demyelinated nuclei (Section 3.3).  
 
3.4.2 Extensive forebrain demyelination due to myelin loss from axon-rich WM tracts 
of CC, striatum and fornix  
 
Forebrain demyelination which accounts for 44% myelin loss (Section 3.3) was 
anatomically delineated to structures like corpus callosum (CC), hippocampal regions 
striatum and fornix. CC is a broad-arched band forming the most distinguishing portion on 
the surface of the cerebrum. If the two hemispheres are observed when they are still 
interconnected, the CC is on the floor of the longitudinal cerebral fissure. Functionally, this 
structure links the two cerebral hemispheres and allows the two sides of the brain to inter-
communicate.  
 
After CZ-treatment it was found that CC and striatum are the most demyelinated regions of 
forebrain. Axon tracts from the entire WM (Figure   22A1, A2, B1, B2) are significantly 
demyelinated. Both these regions portrayed different levels of myelin loss. Collective 
myelination score on LFB stained sections for forebrain areas including hippocampus, CC 
and fornix exhibit 62±0.5%, (p>0.001, n=10) myelin loss (Figure 23E). This method 
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showed higher levels of demeylination relative to sucrose density gradient (Section 3.3).  
This reflects major myelin loss from the CC (Figure   22, Figure   23), which is the largest 
WM tract of brain. Segregated scoring for CC and striatum gave 96±0.2% and 88±0.71%, 
(p>0.001, 0.001, n=10) reduction in myelin for these regions after 8 weeks of CZ challenge, 
indicating that CC is more susceptible to demyelination than striatum (Figure   22, Figure   
23 A1, B1, white boxes 1 and 2). Densitometric analysis revealed differential effect on the 
rostro-caudal end of CC. The myelin loss from the rostral end i.e. genu of CC (gcc) was 
higher than the caudal end (Figure   23A, B, C, E). Similarly striatum junction (Figure   
23A1, A2, B1, B2, D) showed lower susceptibility as compared to rest of the regions of this 
large white matter tract. This confirms varied extent of demyelination within the sub-
regions of CC.  
 
Similarly, fornix (fx) (Figure   22, Figure   23A2, C1) which is a prominent and compact 
bundle of white fiber through which the hippocampus of each cerebral hemisphere projects 
to the opposite hippocampal lobe, septum, anterior nucleus of the thalamus, and 
mammillary body portrayed greater demeylination (Figure   23B1, B2) relative to the entire 
hippocampus after 8 weeks of CZ-treatment. Even though CZ demyelination can be 
employed for studying the hippocampus (Koutsoudaki et al., 2009, Hoffmann et al., 2008), 
LFB stain estimation of hippocampal GM demyelination (Gilmore et al., 2009) was 
supplemented with MBP immunostaining of sections. This allowed distinct visualization of 
CA3, CA2 and CA1 sub-regions and all these structures were extensively demyelinated 
(Figure   22C1, C2) in this study. Most formations of the hippocampus like stratum oriens, 
hilus and stratum radiatum were affected. Entire alveus (rostral and caudal ALV), stratum 
moleculare (SLM) - the terminal layer of the medial prefrontal path were found to be 
demyelinated. The cortex also underwent myelin loss (Figure   22D1, D2). Interestingly 
enough even loss of myelin was obviously visible in parallelly processed MBP labeled 
sections. However, densitometric analysis for both LFB and MBP did not show any marked 
difference between the hippocampal regions of treated and untreated group. Comparison of 
WM tracts exhibits a greater difference. It was hereby noted that even though MBP and 
other myelin protein based IHC could be employed for visualization of demyelinating 
effect in large axonal tracts, a quantitative estimation remained elusive for GM regions, 
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which have larger cell populations. Herein, the possibility of obtaining signals from myelin 
debris cannot be ruled out and, hence, a quantitative estimation of GM demeylination based 
on myelin protein IHCs may remain biased.  However, it is important to note that several 
groups have successfully employed proteolipid (PLP) IHC which is an integral membrane 
protein for myelin to successfully differentiate regional variability  in demyelination of MS 
tissue and animal model as well (Gilmore et al., 2009, Groebe et al., 2009). Irrespective to 
all these, it was concluded that fornix, striatum and CC (Figure   23E) were prominently 
demyelinated regions of the hippocampus.  
 
Hippocampal demyelination owing to the effects of CZ can induce seizure in response to 
stress-induced stimuli. Epileptiform spikes resembling patterns similar to known forms of 
chronic epilepsy, and electroencephalogram (EEG) from hippocampal electrode implant 
study, have indicated alterations owing to axonal pathology after prolonged treatment (12 
weeks) (Hoffmann et al., 2008). This group considered neuronal damage secondary to CNS 
demyelination which might have a potential role in hippocampus induced seizures. 
Considering such deductions, here it implies that the GM demyelinating effects of 
hippocampus after 8 week of CZ feeding are subtle or small, which cannot be robustly 
indicated. However, it might be possible to observe a higher level of quantitative and 
distinguishing loss of myelin after a prolonged period of treatment if the loss becomes more 
extensive. On the other hand functional impact resulting in seizure (Section 3.2.5) was 
noted, even though it cannot be directly extended to any morphological alteration using 
myelin protein IHC.  It is possible that other processes which precede myelin loss and 
debris removal is in place and mild effects are being induced. Such interpretations would 
require ultrastructural analysis of hippocampus, which remains beyond the scope of the 
present study. So, it can be reasonably assumed that the effect of 8 week 0.2% CZ is subtle 
in this region and in order to distinguish GM/WM demeylination further work is warranted. 
It is concluded that the entire forebrain is variously affected and CC is the most altered WM 
tract followed by the fornix. GM tracts appear to be demyelinated but a quantitative 
estimation and conclusive deduction using histochemical techniques is elusive.  
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3.5. Conclusion:  This chapter conclusively describes the establishment of CNS 
demeylination employing a CZ-feeding protocol. Forebrain incurs greater loss of myelin 
relative to entire brain. Most of the axon rich tracts are adversely affected. Cerebellum 
exhibits a differential pattern, where only DCN is affected and CCx is excluded, whereas 
forebrain structures like CC and striatum are entirely demyelinated following 8 weeks of 
CZ-feeding. 
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Figure   20: CZ induces demeylination, but with no apparent effect on body or brain 
weight. 
A. Cumulative weight gain (gms) during 8 to 9 weeks of treatment was obvious. Here UT, 
T1 and T2 indicate untreated and treated groups at 8 and 9 weeks, respectively. B.  The 
total weight of a dissected brain showed reduction in treated groups. This was a non- 
significant change (p=0.4, n=20). C. Body weight gain correspondence to brain weight 
was examined during the course of treatment to note any difference in individual response. 
It was found that T1 animals had a synchronous response; variability sets in only at T2, 
shown as spread of red diamonds (n=20). D. Lateral view of a brain to show the regions 
used to delineate forebrain and total brain for myelin content quantification. The arrows 
pointing downwards indicate the position of incision(s). Horizontal arrows represent the 
brain regions used for analysis (top panel). E.  Schematic mid saggital view of murine 
brain shows the anatomical location of the ROIs in this study. The forebrain system (box1) 
includes corpus callosum (cc), striatum (Str), and fornix (fx). The caudal end of corpus 
callosum, and hippocampus (box2) and cerebellum (box3) are marked in the boxes. F.CZ 
feeding induces loss of total myelin content from the brain (total) and forebrain (p=0.02 for 
both groups, n=3). Normalized values of myelin (mg dry wt./brain wet wt.) is represented 
here, □ untreated, ■ treated.    
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Figure   21: DCN demyelination due to CZ feeding. 
 
 
A. Cresyl Violet stained mid-saggital sections (30µm) representing the general architecture 
of cerebellum, black double arrows point cerebellar peduncle, marking the WM and DCN 
from control group. B. CZ-treated cerebellum stained with CV shows similar organization. 
C. Myelin specific stain for LFB highlights the WM tracts stained blue (black arrow) and 
GM (light blue stain) in the cerebellum of untreated control. D. Diminished LFB stain from 
DCN of CZ-treated cerebellum. Red arrows point to the myelin-rich area at the junction of 
cerebellar folia and boxed areas represents single folia of the cerebellum. The CCx 
comprising the foliar tract did not undergo demeylination after CZ feeding. E. The region 
squared in C has been enlarged to illustrate intact DCN of control brain. F. The region 
squared in D has been enlarged to show specific demeylination of cerebellar marrow. A 
complete loss of myelin can be noted in this region relative to the untreated group. The PL, 
GL and ML did not show any distinguishable effect on the myelin using LFB stain. G. 
Myelination score for the entire cerebellum including all folia extending from rostral to 
caudal end and CM shows a highly significant decrease after treatment (p>0.001, n=10). 
H. Histogram summarizing the prominent effect of CZ demeylination on DCN relative to 
other regions of cerebellum, □ untreated, ■ treated. Cerebellar cortex (CCx), Cerebellar 
matrix (CM), Purkinje layer (PL), granular layer (GL), Grey matter (GM) and molecular 
layer (ML), deep cerebellar nucleus (DCN), White matter. Scale bar, 500µm for A-D.    
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Figure   22: Forebrain demeylination. 
 
A1. CV stained mid-saggital sections (30µm) of untreated brain representing the general 
architecture of CC, striatum and fornix. B1. Similar sections from CZ-treated group 
showing diminished WM tracts (brown color). A2. Similarly these regions have been 
identified in LFB stained comparable sections of control. B2. Overall loss of myelin is 
obvious relative to the control group. C1. MBP stained mid-saggital section of control 
brain showing the myelinated tracts of forebrain, highlighting the hippocampal formations 
like CA1, CA2, CA3 and DG. C2. Similar sections from treated group show low intensity of 
stain for MBP in these regions and CC. D1. Hippocampus of untreated group sample 
showing the levels of MBP in ALV, SLM and HDG. D2. Visible loss of myelin stain within 
these ROIs of CZ-treated brain is evident. Scale bars 500µm (A1, A2, B1, B2, C1, C2), 
250µm (D1, D2). E. Histogram showing significant loss of myelin from hippocampus, 
(p>0.001, n=5). F. Similar histogram represent loss of myelin from CC and striatum 
(p>0.001, >0.001, n=5) as well based on myelination score in 0-5 scale, □ untreated, ■ 
treated. Lateral ventricle (LV), fornix (fx), striatum (Str), corpus callosum (cc), dentate 
gyrus (DG), cornu ammonis (CA1, CA2, CA3), stratum lacunosum moleculare (SLM), 
rostral alveus (rALV), caudal alveus (cALV), and hilus of dentate gyrus (HDG).  
 
 135 
 
 136 
 
Figure   23: Hippocampus and fornix demyelination. 
 
A1. CV stained mid-saggital sections (30µm) representing the general overview of 
hippocampus and associated structures in control. B1. Similarly, these structures have 
been identified in the experimental group, where WM tracts (brown color) appear to be 
diminished. A2. LFB stained comparable sections from control group showing intact CC, 
striatum and fornix with prominent axon tracts (dark blue). B2. Note the loss of these WM 
axon rich tracts from the demyelinated brain. These structural details (boxed A1, B1) have 
been highlighted in the bottom panel (C, D). C. The fx (C1 and C2), gcc (C3 and C4), show 
marked loss of myelinated tracts. More prominent loss of gcc is noted compared to fx.  D. 
Similarly, the junction of cc at the LV (D1 and D2), and striatosomes (D3 and D4) of the 
striatum have been highlighted to show the loss. E. Histogram representing differential loss 
of myelin as assessed by densitomeric analysis of defined ROIs, Rostral CC (Ros. CC), 
caudal CC (Cau CC), corpus callosum (CC), fornix (Fx), striatum junction (Str. Jnc), 
striatosomes (Str.) genu of corpus callosum (gcc), □ untreated, ■ treated,  scale bar500µm 
(A1, A2, B1, B2), 100µm (C1- C4, D1-D4). 
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CHAPTER 4 
 
OPTIC NERVE DEMYELINATION LEADS TO LOSS OF 
MYELIN MEMBRANE PERIODICITY AND 
INCREASED HYPO-PHOSPHORYLATION OF 
NEUROFILAMENT 
 
 
4.1. Introduction 
 
Further to the convincing and reproducible evidence for CNS demeylination from WM 
tracts following CZ-treatment, the myelin status of ON axons was analyzed to elucidate 
axo-oligodendrocyte features. Clinically MS is often presented as an acute unilateral optic 
neuritis, a condition leading to complete or partial loss of vision (Soderstrom, 2001, Smith 
and Hall, 2001). Such conditions may or may not turn out to be clinically definite MS 
(CDMS), but with well-informed cases and emerging pharmaco-therapy, the distinction 
between such patients has become more important than ever (Barnett and Sutton, 2012). 
These suggestive cases often evidence subclinical demyelination in their brain MRI and 
they respond positively to the treatment resulting in reduction of development of CDMS. 
Neurotherapeutic intervention to contain the disease progression at such a stage can be 
equally important in preventing disability amongst the patients, which arise due to 
continued myelin loss. One of these therapeutic strategy that is expected to be detrimental 
is Kv channel blocking (Section.1.16) (Judge and Bever, 2006, Sherratt et al., 1980). 
Mismatched action potential propagation leads to interrupted or disrupted axon conduction 
resulting in cognitive and motor dysfunctions of MS. This is an infestation of myelin loss, 
which in turn affects Kv channels located at the JXP. Their clustered and sub-domain 
specific expression in an axon is dependent on the compacted nature of myelin irrespective 
of oligodendrocyte attachment to the axolemma (Baba et al., 1999). This morphological 
feature has been described for development, but it also co-relates to demyelination, when 
axo-myelin association is disrupted due to a reverse process. This type of attribute leads to 
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loss of continuity within the cable like structure of myelinated axon. If such a myelin 
disruption is considered as dysmyelination (disorganized myelin membrane), then it 
precedes demyelination (disappearance of myelin membrane) (Song et al., 2002, Sun et al., 
2006) which involves loss of myelin membrane from the internodal segment. Identification 
of such features to make a progressive research on the lines of Kv channel blocking strategy 
in animal models is anticipated to prove relevant for neurotherapeutic intervention. 
Collectively, these facts are foreseen to augment Kv channel therapeutics, allowing an early 
stage intervention (Compston and Coles, 2002) rather than usually-recognized importance 
in late stage symptomatic relief (Judge and Bever, 2006) in MS. Unfortunately, most of the 
animal model studies involving role of Kv channels have been conducted on developmental 
stages of myelination in ON  (Rasband et al., 1999b, Dangata et al., 1996, Foster et al., 
1982, Roncagliolo et al., 2006) or peripheral nerves. Studies based on adult nerve features 
have usually been conducted on mutant models (Devaux and Gow, 2008, Griffiths et al., 
1998), which are suitable for analyzing the effect induced by one particular protein. 
Whereas MS is a chronic CNS disease of adults, and analysis in systemic demyelinating 
animal models can establish global or a broad spectrum clinical bearing which has not been 
established so far. Research on functional aspects of ON has been equally lacking in these 
models and hence the understanding remains incomplete.  
 
Anatomically, ON is an extension of the retinal ganglion cell (RGC) axons of the retina and 
is highly susceptible to functional blockade (Stys, 2004). During demyelination axons have 
an inherently low safety factor for conduction, and are predisposed to the effects of soluble 
factors as well (Section 1.8) (Smith and Hall, 2001, Waxman, 2005). As the disease 
progresses, profound effect can be manifested due to synergistic or collective action of 
several factors (Coleman, 2005, Waxman, 2005). Such a global perspective is important for 
an increased understanding of the development of therapeutic strategy. So, this study 
undertakes evaluation and analysis of demyelinating effects in such a model. The myelin 
content, quality, and extent in addition to changes in surrounding cellular pattern due to CZ 
were investigated in axons of adult ON. Additional use of TEM based ultra-structural 
analysis has been beneficial in establishing elaborate effects induced.  
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4.2.1. Cross sectional surface area of the ON increases after CZ-treatment  
 
ON is a tiny structure relative to other regions described earlier (Section 3.4). So, no 
difference was noticed amongst the isolated nerve from both groups. It had a uniform 
appearance which measured 2.2 mm long and was lodged in between the optic foramen and 
chiasma. The distal (distal to mid body axis, i.e., close to the optic foramen) and proximal 
end (proximal to mid body line correspondingly close to the chiasma) width (diameter) was 
250 and 500µm. Microscopic investigation of CV stained 30µm radial cryosections from 
both ends did not display any drastic change in morphology.  The entire nerve exhibited no 
significant change in appearance (Figure   24A). Average cross sectional area was analyzed 
on slide mounted cryosections and was found to be 49.2 ± 7.7 and 68.0 ± 7.6 mm2 , n = 5, p 
=  0.13, ranging between 15 to 69 mm2 and 56 to 83 mm2 for control and treated group in 
these preparations (Figure   24D). The wide range of cross-sectional area in the untreated 
group signified that the nerve was more slender at one end relative to the experimental 
group. An estimation of nerve diameter at both ends, namely proximal and distal showed 
that proximal end is relatively swollen after CZ-treatment. The average perimeter was 
813.3 ± 76.1 and 927 ± 41.9 µm, n = 5, p = 0.28 ranging in between 460 to 960 µm and 860 
to 1000 µm for untreated and treated ON (Figure   24C). This corresponded to 38.3% and 
13.9% increase in average area, and perimeter of ON when the CV stained cross sections 
were assessed; thus indicating swelling of the nerves at one end. 
 
4.2.2. Inter-fascicular cells of ON re-orientate in between the axons of CZ-treated 
group 
 
Light microscopic examination of mid-nerve cross sections (5µm) stained with toluidine 
blue was used to reveal the fascicular organization of ON. The inter-fascicular space 
appeared larger in the treated group (Figure   24B). The ON axons were uniformly spread 
within these fascicles. Axonal counts in the untreated and treated groups were 310.3 ± 13.2 
vs. 272.4 ± 19.1 per µm2; p = 0.15, which was indicative of a minor non-significant 
decrease (Figure   24E). Intercalated cells in between the fascicular space within the nerve 
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appeared to re-orientate themselves. This was more noticeable in longitudinal sections, with 
cells exhibiting various types of nuclear and cellular morphology (Figure   24H-I). Even 
though  the identity of these cells was not established in this study, they could be 
oligodendrocytes, astrocytes, microglia and NG2-glia as they are the main inter-fascicular 
cells of ON (Butt et al., 2004). All these cells perform varied functions; hence, this 
observation could only be an indication of a consequential effect of CZ on ON cells. 
However, the exact nature of these changes remains unknown in this study. It would not be 
surprising, if they are astrocytes as shown in a recent study (Skripuletz et al., 2013), even 
though not established here as this was beyond the main objective. 
 
4.3. Influence of CZ on myelin proteins of ON  
 
Myelinated axons are one of the most complicated biological structures owing to the 
intimate association (Section 1.1) between the axon and glia (Nave, 2010b, Nave, 2010a, 
Rash, 2010). Lipid-enriched myelin contains large amounts of proteins like, proteolipid 
protein (PLP) and myelin basic protein (MBP) (Siegel, 2005, Nadon et al., 1997). An array 
of such protein maintain the integrity of myelinated axons (Baumann and Pham-Dinh, 
2001, Nave, 2010a).  Some of the major myelin proteins, namely myelin basic protein 
(MBP), proteolipid protein (PLP) and 2',3'-Cyclic-nucleotide 3'-phosphodiesterase 
(CNPase) were assayed herein from the homogenates of ON, and further analyzed by 
confocal microscopy to elucidate the axo-myelin morphological features. 
 
4.3.1. Myelin proteins are marginally decreased in homogenate of ON 
 
Whole nerve homogenates were assayed for MBP which is an intercalating peripheral 
protein present in between the myelin membranes. The normally phosphorylated form of 
MBP is hypo-phosphorylated in MS brain (Kim et al., 2003).  It is a complex protein, 
transcribed from multiple transcription sites. Here five isoforms of MBP varying size ~14, 
~17.2, ~17.3, ~18 and ~21 kD were detected from ON homogenate under denaturing 
conditions using SDS-PAGE.  The most prominent form was ~18kD (Figure   25A) band 
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hence, this was considered as a representative for quantitative evaluation. CNPase was 
identified as a doublet of ~46-48kD and PLP as ~30kD band on these blots (Figure   25A). 
In spite of established robust CNS demeylination of these mice (Section 3.3, 3.4), 
surprisingly there was no apparent difference between the myelin proteins of ON. However 
normalizing the quantity relative to the tubulin band (~55kd) was indicative of varying 
levels of non-significant loss (n = 3). Nevertheless it was always found to have a 
considerable amount of variability in between sample preparations.  This could not be 
overcome by use of antibodies against house-keeping proteins as a loading control. Even 
though tubulin is regularly used as a control, surprisingly here, quantities of tubulin 
exhibited 40-43% variation between untreated and treated groups, indicating that such 
proteins are affected following CZ-treatment.  Then, it was further questioned whether this 
variability is specific to ON or other tissues as well. Evaluation using retinal protein did not 
show such variation for tubulin; which remained within acceptable limits of 0.70-0.73% in 
equal amounts of BCA quantified protein for both groups.  Thus, evaluation of myelin 
proteins using this method remained unreliable.  
 
4.3.2. Altered expression of myelin proteins in CZ-treated axons indicated structural 
changes  
 
To investigate the above observations, ON axons were labeled for IHC analysis; their 
microscopic evaluation provided some insight into the effects induced after CZ-treatment. 
Confocal microscopy was performed for 10µm thick ON longitudinal sections fluorescently 
labeled with Alexa Fluor® for MBP and NF (Figure   25B1-C2), CNPase and PLP/DM20 
in order to identify the axons. Interestingly, all the myelin proteins in these preparations 
revealed three different types of structural changes in axo-myelin association. Firstly, NF 
positive axons (Figure   25C1, C2) overlapped with MBP-labeled myelin sheaths in both 
groups (Figure   25 B1, B2), indicating none of the axons are completely devoid of myelin 
(Figure   25B). Secondly, the fluorescence intensity for MBP did not vary amongst the 
treated and untreated groups, but structural disruption of the myelin layer marked by 
vacuolization was noticed in both MBP and CNPase (Figure   25 D1, D2, E1, E2) labeled 
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axons.  The axon-myelin (MBP) associations appeared disrupted in the treated group 
(Figure   25 D1, D2). This effect was more prominent when they were labeled with 
CNPase. It exhibited a loss of emerging processes radiating out of the soma of the 
oligodendrocytes in treated group, whereas these remained intact in the control groups 
(Figure   25E1, E2). This observation was indicative of loss of CNPase, as it is readily 
affected by CZ-induced demeylination (Carey and Freeman, 1983). Lastly, use of 
PLP/DM20 specific antibody to reveal axo-myelin association indicated widespread loss of 
compact myelin. Untreated group myelin appeared as uniform and regular structure 
whereas in the treated group axons they acquired a striated sheet like structure. Collectively 
these results provide evidences of ON myelin proteins being adversely influenced due to 
CZ, so that there is disruptive loss of axo-myelin.    
 
4.3.3. Glial astrocyte fibrillary protein indicate hypertrophy in treated ON  
 
It was evident from the above-described observations that the cells surrounding axons are 
differently affected by CZ-treatment. Astrocytes are one of the cell type which occupy 30% 
of space in ON (Perge et al., 2009) and they have numerous projections which anchor 
neurons to their blood supply (Rash, 2010). So, specific labeling of astrocytes with glial 
fibrillary acid protein (GFAP) was employed to analyze their association with axons; and 
this displayed two interesting features. Firstly, the shape of astrocyte was changed in the 
treated group. The astrocytes changed their shape. The control ON astrocytes possessed a 
few (4-5) short processes (Figure   26A1, A2) whereas in CZ-treated samples they were 
hypertrophic and multipolar. It had acquired profusely branched processes in the 
experimental group. Even though astrocytosis would involve both hypertrophy and 
hyperplasia, herein an increase in astrocyte branching and area was easily observable 
(Figure   26B1, B2). Each process of the astrocyte has several sub-branches after treatment 
(Figure   26B2). A representative electron micrograph is presented here (n = 3), which 
shows the marked appearance of processes invaginating in between the axon clusters, 
indicating typical astrocyte activity (Figure   26C). An analysis of the signal from the two 
groups exhibited 10% increase in average fluorescence per mm2 following CZ treatment. It 
was 39.23 ± 5.43 for control and 59.19 ± 2.06 (AU/mm2) for the treated samples, n = 35, p 
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= 0.03 (Figure   26D). These cells regulate the external chemical environment of neurons 
by removing excess ions, notably K+, and, also, recycle neurotransmitters released during 
synaptic transmission (Adelman and Fitzhugh, 1975). Overall, these observations indicate 
an increased astrocyte activity in the ON metabolism during CZ-induced demyelination. 
 
4.4. Ultrastructural changes in ON after CZ administration 
 
4.4.1. Axon and myelin  
 
The susceptible axo-myelin interactions  (Chomiak and Hu, 2009, Piaton et al., 2010, Trapp 
and Nave, 2008) undergo subtle structural changes during injury or disease, which 
influence the myelinated axon(s) and/or its surrounding(s), capable of inducing functional 
deficits (Devaux and Gow, 2008, Moran and Mateu, 1983, Sun et al., 2006, Song et al., 
2002, Nave, 2010b). So the myelin structure, and its surroundings within the nerve, was 
further evaluated by employing transmission electron microscopy (TEM). Usually ultra-
structural CNS response to CZ involves induction of status spongiosus, characteristically 
affecting the myelin sheaths and glial cells (Suzuki and Kikkawa, 1969) of the brain. 
Herein, for the first time, ON features in CZ-induced demeylination was explored to assess 
the extent of effect on myelin. Several parameters like myelin sheath thickness, fiber-and 
axon-caliber and “g” ratio were evaluated to establish the axo-myelin status after CZ-
treatment.  
 
4.4.1.1. Most of the axons remain myelinated after CZ treatment 
 
TEM images of myelin sheaths were assessed in longitudinal and cross sections for both 
the groups. They appeared to have similar myelin membrane profiles at 5µm scale. At 
higher magnifications, different types of membrane-associated changes were noticed 
(described in subsequent sections 4.4.1.2, 4.4.13, and 4.5). Virtually all axons appeared to 
be myelinated 96.8 ± 5.06 %, n = 1525 in the control group. The treated group also showed 
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similar profile 95.2 ± 4.23 %, n = 1289 (Figure   27A, B). The minor unmyelinated 
population of axons noticed in both groups 3.2 vs. 4.7% was as expected attributed by the 
small diameter cross sectional profiles of the nodes of Ranvier. Average fiber thickness 
(di+do) defined as the total diameter including the axolemma bound inner diameter (di) and 
the thickness of the myelin membrane bound to the outer diameter of the myelin sheath 
(do) was 1.16 ± 0.04 and 0.96 ± 0.03 µm for control and experimental group (Figure   
28C). These measurements were manually obtained using ImgaeJ (NIH) by drawing lines 
between the delimiting membranes. They range between 0.36-3.70 µm for control and 
0.10-3.50 µm for the treated sample; on the other hand “di” was 0.27-3 µm and 0.13-3 µm 
for control and treated group (Figure   28C). Individual axons of treated mice appeared less 
annular. Their profiles could not be considered as exactly round in shape (Figure   27B). In 
order to get the reliable values herein, the less annular axons were sampled twice or thrice 
along their radial axis passing through the centre of these profiles and the average for each 
axon was considered as a representative measurement. These analyses were conducted on 
TEM images from three sets of experiment.  
 
4.4.1.2. Loss of myelin thickness is eminent 
 
As the myelin sheath gets thicker it occupies an increasing proportion of the surrounding 
volume which, in turn, alters its resistance and capacitance, thereby, changing the axon 
function. Myelin thickness was measured as (do-di) from the TEM 500nm images. Average 
myelin thickness for untreated group was 0.26 ± 0.01µm, n=1087 and 0.16 ± 0.08µm for 
the treated group, n = 805, p > 0.001 (Figure   27E).  Their range (0.01- 1 µm) was same 
for both the groups.  
 
For the untreated group the peak average frequency (21.48 ± 1.49 to 22.96 ± 2.68%) of 
myelin thickness was between 0.2-0.3µm. The second (13.01 ± 1.8%) and third (12.80 ± 
2.15%) most frequent myelin thickness were 0.1-0.4 and 0.4-0.5 µm.  The remainder 
accounting for the thickest and thinnest myelin layers was found to be in a narrow 
frequency range of (8.6 ± 1.08 to 6.55 ± 1.04%). Some of them were also categorized as the 
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least frequent (1-2 %) (Figure   28A).  None of the axons exceeded myelin thickness of 
1.3µm in these preparations. Similarly, for the treated group peak average frequency was 
between 35.24 ± 2.00 to 37.08 ± 2.66% for myelin thickness range 0.01-0.1 µm. The 
second most prevalent thickness was 0.2µm, with a frequency of 13.69 ± 1.87%. The 
remaining had a thickness of 0.4-0.5µm, and was within a frequency range of 3.34 ± 2.05 to 
1.44 ± 0.69% respectively (Figure   28A). This frequency analysis indicates an increasing 
trend for low myelin thickness in the treated axons signifying loss of myelin from the 
internodal segments.  
 
So, according to this parameter for measuring myelin 4.7% axons were accounted to be 
devoid of myelin membrane in the treated group relative to 2.2% in the untreated group.  
This was in fair correspondence to the measurements described in the above paragraph 
where myelinated axons were accounted on the basis of visual assessment of electron 
micrographs (Section 4.4.1). The myelin membranes had a remarkable difference in their 
morphology. Apart from the usual myelinated axons, some circular and rounded profiles 
were observed in the treated group which could not be classified as axon, since they lacked 
the regular myelin membrane stacks. These cross sections had a central cytoskeleton and a 
surrounding thick membranous layer which was not distinctly multi-layered, as expected 
for a myelinated axon (Figure   29E, F).  Several layers of membrane appeared to be fused 
along the axon radius (Figure   29F). This pattern possibly reflected a minor type of 
induced effect which remains unexplained here. Axons with this type of myelin pattern 
were not found in controls. These analyses were conducted on TEM images from three sets 
of experiment.  
 
4.4.1.3. Alterations in “g” ratio and myelination index indicate loss of myelin 
 
Further on, in order to evaluate the structure-function co-relate in CZ-treated ON axons, 
“g” ratio was analyzed. Rushton’s view  (Rushton, 1951) that “g” ratio (the ratio of the 
inner axonal diameter to the total outer diameter) is a reliable way for assessing axonal 
myelination, is a parameter which is widely accepted and used. The ratio becomes unstable 
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during demyelination and the changes reflected loss of myelin. An increase in the “g” ratio 
implies a relative reduction in the thickness of the myelin sheath, as fiber diameter 
approaches that of axon diameter (Beuche and Friede, 1985). CNS and PNS are 
differentially susceptible to such changes (Chomiak and Hu, 2009, Perrot et al., 2007). Here 
in this study, the average “g” ratio for untreated and treated group was assessed as 0.779 ± 
0.008, n = 1087 and 0.827 ± 0.01, n = 805, p > 0.001, respectively (Figure   27A). They 
ranged in between 0.3 - 1.1 for both groups, whereas, the average myelination index (do/di) 
exhibited a decrease in the experimental group (Figure   27B). Collectively, these results 
indicate that demyelination of ON axons take place here owing to CZ-treatment.  
 
4.5. Loss of myelin membrane periodicity due to collapse of IPL is a major effect  
induced by CZ   
 
Even though both groups appeared to exhibit similar axon cross section profiles at low 
magnification (Section 4.2.1) the membrane structure varied. Untreated group axons had 
compact myelin with distinct periodicity, whereas the treated group exhibited several intra-
myelinic changes. Vacuolization in between the myelin membranes was a prominent effect 
noticed after CZ administration. This intra-myelinic change was due to disruption of myelin 
layer (Figure   29A, B) and loss of regular membrane stacked structure owing to 
interruptions in the compacted myelin (Figure   29C, Figure   30A, B), rendering it loose 
at several places in radial and longitudinal sections and yielding a vacuolated appearance 
(Figure   29C, D, E) of IPL. They are formed due to the apposition of external myelin 
plasma membranes surfaces (Figure   29A, B). The myelin vacuoles were lodged in 
between the successive membranes, which were always found between the IPL. 
Interestingly, these vacuoles were not continuous to the extracellular space. Small diameter 
axons appear to have lesser disruptions. A single axon in its radial section could exhibit 1-
10 such disruptions, indicating varied impact on each of them. The extent of such 
interruptions could be mild, where it generates a single gap between the successive myelin 
layers (Figure   29B), or have several large vacuoles such that the stack like structure of 
myelin falls apart (Figure   29C, Figure   30A, B). In cases of even more extensive 
breakdown, these membranes could invaginate inside the axoplasm (Figure   29D). Even 
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though unexpected, yet such disruptions were present in some control samples as well, but 
the effect was much higher in the treated samples. In order to examine the periodicity of 
intact stretches of myelin in both groups, a detailed densitometry was performed. A 
representative scan across the myelin sheath is shown (Figure   30). Even though the 
disruption is not apparent in these remaining stretches of myelin sheath (Figure   30A, B) 
loss of compactness was evident (Figure   30D). Linear densitometric scan profiles along 
these portions of myelin sheath in the treated group exhibit reduced height or amplitude of 
the crest and trough which are representations of MDL and IPL (Figure   30C, D). 
Collectively, these structural evidences prove the presence of non-uniform, faltering myelin 
covering in CZ-treated axons, which may appear intact, but has resulted in loss of its 
periodicity and compaction.  
 
4.6. Decreased PLP/DM20 ratio; a jeopardizing factor for loss of periodicity  
 
Glia to axon signaling requires intimate cellular interaction at a global and local level as 
well (Perrot et al., 2007, Nave, 2010b, Nave, 2010a); and lipophilins are one of the 
important implicating factors. Specifically, the proteolipid (PLP) and it’s variant DM20, 
which are integral hydrophobic components of CNS myelin sheaths. They bestow essential 
compaction of myelin lamellae required for efficient saltatory conduction. The electron 
microscopic data established that myelin membrane looses its uniformity (Figure   29, 
Figure   30) due to the collapse of the intraperiod line (IPL), leading to clustered major 
dense line (MDL) and thus, creating intra-myelinic vacuoles (Figure   30B).  
 
Cross-sectional view of a single axon illustrates such regions, which indicates extensive 
myelin disruption. The intact stretches of these sheaths also show a loss in their periodicity, 
which were pronounced in the densitograms (Figure   30D). It was noted that the lipophilin 
group specific proteolipid protein (PLP) and its variant, DM20 are structural constituents of 
the myelin sheath, which maintains the integrity of IPL. Hence, these were analyzed in 
purified myelin obtained by sucrose density gradient centrifugation and detected with 
Western blotting. Use of SMI99 antibody allowed detection of both PLP and DM20 as it 
identifies epitopes corresponding to amino acids 109-128 which are common to both. A 
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minor ~42kD contaminating band was not included in the analysis or interpretation because 
its molecular weight does not correspond to any protein from the lipophilin group. The 
three specific bands separated correspond to the expected protein sizes of PLP ~30kD, 
DM20 ~26kD and a small ~10kD band (Figure   31A). DM20 is an alternative spliced 
variant of PLP transcript and they together form the transmembrane protein of myelin 
which holds them together like a zipper and maintains compact myelin. ~10kD band is 
often referred to as a degradation product of PLP (Macklin et al., 1987, Nave et al., 1987). 
Normally, PLP and DM20 are expected to be present in equal proportions, a 
disproportionate increase or decrease leads to altered myelin compaction. Here, in the 
treated samples, the level of DM20 increased whereas PLP decreased in the total lipophilin 
pool, relative to the untreated samples (Figure   31B, C).  Expressing these two proteins as 
% of the total lipophilin pool, which would contribute to maintaining the periodicity of 
myelin membrane, showed lower ratios (PLP/DM20) for the experimental samples (n = 3), 
relative to the control group in ON, total brain and forebrain (Figure   31).  This was a 
consistent pattern observed in ON and total or forebrain myelin. 
4.7. CZ influences cytoskeletal organization of axon and surrounding glia 
 
Demyelination exerts an adverse impact on the axon. Cytoskeleton changes are often 
suggestive of the pathological state and mechanism(s) involved which, in turn, might affect 
trafficking of proteins, axon diameter and axon-myelin associated functions. An impact on 
the NF cytoskeleton is a widely accepted  aspect of disease progression in MS (Trapp et al., 
1998, Schirmer et al., 2011, Dziedzic et al., 2010, Salzer et al., 2010, Trapp and Stys, 
2009). Herein, on the basis of ultrastructural TEM analysis, the axonal NF and cytoskeleton 
of surrounding cells were found to be affected in the CZ treated group.  
 
4.7.1. Axonal neurofilament gets disorganized following CZ-treatment  
 
Axon cytoskeleton cross sections of untreated control group appeared as a discretely 
organized association of microtubules and NF in transmission electron micrographs. At 
high magnification (100nm, scale bar) the axoskeleton represented the typical NF and 
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microtubule interaction. Microtubules (25nm) were representative of typical round hollow 
structures and the NF (10nm) is a solid globular structure with several filamentous 
processes or arms attached to the microtubule in axon cross sections (Figure   32C). These 
collectively form a distinguished network in control which was lacking in the experimental 
group (Figure   32D). They appear as long organized, but trailing structure in longitudinal 
sections (Figure   32B). This discrete and uniform organization was prevalent in untreated 
group only. The treated group axon exhibit intermittent stretches of organized and 
disorganized cytoskeleton (Figure   32A). Loss of such association or network was more 
evident in the cross-sections (Figure   32C, D). It was interesting to note that this kind of 
assembly was better maintained in relatively small diameter axons. This axoplasmic 
randomness caused due to cytoskeletal disorganization was measured by calculating the 
particle density within the defined ROIs of an axon. According to this analysis the 
untreated group exhibited low density when expressed as particles/nm2. The treated group 
exhibited 29% increase (n = 60, p > 0.001) indicating disorganization of the cytoskeleton 
(Figure   32D). The impairment of the NF was a localized event as noticed in longitudinal 
sections of ON axon (Figure   32A). Herein, loss of NF arm has been indicative of hypo-
phosphorylation of neurofilament leading to disorganization of axo-cytoskeleton.  
 
4.8. Increased hypophosphorylation of NF is a liable factor for axoskeleton 
disorganization  
 
These changes might lead to loss of axon rigidity which is essential for uniform 
propagation of action potentials and trafficking of proteins as well. NF plays a vital role in 
maintaining an uncompromising structure. It is mostly implicated with their radial growth 
(Xu et al., 1993). The subunit composition (NFH and NFM) of NF specify  axon diameter 
(Xu et al., 1996). The relatively higher proportions of phosphorylated form NFH renders 
them more rigid and it is a phosphorylation dependent phenomenon. Loss of myelin protein 
like MAG (myelin associated glycoprotein) results in reduced axon caliber, owing to 
decreased NF phosphorylation. This in turn reduces spacing between cytoskeleton (Yin et 
al., 1998, Garcia et al., 2003) and loss of rigidity. Such studies have indicated that myelin 
and NF phosphorylation collectively maintain a healthy and normal axon diameter essential 
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for efficient action potential propagation. Ample evidence has been gathered so far in the 
present study, which has implied a role of NF phosphorylation.     
 
NF represented as NF200 (NFH) was easy to detect on western blots and it did not exhibit 
any change in quantity (Figure   33A). So, it was hypothesized that the phosphorylation of 
NF is perturbed with respect to the total pool in ON cytoskeleton. De-phosphorylation of 
NF in axons and hyper-phosphorylation in neurons are indicators of disturbed axon 
transport and neuron damage in MS (Schirmer et al., 2011, Trapp et al., 1998, Pitt et al., 
2000). Hence, in order to further characterize the divergent features of axon induced by CZ 
demyelination in MS pathology use of SMI antibodies were employed. SMI 31 (SMI® 
Monoclonal Inc. or Steinberger product from Covance) is an antibody which extensively 
reacts with the phosphorylated epitope of neurofilament both heavy (NFH) and medium 
(NFM) (Tsuda et al., 2000). It was used herein to distinguish the relative state of C-terminal 
region, as SMI 31 recognizes the phosphorylated form of a highly conserved consensus 
phosphorylation site KSP (Lysine-Serine-Proline) repeats of the NF arm. On the other hand 
SMI 32 recognizes the less phosphorylated NF (Tsuda et al., 2000).   
 
Cytoskeletal protein preparation from ON was resolved by SDS-PAGE, followed by 
Western blotting and detection of phospho- NF (p-NF) and dephospho-NF (dp-NF) bands. 
This showed a decrease in the p-NF and increase in dp-NF following treatment. The total 
pool of NF cytoskeleton was assessed by combined use of both antibodies SMI31 and 
SMI32 as described by Tsuda (Tsuda et al., 2000). SMI 31 labeled bands (~200, 168 kD) 
indicated the quantity of p-NF and SMI 32 labeled bands (~200kD) indicated the quantity 
of dp-NF (Figure   33A). The sum of these two signals was considered as the total pool and 
percentage values for p- and dp-NF was calculated as:  
 
% of total p-NF =31/ (31+32)*100;  
% of total dp-NF= 32/ (31+32)*100. 
 
p-NF levels were low (p > 0.01, n = 3) (Figure   33B), whereas dp-NF was increased (p > 
0.001, n = 3) (Figure   33C) after CZ-treatment in ON axons. The p-NF/ dp-NF ratio in the 
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total pool of NF cytoskeleton was expected to reveal the impact on maintenance of axon 
diameter. When this was expressed as % of the total NF pool it was found to be highly 
altered owing to increase in dp-NF levels (Figure   33D).  
 
4.9. Increased dp-NF is a hallmark of large diameter CZ-treated axons 
 
The observed hypophosphorylation of NF in electron micrographs were further established 
by fluorescence labeling of ON axons with p-NF (SMI31) and dp-NF (SMI32). 
 
The % frequency of p-NF and dp-NF positive axons in both control and treated samples 
were detected in confocal micrographs. The axon diameter from both groups of ON follow 
same pattern, where they fall within this broad range. p-NF positive axons are within 
diameter 0.2-2.24µm in both groups. But, the majority of these are in a range of 0.2 to 
1.8µm. Occurrence of very large diameter axon is infrequent. This is an observation similar 
to that noted in Section 4.4.1.2. Control ON represents higher level of dp-NF in small 
diameter axons, which is assumed to be immature. The mid range axons which is expected 
to be mature have an intermediate level of p- and dp-NF (Figure   34A). This pattern is 
shifted to the right in treated ON, indicating increase in dp-NF of large diameter axons 
(Figure   34B). This was further indicated by the medial distribution of p-NF (2.39 and 
2.50) and dp-NF (3.15 and 8.91) in UT and T samples.  The shift in the indicated pattern 
has been highlighted by the shaded portion in the graph (Figure   34). These observations 
collectively indicate that NF phosphorylation is perturbed by CZ-treatment and in affects 
the axon diameters, increasing hypophosphorylation mostly in the larger axons. 
4.10. Organization of inter-axonal cytoskeleton indicate activity of surrounding cells  
 
Some prominent cytoskeletal changes were also observed in the surroundings of myelinated 
axon. The micro-filaments were found to be well organized as striations packed around the 
myelinated axons in treated group in electron micrographs (Figure   35A, box). This 
organization is typical for astrocytes and is remarkably different from axon cytoskeleton 
(Figure   35B) shown in (Figure   35C, D). A globose structure attached to the myelin 
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layer of axons was also noticed. They were present in both groups and represented a 
decrease after CZ-treatment (Fig. 30C, D) n= 1525, 1289. At several occasions these cells 
with profuse micro-tubular elements had some membrane enclosed organelles embedded in 
between them. These organelles have stacks of horizontally organized membrane and 
looked very similar to mitochondria (Figure   37F). However, the shape appeared to be 
distinctly different from the mitochondria found in the axons, which could be easily 
identified due to its presence in the myelin, enveloped axon and a typical textbook 
appearance (Figure   37A, B).   
 
4.11. CZ induced change in nuclear morphology was indicated by altered chromatin 
pattern 
 
Apart from all these another obvious and interesting observation was evident from these 
TEM micrographs.   Treated ON had alterations in the nuclear organization of cells 
intercalated in between myelinated axons. Two types of cells were observed which differed 
in the electron density of their cytoplasm. One type of cell had a denser material relative to 
the other. The electron dense cells were smaller in size with respect to the translucent cells 
(Figure   36A). Their corresponding nuclear size also differed; the smaller ones had tinier 
nuclei (yellow arrow) relative to the larger ones (white arrow) (Figure   36A). The nuclei 
of translucent cells exhibit more dispersed pattern of chromatin (Figure   36C1, C2) and 
the electron dense cells had more compacted look. (Figure   36B1, B2). Similar cells were 
found in both groups, which were indicative of presence of two different types of cells. 
They differed in their chromatin distribution after CZ-treatment.   They appeared to be 
differently organized in the treated group, with an apparent perinuclear scattering of the 
chromatin in the translucent cells (Figure   36C2, B2). These morphological changes 
observed in the nuclei after CZ-treatment collectively indicate an induced effect, which 
might have a transcriptional role. This observation remained beyond the main objective of 
the study, hence it their involvement in any functional aspect was not investigated. 
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4.12. Loss of mitochondrial inner membrane integrity in ON axon  
 
CZ is a copper chelator and is expected to have an effect on the mitochondria and 
consequential supply of energy (ATP). On the other hand increased energy demand needed 
for electrical conduction in viable demyelinated axons, combined with reduced axonal ATP 
production, leads to a state of virtual hypoxia in chronic lesions of MS (Trapp and Stys, 
2009). Herein, for the first time evidences for morphological changes in demyelinated ON 
axon after CZ-treatment is being presented. The general appearance of mitochondria 
indicates that they are 250nm to 150µm long or oblong structure in the longitudinal 
sections of ON axon. Cross sectional view of an axon exhibit the presence of as many as 1-
3 mitochondria, which were spherical in shape and their diameter was 400-500nm. This 
was true for both groups. They were mostly located on the periphery of axoplasm and in 
close proximity to the axolemma. In some cases, they were found to be centrally located. In 
these cross sections, the inner membrane appeared intact, but the cristae were blemished. 
Even though it was not possible to analyze the exact distance at which these mitochondria 
were interspersed within an axon, as a 3D reconstruction of nerve would be needed, it was 
evident from these TEM micrographs that they were in close proximity (1µm or even less). 
 
The inner and outer membrane could be easily distinguished in these preparations, 
rendering it a double membrane bound structure. The outer and inner membranes of 20 out 
of 25 mitochondria examined became wavy (Figure   37B, black arrow head) after CZ-
treatment. Many cristae show club-shaped dilatation, with accumulation of moderately 
dense homogeneous material (Figure   37B, red arrow heads), whereas in other areas, there 
is almost complete loss of cristae, accounting 3/4th membrane span of a single 
mitochondria. Such expanse of mitochondria are bordered only by single membranes, 
which appear to be protruding outward (Figure   37B, D black arrow head) from the 
regular contours. This feature has been highlighted in the outline trace generated for such 
an electron micrograph (Figure   37D, black arrow)  Thus morphologic evidence  favors 
the altered permeability of mitochondrial membranes (Suzuki, 1969). The average 
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membrane density per unit area (nm2) was 192.19 ± 1.28 and 173.83 ± 1.78 for control and 
treated group, n = 25, p > 0.001 (Figure   37E). This was analyzed by defining the 
mitochondria as a ROI and then calculating the length of traced line per unit area using 
ImageJ software. This reflected an apparent loss of cristae from the mitochondria. 
Interestingly, no obvious difference could be distinguished for the mitochondria of 
surrounding cells in samples from both groups. However, some elongated and profuse 
membrane stacked structures were observed in both groups (Figure   37F). Collectively, 
these observations here in the ON axons provide direct evidence for loss of inner membrane 
integrity of axonal mitochondria.  
 
4.13. Conclusion 
 
This chapter conclusively provides evidence for ON demyelination, marked by an increase 
in “g” ratio and loss of myelin membrane periodicity in axons after 8 weeks of CZ-feeding. 
Differential increase in DM20 and a corresponding decrease of PLP alters their ratio in the 
entire lipophilin pool, which is a possible cause of the described myelin disruption. 
Additionally, increase in hypo-phosphorylation of NF indicates an impact on the axons, due 
to referred myelin loss. Alterations in the surrounding cells are indicative of induced impact 
on the delicate balance of neuron-glia association following CZ treatment.  
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Figure   24: ON morphometrics before and after CZ treatment. 
 
A. CV stained ON cross sections (30µm), from the distal (facing eye ball), medial and 
proximal end (facing chiasma) showing the general profile of nerve.  B. Toluidine blue 
stained cross sections of ON from control (left) and treated (right) group showing an 
increase in interfascicular space (black arrows) following CZ treatment. C. Histogram 
showing an increase in average cross-sectional nerve perimeter (µm). D. Histogram 
showing a non-significant increase in the average cross sectional area (mm2) of the nerve 
and E. decrease in the number of myelinated axons/µm2 □ untreated, ■ treated. F. The glial 
cells within the fascicle remain randomly oriented in untreated (UT) group (left). The white 
box shows the broad view of a cell which has been expanded and represented in the inset to 
show the shape of this cell (left). G. Glial cells get realigned longitudinally in between the 
inter-fascicular space of the treated ON. The cell in white box is an expanded view of the 
same cell (inset top left). H. Longitudinal section of optic nerve exhibits sequestered and 
realigned cells in between the fascicles (pointed by white arrows) in untreated group. I. 
Similar cells in treated group ON highlighting the marked change in the shape of some of 
these streaming cells.  
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Figure   25: ON axons and expression pattern of myelin proteins. 
 
A. Myelin proteins MBP (~21, 18kD), CNPase (~46-48kD), PLP (~30kD), NF200 
(~200kD), tubulin (~55kD) were detected on western blots from ON homogenate. B-F. 
Representative IHC panels show myelinated (UT) and demyelinated (T) ON axons from 
10µm thick cryosections labeled for various myelin proteins. B. Axons double labeled for 
MBP (red) and NF (green), show the axo-myelin pattern in control B1, and CZ-treated 
nerve B2.  C. Axons labeled for axonal protein NF (C1, C2). The NF labeling for CZ-
treated axons have a creased appearance (C2) relative to controls (C1) (white arrow). D. 
MBP stained myelin protein showing the structure of the same axons (D1, D2). They have a 
vacuolated appearance in treated axons (white arrow). E. This effect is more prominent 
when the axons are labeled with CNPase (green) (E1, E2). They show marked disruption of 
double layered myelin which surrounds the axon longitudinally along its axis (red double 
arrow). This can be distinguished from the somatic formation (white double arrow). F. 
PLP/DM20 (green) stained sections (F1, F2) show a difference in the morphology of 
myelin layers, it bears a more striated appearance in the treated group. The boxed regions 
in F show the change.   Scale bar is 2µm and 5µm for B, C and D, E, F respectively.  
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Figure   26: Astrocytic reaction to CZ-treatment. 
 
A. Longitudinal sections of control ON labeled with GFAP (10µm, A1). An individual 
GFAP-positive cell shows the normal morphology of an astrocyte which has few processes, 
scale bar 5µm (A2).  B. Similar section from treated ON displays labeling for GFAP; scale 
bar 10µm (B1). An astrocyte from the experimental ON show profusely branched processes 
emerging out of the cell soma, scale bar 5µm (B2). Astrocyte shape in CZ–treated ON 
differs in morphology owing to several processes which emerge from their soma. C. 
Representative electron micrograph shows streaming inter-axonal glial processes 
signifying activity of these cells upon CZ-treatment. Red star marks the invading 
cytoplasmic strands of the glial processes in between axons. Demyelination of axon is 
indicated by appearance of large axo-myelinic space (blue star) and a mass of deranged 
myelin membranes (white arrow), scale bar 500nm. D. Histogram showing an increase in 
GFAP fluorescence signals represented as AU/unit area (µm2), (p=0.03, n=35), □ 
untreated, ■ treated.    
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Figure   27: Ultrastructural myelin loss from ON axons due to CZ. 
 
 A. Cross sectional view of ON from control group, showing rounded and smooth profiles 
of normal myelinated axon (red arrow). B. Cross-sectional view of ON from experimental 
group exhibit, a prominent presence of myelinated axons (scale bar 5µm) but with less 
annular profiles. C. The “g” (di/do) ratio increased after CZ-treatment (n=1087, 805, 
p>0.001). D. Whereas there was a slight decrease in myelination index (do/di), it did not 
read significance (p=ns). E. Average myelin thickness was also lower after treatment 
(p>0.001) (□ untreated, ■ treated).    
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Figure   28: Morphometric changes in ON axons after CZ treatment. 
 
A. Frequency distribution of myelin thickness in both groups show a shift towards reduced 
number of myelin membrane. B. Frequency distribution of axolemma bound axon diameter 
(di) remains comparable in both groups. C. Axon diameter, including the axolemma 
delimiting axon (di) width and myelin membrane thickness (do), was analyzed from random 
fields selected across the entire nerve cross-section show a shift towards increase in mid-
range axons and decrease in large diameter axons, □ untreated, ■ treated, n= 1525, 1289.    
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Figure   29: Altered myelin sheath morphology in CZ-treated axons. 
 
A. Organization of myelin membrane stacks in the ON axons of control group, showing a 
normal spacing between the axolemma and myelin membrane (black arrow) in a healthy 
myelinated axon; scale bar 100nm. Arrow pointing left shows the adaxonal membrane and 
the one pointing downwards indicate and intact sub-myelinic periaxonal space. B. Myelin 
membrane disruption and changes induced after CZ-treatment. The change could be subtle, 
so that it separates one layer from the other in inter-myelinic membrane stack (black 
arrow, center) creating a localized bifurcation within myelin or in between the adaxonal 
membrane and axolemma so as it increases the submyelinic-periaxonal space locally 
(black arrow left bottom) scale bar 100nm. C. Several membranes might collapse leading 
to loss of IPL and creating space or gap between the axons, scale bar 250nm. D. Severe 
cases of demyelination exhibit the collapse of myelin membrane which can be accompanied 
by an invaginating membranous structure formation, so, that it squeezes the axoplasm and 
occupies the majority of axonal space; scale bar 500nm. E.  An axon showing deviant 
membrane organization in the treated group which has fused stacks (white box), 500nm. F. 
Boxed region from F has been expanded to show this aberrant feature which arises after 
CZ-treatment. Scale bar, 250nm. These images represent the patterns noted through 3 sets 
of experiment. 
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Figure   30: Loss of membrane periodicity and decreased levels of PLP in ON from 
CZ-fed mice. 
A. high magnification electron micrograph of intact myelin membrane spans of ON axons 
from control (A) and (B) CZ-treated group. C. Densitometric scans profiling the myelin 
diameter from untreated (A) showing normal lamellar pattern of IPL (intraperiod line) and 
MDL (major dense line) represented by the crests (downward arrow) and troughs.  D.  
Loss of periodicity in treated axons within intact stretches of myelin is noted by irregular 
crests (downward arrow) and troughs. Images in A and B represent myelin from 3 sets of 
experiment.  
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Figure   31: Altered ratio of PLP/DM20 in ON of CZ-fed mice. 
A. Western blot analysis PLP (proteolipid protein) and its splice variant DM20 from 
density gradient purified form of  myelin reveal differential levels of these two proteins in 
total brain (TB),  forebrain (FB) and ON samples from both groups (control, UT and 
experiment T). DM20 increases after. PLP and DM20 were identified as ~30kD and ~26kD 
proteins; the ~10kd band indicates a degradation product (D.P) of PLP (Lees and 
Bizzozero, 1992). B. Histogram showing decrease in PLP following CZ- treatment 
compared to the control. C. DM20 levels showed an increasing trend in the treated group. 
The values are plotted as % of total (PLP+DM20) (p=0.03, 0.01, 0.03, n=3, □ untreated, ■ 
treated).    
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Figure   32: Organization of axonal cytoskeleton in CZ-treated ON. 
 
A.  A representative 25µm long axon exhibits irregular width and disorganized 
cytoskeleton in treated ON. Red color double arrows show intermittent increase in axon 
width of the same axon is shown in longitudinal section. Such axons are interspersed in 
between cells with prominent cytoskeleton which is different in organization, scale bar 
5µm. B.  The NF cytoskeleton is discretely organized in the untreated group and helps in 
maintaining the axon caliber as seen in longitudinal section, scale bar 1µm. C. The 
interaction between microtubule (black arrow pointing right) and the extended arms NF 
(black arrow pointing down) form a nexus essential for maintaining a rigid structure. D.  
Such an organization is lacking in treated axons and hence leads to a random form of 
cytoskeleton marked by the increased particle density. E. Histogram showing increased 
particle density in treated axons (p>0.001, n=60, □ untreated, ■ treated).  Scale bar 100nm 
for C and D.   
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Figure   33: CZ perturbs NF phosphorylation in ON axons. 
 
A. Differential levels of p- and dp-NF detected in ON after demyelination using Western 
blot analysis. There is a loss in smaller size p-NF (~168kD) relative to the larger one 
(~200kD). Correspondingly there is an increase in the dp-NF (~200kD) in the treated ON.  
No change was noted for NF200. B. Histogram representing significant decrease in the 
quantity (arbitrary unit (AU) x 100) of p-NF (p>0.01, n=3) (C) and an increase in dp-NF 
(p>0.001, n=3). D. This accords much larger difference in the levels of p-NF and dp-NF in 
the total pool of NF after CZ treatment (p>0.001, n=3). □ untreated, ■ treated.     
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Figure   34: p-NF and dp-NF represents varying diameters of axons in ON. 
  
 A. A comparison of axon diameters labeled with p-NF and dp-NF indicate the threshold 
(dashed vertical line), when p-NF exceeds dp-NF. This trend is true for axons between 0.4 
to 1.4µm diameter (shaded portion). B. Whereas for the treated group the trend is reversed 
(dashed lines) as there is an increase in dp-NF labeled axons showing a shift (shaded 
portion) favoring large diameter axons (0.6 to 2.2µm). The median of frequency occurrence 
of dp-NF positive axons show an increase (box, A and B) following CZ-treatment (n = 235, 
286), UT = untreated, T = treated, dp-NF = dephosphorylated NF and p-NF = 
phosphorylated NF.   
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Figure   35: Inter-axonal organization after CZ treatment. 
 
 
 A. Representative visuals fields from TEM cross sections of treated ON section showing 
various types of streaming processes in between the myelinated axons. These inter-axonal 
spaces are filled with various types of membranous structures. The white arrow points the 
collapse of axolemma and formation of wider submyelinic periaxonal space. The axon on 
top (12 o’clock position) and middle shows the vacuolization of axoplasm. Right bottom 
corner is a well organized micro-tubular cytoskeleton of an intercalating cell (white box). 
B. This has been highlighted (double white arrow) in (B) to show the difference in 
organization of cytoskeleton relative to axons (refer Fig. 27). C. Occasional globose 
structures (white double arrow) were observed, which remained lodged on the outer 
periphery of myelinated axons (black double arrow) of treated axons only. D. Such cells 
were found to be reduced (non-significant) after CZ treatment, □ untreated, ■ treated 
groups, n = 1525, 1289, p = ns  
 
 
 179 
 
 
 
 
 
 180 
 
 
 
 
 
Figure   36: Nuclear morphology of inter-fascicular cells change after CZ treatment. 
 
 
A.  Representative image form treated ON showing two types of cells, one surrounded with 
electron dense (yellow arrow) and the other with electron translucent (white arrow) 
material, scale bar 1µm. They differ in their nuclear size. B. Electron dense cells and C. 
electron translucent cells of ON. Both these cells have different nuclear morphology owing 
to the scattered distribution of chromatin material in the perinuclear region (dark blobs) 
(B2, C2). Red arrows indicate electron dense material and yellow arrows show the 
perinuclear distribution of chromatin in treated group. D.  Eminent hypertrophic processes 
of the intercalating cells exhibit invaginating processes (white arrow) with membrane filled 
subcellular structures.  These cells have distinct nucleus with a marked perinuclear margin 
(black star). The scale bars are 1 µm (A and D), 5µm and 2µm for B and C panel 
respectively, □ untreated, ■ treated.    
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Figure   37: Evident partial loss of inner membrane of mitochondria and organized 
cristae in CZ treated axons. 
 
A. Representative electron-micrograph of untreated control mitochondria from axon 
exhibit intact inner and outer membranes (scale bar 200nm). B. The treated group show 
eminent loss of inner membrane (scale bar 200nm). Black arrowhead points to the wavy 
outline of these membranes C. Outlined trace of control mitochondria (A) highlights the 
perfect membrane integrity. D. Similar outlined trace of mitochondria from experimental 
group (B) shows disruption, black arrow points to the single membrane span. E. Histogram 
plot showing loss of inner membrane density (represented as membrane density/nm2) of 
mitochondria following CZ treatment (p > 0.001, n = 25, □ untreated, ■ treated). F. 
Membrane stacked structure of the mitochondria from the surrounding cell differ in 
morphology (scale bar 500nm).  
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CHAPTER 5 
 
CZ INDUCES ALTERED EXPRESSION OF Kv1 CHANNELS  
IN OPTIC NERVE AXONS 
 
5.1. Introduction 
 
Kv channels are well known therapeutic targets for neurons, cardiac and immune T cells 
(Judge and Bever, 2006).  Neuronal Kv1 channels could be of synaptic or axonal origin 
with different functional attributes like neuro-transmission (Caleo, 2009, Michaelevski et 
al., 2007, Wang et al., 1994), or mediating action potential propagation (Mert, 2006, 
Debanne, 2004). Axonal Kv1 channels are usually present as a paired cluster apposing each 
other on the longitudinal axis, often described as punctate expression. These specialized 
compartments or sub-domains are known as JXP of an axon (Rasband, 2004). They flank 
Nav rich unmyelinated part the focal node. Myelin concealed JXPs (Chiu and Ritchie, 1980, 
Rasband et al., 1999b) maintain subcellular segregation of Kv channels from nodal Nav, 
which is the basis of action potential propagation. This is essentially true for saltatory mode 
of fast conduction (Section 1.2). Disease conditions leading to demyelination result in 
compromised axon architecture of the surviving axons due to several types of local and/or 
global changes associated with it (Hu et al., 2008, Arroyo et al., 2002, Baba et al., 1999, 
Bitsch et al., 2000, Cerda and Trimmer, 2010, Rash, 2010, Gubitosi-Klug et al., 2005). The 
underlying effects rendered by such surviving/spared axon(s) in addition to those of the 
affected ones together contribute to neurological deﬁcits. In case of MS although 
demyelination and axon loss are marked at the onset (Compston and Coles, 2002), the 
subsequent malfunctioning of surviving axons following disease inception is of prime 
importance in the development of a therapy. Unfortunately, these events which affect the 
nervous system are detected late in clinical assessments. The major contributors of axonal 
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conduction deﬁcits (Lasiene  et al., 2008) include depletion of myelin and consequential 
effect induced on other structural elements of axons. Such changes in turn may be 
associated with altered activity of ion channels which play important roles (Nashmi and 
Fehlings, 2001) in neuronal co-ordination.  
 
5.2. Kv1 channels as a therapeutic target in multiple sclerosis 
 
It has been theorized that exposure of Kv channels as a result of demyelination would 
induce a reduced safety factor (Waxman, 2005) (the ratio of available current to an axon 
divided by the current sufficient for axon membrane to attain excitation threshold) of action 
potential propagation across demyelinated region of the axon (Section 1.12). Low safety 
factor means lower probability of an action potential to traverse the axon (Nashmi and 
Fehlings, 2001). Although this theory was originally conceived on the basis of 
electrophysiological studies and nodal features of Nav channels, it is important to note that 
efficient AP propagation is equally dependent on the JXP Kv1 channels of a myelinated 
axon. The roles of these channels are further highlighted by pharmacological studies 
involving Kv channel blockers on animal nerve preparations (Gordon et al., 1988).  
Investigations of neuron function using 4-aminopyridine (4-AP) a blocker of rapidly 
activating Kv channel has established its relevance as a therapeutic agent in MS and injury 
where demeylination is an eminent feature. Several preliminary clinical trials of Kv 
channels inhibitors have demonstrated therapeutic beneﬁt in MS (Stefoski et al., 1987) and 
spinal cord injury (Nashmi and Fehlings, 2001) although it induces epileptogenic activity 
due to off-site action. 
 
This study for the first time presents JXP Kv1 expression analysis of ON axons in CZ-
treated mice. The use of a murine model for sub-chronic CZ-induced CNS demyelination to 
establish the relevance of Kv channels in axons was anticipated to be revealing, since little 
is known about Kv1 channel associated deficits in this type of system(s).  
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5.3. Multiple Kv1 α-subunits are present in the ON axons 
5.3.1. Kv1.1, 1.2 and 1.4 are the major Kv1 α-subunits in the ON of both groups 
 
In order to detect the expression of CNS axolemmal Kv1 channels from mice, detergent 
solubilized ON membrane protein from both untreated control and treated samples were 
resolved in SDS-PAGE gels under denaturing conditions and probed with antibodies for the 
six major Kv1.x channels on PVDF membranes (Figure   38). Of all the six α-subunits 
Kv1.1- 1.6, signal was obtained only for three namely Kv1.1, 1.2 and 1.4. Kv1.3, 1.5 and 1.6 
remained undetected in this type of analysis. The molecular weight for Kv1.1 and Kv1.2 
bands were always higher than ~60kD in the solubilized membrane extract. Even though 
both were detected within a similar range, Kv1.2 tended to be of a larger size as broad and 
fuzzy bands. These corresponded to ~65kD for Kv1.1 and ~70kD for Kv1.2 (Figure   38A). 
The broad Kv1.2 signal could be resolved into three bands of ~77, 71, and 68kD size 
respectively, but it was impossible to achieve such a resolution for Kv1.1 in these 
preparations (Figure   38B). The higher molecular weight of Kv1.2 obtained from the 
membranes of ON were similar to bovine brain membrane (Scott et al., 1990) and human 
CNS (Coleman et al., 1999). The densitometric quantification of Kv1.1 on Western blots 
from 15µg of ON protein showed a minor, but non-significant increase (29.37 ± 2.13%, p = 
0.39, n = 3), whereas Kv1.2 exhibited a decrease (3.8 ± 1.02%, p = 0.85, n = 3) in the CZ 
treated samples. This indicated some kind of dysregulation of Kv1 channels following CZ 
treatment, but remained inconclusive, possibly owing to variation induced due to individual 
response.  
 
5.3.2. Molecular weight of Kv1.4 in ON protein is larger relative to Kv1.1 and 1.2 
 
Unlike Kv1.1 and 1.2, Kv1.4 signal from ON of CZ-treated and untreated group was always 
obtained as a doublet of much larger size corresponding to ~94 and 86kD in Western blot 
analysis. These were similar to human CNS membranes (Coleman et al., 1999). They were 
sharp bands in comparison to Kv1.1 and 1.2 (Figure   38A). This is because the mouse 
Kv1.4, from brain and cardiac tissue has two distinct mRNA species, ~ 3.5 kb and ~ 4.5 kb 
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in length (Wymore et al., 1996, Jang et al., 2008). These mRNA differ in the 3' non-coding 
region corresponding to potential polyadenylation determinants, located ~ 0.2 kb and ~ 1.2 
kb downstream of the coding region (Jang et al., 2008, Wymore et al., 1996, Wymore et al., 
1994). Study in Xenopus oocytes has indicated differential levels of Kv1.4 current owing to 
the expression of these two forms. Here in this study an quantitation of these two protein 
bands, which is anticipated to correspond to the two different proteins translated from the 
said transcripts, indicated 8.7 ± 0.03%, p = 0.01, n = 3 higher levels of the ~94kD band in 
the experimental CZ treated group. Collectively, these two bands for Kv1.4 correspond to a 
non-significant 4.33 ± 2.08%, p = 0.51, n = 3 increase following treatment. These 
observations (Section 5.3.1 and 5.3.2) proved that Kv1.1, 1.2 and 1.4 are the major 
membrane associated Kv1 channels present in the ON.  
 
5.3.3. Dysregulation of Kv1.1, 1.2 and 1.4 α-subunits of ON after CZ-treatment 
  
Neurons and their networks undergo a process of homeostatic plasticity that stabilizes 
neuronal output by integrating activity levels with network and cellular properties to 
counter perturbations. The excitability of an individual neuron is governed by the extent of 
commonality at the most fundamental and basic level, and yet little is known about these 
processes (Ransdell et al., 2012). Dysregulation of ion channels is one of the factors, which 
regulate such processes. Demeylination associated deficits in function are known to result 
due to several components (Section. 1.9).  Herein the relative level of Kv1 channels 
localized on the JXP (see below) of ON axons was examined employing a sensitive 
detection system for the homogenates.  
 
5.3.4. Kv1.1 and 1.4 is up-regulated, whereas Kv1.2 is down-regulated  
 
Western blot analysis indicates a dysregulation of Kv1 channels in ON after CZ-treatment, 
but they could not be reliably evaluated for an individual nerve owing to their low protein 
yield. Hence, the expression level in nerve homogenate was further explored by combining 
two sensitive detection systems like ELISA (Enzyme linked immunosorbent assay) and 
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CSPD chemiluminescence. This permitted investigation of samples from individual nerves, 
using very less amounts (3µg) of ON protein. Known quantities of Glutathione- S- 
transferase (GST) fusion peptide corresponding to sequence from Kv1.1, 1.2 and 1.4 (Table 
1) were used to generate a standard curve, against which the unknown samples i.e., ON 
homogenate from CZ-treated and untreated control mice were compared. This strategy 
allowed evaluation of the relative levels of Kv1.1, 1.2 and 1.4 α-subunits against a known 
standard and expression as relative luminescence unit (RLU). This methodology allowed 
assay of the relative levels of Kv1.1 and 1.2 in a nerve. Kv1.1 exhibited a significant 54.04 ± 
0.12% (p > 0.001, n = 6) increase (Figure   39A) whereas Kv1.2 represented 45.35 ± 0.01% 
(p > 0.001, n = 6) decrease (Figure   39B) in CZ-treated nerve. Interestingly, Kv1.4 also 
exhibited an increase of 62.53 ± 0.29% (p > 0.001, n = 6) (Figure   39C) in the treated 
samples. The peptides used in this experiment corresponded to C-terminus (Table 1) such 
that only mature forms of these proteins were detected herein. Hence, these observations 
are indicative of the changes in the mature form of α-subunits which are possibly the 
membrane pool. The greater difference observed here relative to western blot, could be due 
to the detection of non-axolemmal contaminating pool in those samples. Negative controls 
for background elimination arising due to protein coating, buffer salts and washes were 
included in these experiments. The samples were quantified in serially-diluted range of 
concentrations and the average difference between treated and untreated sample was 
considered for evaluation. The experiments also allowed estimation of the relative levels of 
all three Kvs in untreated and treated groups. Their normal levels (Kv1.2>1.1>1.4) in ON, 
shifted in the CZ-treated group (Kv1.1>1.2>1.4) which was indicative of predominance of 
Kv1.1 after demyelination. This in turn might signify an anticipated change in the α-subunit 
associations of ON, specifically Kv1.1 and 1.2.  
 
5.4. Kv1.1 and 1.2 are the major Kv channel constituents of ON axons and they attain 
disparate expression after CZ treatment  
 
Kv channels regulate a variety of neuronal properties, including action potential amplitude 
and duration, frequency of ﬁring, neurotransmitter release, and resting membrane potential 
(Hille, 2001). Their precise location is a determining factor for such an attribute. JXP 
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localization is vital for saltatory conduction in myelinated axons. Herein, following 
induction of demeylination by CZ, there was a loss of compact myelin which is an 
important regulator for expression, of Kv1 channels (Baba et al., 1999). Hence, immuno-
labeling experiments were performed using 10µm longitudinal cryosections of ON. Kv1.1 
and 1.2 specific antibodies visualized apposing punctate structures of axons on the 
longitudinal axis in the control group as expected. A broad view micrograph shows several 
such structures which appear as elongated dots (Figure   40A, red box) representing the 
JXP location of these channels.  Similar pattern was observed in CZ-treated ON (Figure   
40B, red box). Most of the JXPs showed intense labeling of Kv1.1 and 1.2. All Kv1.1-
labeled JXPs overlapped with 1.2 positive JXPs in the untreated group thereby, exhibiting 
100% overlap whereas, experimental group axons showed only 96% overlap (Figure   
40B).  Even though one would expect Kv1.1 and 1.2 to exhibit an absolute co-localization, 
these JXPs had relatively greater Kv1.2 signal in controls than the experiment. Accordingly 
Kv1.1 signal appeared higher in the experimental group than the controls. Further analysis 
(Section 5.10), showed an array of JXP pattern in the treated group, indicating CZ induced 
disparity.    
 
5.5. CZ induces two types of alterations in the expression of JXP Kv1.1 and 1.2  
 
CZ-induced heterogeneity in the expression of JXP Kv1.1 and 1.2 was eminent and it 
could be classified as two distinct categories. 
 
 Internodal Kv1: Firstly, several JXPs appeared elongated such that labeling of 
Kv1.1 and 1.2 spread along the entire length of internodes. Some axons had lost 
demarcated JXPs and it appeared as smeared, elongated structure along the axon. 
Apparently, these represent the most affected axon following due to CZ and have 
lost their typical punctate identity (Figure   40B (white box) C, D). This kind of 
exclusive feature has never been reported before, specifically CNS featuring axons 
of ON with defined demyelinating pattern 
.  
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 Elongated JXP: Secondly, the remaining JXPs showed loss of paired punctate 
labeling in these micrographs. Even though it was a visible feature, yet in order to 
avoid any ambiguity that might arise owing to visualization of JXPs on these 
micrographs, this was analyzed in affiliation to the nodal labeling with pan Nav 
(described in a later, section 5.11) 
5.6. Associated α-subunits in Kv1 channels of ON  
 
Unlike nodal Nav channels, which are single chain proteins, the functional axolemmal Kv1 
channels are formed by the assembly of four subunits into a tetrameric protein which spans 
the membrane and collectively forms the domains essential for the flow of K+. Even though 
one might assume a huge number of combinations of subunits, owing to the 
oligomerisation often being restricted within the same Shaker subfamily (Shamotienko et 
al., 1997), Kv1 channels are tailored in this way only to a limited set of combinations 
explaining the basis for fine-tuning of neuronal function by regulating K+ conductance 
along the membrane (Shamotienko et al., 1997, Akhtar et al., 2002). For instance, Kv1.1 
exerts a more dominant influence on Kv1 channel activation, with lowered voltage 
threshold for activation; this is shifted negatively upon increase in the number of Kv1.1 
subunits relative to Kv1.2 in a tetramer. Thus, depending upon the numbers of these 
subunits in a tetramer their biophysical and pharmacological profile might differ (Bostock 
et al., 1981, Sokolov et al., 2007, Akhtar et al., 2002, Al-Sabi et al., 2010). Interestingly 
Kv1.1 shows higher sensitivity to 4-AP relative to its known obligate associate Kv1.2 in 
expression systems (Scott et al., 1994b). Since MS demeylination also leads to an increase 
in 4-AP sensitivity as indicated by the therapeutic benefit rendered by similar compounds 
(Dunn and Blight, 2011), an apparent role of Kv1.1 α-subunit is anticipated.  
 
5.6.1. Kv1.2 α-subunit associate with Kv1.1 to form hetero-oligomers 
 
In order to investigate the possible associations of Kv1.1 and 1.2 in JXP of ON, co-IP 
experiments were performed. ON homogenate was briefly incubated with polyclonal 
antibody against Kv1.x (Section 2.12) and then the complexes were pulled down using 
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protein-A Sepharose beads and probed for other Kv1.x α-subunit(s) (Shamotienko et al., 
1997). Combinations of α-subunit specific antibodies were used to decipher the 
associations (Figure   41A). Kv1.2 antibody could pull down Kv1.1 α-subunits from both 
treated and untreated samples. Reciprocal IP using Kv1.1 specific antibodies yielded Kv1.2 
signals. This indicated that these two subunits co-associate in ON.  
 
5.6.2. ON homogenate has self-assembled homo-oligomers of Kv1.1 
 
On the basis of the noted up-regulation of Kv1.1 protein (Section 5.3.4), an effect exerted 
mainly due to this particular channel is anticipated, so the possibility of its homo-
oligomeric association was explored by employing a sequential-immunoprecipitation (seq-
IP) (Shamotienko et al., 1997). This involved three stages of IP, namely IP-1, IP-2 and IP-3 
(Figure   41A). Since the content of Kv1.4 is the lowest in ON, the first IP was conducted 
to precipitate all possible oligomers of Kv1.4 (Kv1.4-1.2, 1.4-1.1, 14-1.4). These 
combinations were not confirmed, but it was ensured that the resulting supernatant did not 
contain any remaining Kv1.4 signal, implying that all these possible oligomeric associations 
(if present) are eliminated in this step. Second step (IP-2) involved precipitation of Kv1.2 
containing oligomers (1.2-1.2, 1.2-1.1) and, finally, and the last step IP-3 employed 
precipitation with Kv1.1 antibody. Signals were obtained in each stage of seq-IP, 
reconfirming the presence of all these three α-subunits. Interestingly, Kv1.4 precipitation 
detected a doublet band, similar to that obtained from membrane extract. On the other hand, 
Kv1.2 precipitation yielded a broad band (~60-70kD). This possibly indicated the presence 
of various types of oligomeric associations even though that remains to be confirmed. Since 
it was of interest to investigate homo-oligomeric association of Kv1.1, the supernatant was 
subjected to the last IP-3 to further precipitate proteins with polyclonal Kv1.1 IgG and this  
allowed detection of two low molecular weight bands of ~55 and 50kD (Figure   41B). 
Kv1.1 protein of this size was not detected in the membrane extract.  
 
So, it was reasoned that these bands corresponded to the cytoplasmic protein, probably of 
Golgi origin, because, nerve homogenate had to be used in these experiments (n=2) as they 
required larger amounts of protein (45µg). Use of lower amount of protein did not yield any 
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band at the end stage. Alternative explanation may stem the fact that, these bands represent 
free peptides from the axoplasmic protein pool or a form of membrane protein which has 
not undergone post-translational changes. In a pioneering study, on in vitro assembly of 
Kv1.1 transcript it has been shown that ~55kD band corresponds to Kv1.1 protein in 
absence of microsomal membranes, whereas it acquires high molecular weight in their 
presence (Babila et al., 1994). Taken together,  ~50kD band is apparently an 
unglycosylated form of Kv1.1, but the ~55kD peptide corresponds to a glycosylated form 
(Manganas et al., 2001). In a separate study on the hydrodynamic nature of Kv1.1 protein it 
has been indicated that such a heterogeneity underlies the heterogeneous pattern of 
oligomer association under a given condition (Shen et al., 1993) which is expected to vary 
greatly in a neuronal environment compared to any in vitro expression system. It was 
anticipated, that if a minor population of Kv1.1 homo-oligomeric axolemmal form is 
present in the ON, it would remain undetected here in these experiments, but lead to the 
fine tuning of nerve function.  
 
Herein, there is a possibility of existence of other homo-oligomers for Kv1.2 and 1.4, but it 
has remained unexplored in the present study, partly because it was not of relevance to 
establish their identity and partly because of the paucity of protein due to low yield from 
ON.  
 
5.6.3. In situ localization of Kv1.1 and 1.2 interacting subunits in ON axons 
 
In-spite of extensive evidence supporting the formation of Kv1.1-1.2 hetero-oligomers in 
the nervous system, the conclusive existence of these complexes in their native 
environment has not been demonstrated. For myelinated axons, such interpretations have 
remained difficult owing to the myelin concealed location of JXP and expression of these 
two α-subunits within a micro-domain. So PLA was adopted herein to decipher the in situ 
localization of Kv1.1 and1.2 interacting subunits if in close proximity, <16nm (Trifilieff et 
al., 2011). Localization of Kv1.1 containing α-subunit was detected using two specific 
antibodies one directed against the extracellular epitope (mAb) and the other for an internal 
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intracellular epitope (rabbit polyclonal) (Table 1, 2) to yield fluorescent signals (Figure   
42A). Similar to the patterns observed using IHC and described in the paragraph above, the 
JXPs from CZ-treated nerve represented various types of patterns. This allowed detection 
of Kv1.1 signal only and, interestingly, this corresponds to elongated JXP signals. Many of 
them acquired a much more elongated and smeared appearance, but their exact identity 
could not be established in the present study. Probably these were the much extended 
internodal expressed Kv1.1 observed in treated group. Collectively, these indicated a wide 
distribution of Kv1.1 along the JXP which tend to spread out to the internode (Figure   
42B1). Whereas detection of Kv1.1-1.2 interacting subunits using antibodies directed 
against Kv1.1 extracellular (mAb) and Kv1.2 intracellular epitope (rabbit polyclonal), 
showed that Kv1.1-1.2 interacting subunits remain in close proximity to the nodal gap 
(Figure   42B2) in the treated group samples. This is the first demonstration of such an in 
situ interaction between the two channels of JXPs in ON axon. 
 
5.7. Minority of Kv1.2 expressing JXP co-localize with Kv1.4 
 
Even though the exact role of Kv1.4 in MS or demeylination is not established (Wulff et al., 
2009), a prominent and consistent Kv1.4 signal was obtained from the ON homogenate 
using Western blot analysis (Section 5.3.2);  hence, it was further investigated by IHC 
analysis. Longitudinal sections (10µm) were treated with antibodies for Kv1.2 and 1.4 
because; Rasband group reported the presence of Kv1.4 on 1.2 positive JXP. (Ogawa et al., 
2010) Surprisingly, very little Kv1.4 signal was found on the usual punctate JXP (Figure   
43A, B) structure described in above paragraph. Microscopically, it appeared as fuzzy 
background. The number of Kv1.2+ve JXPs that were also Kv1.4+ve represented a minor 
population. Only 18.6 ± 1.8% vs. 9.2 ± 1.2% (p > 0.001, n = 1161, 892) JXPs showed such 
an overlap in the untreated control and treated groups. The remainder did not show any 
overlap and were found to be either Kv1.2+ve of Kv1.4+ve. For the JXPs which did not 
overlap Kv1.4 exhibited a decrease and the Kv1.2 showed a corresponding increase in CZ-
treated ON (Figure   43C) but these changes were non-significant.    
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5.8. Area and length of surviving JXPs co-labelled with Kv1.1/1.2 increases after CZ 
treatment 
 
The alterations in JXP expression pattern of Kv1.1/1.2 label were so prevalent that 
sometimes it was difficult to account for the entire internodal length, even though it was 
visibly a prominent feature. So morphometric analysis of the surviving JXPs was 
performed. This included all of those which appeared as a single lone unit or a paired 
apposing structure along the axons. Area and length were measured manually for each JXP 
by outlining the ROIs. Kv1.1 and 1.2 co-labeled images exhibiting yellow signal signifying 
the overlap of these two fluorescence namely red (Kv1.1) and green.(Kv1.2) The border of 
these ROIs was defined by setting a threshold where yellow signal diminished and 
red/green or ceased/emerged. The average JXP area before and after CZ-treatment was 
10.31 ± 0.81 and 12.46 ± 1.06 µm2, (p = 0.06, n = 46, 42) (Figure   44B). The area range 
was 3.43 to 26.78 µm2 before and 2.76 to 40µm2 after treatment (Figure   44A). A binned 
frequency distribution of these JXP areas is represented in Figure   44 A. The Kv1.1/1.2 
labeled JXPs of the experimental group occupied larger axon area relative to the untreated. 
This indicated spread of Kv1 channels into a wider space along the internodal length of the 
axon after treatment.  
 
Based on the same defined ROI, their length was assessed from the point of peak signal 
intensity close to the nodal gap till the other end which extends into the internode. The 
average JXP length increased from 4.0 ± 0.32 to 5.90 ± 0.35 µm (p > 0.001, n = 46, 42) 
after treatment (Figure   44D). Binning of these length measures (Figure   44C) to evaluate 
the trend did not prove conclusive. Considering the increase in area, it was expected that 
the length changes would be proportionate, but that was not the case; apparently, the axon 
diameter is a contributing factor here.  Taken together, these measurements indicate a 
widespread increase in the internodal expression of Kv1.1 and 1.2 following CZ-treatment.   
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5.9. Inter-JXP length increases in the treated group 
 
Edges of JXP adjoining the node exhibited variations, which appeared as extensions 
beyond their restricted domain. This was evident due to the different shapes they acquired 
following CZ treatment (Figure   45). These could be normal blunt ended (Figure   45 A1, 
B1) or pointed cone like (Figure   45A2, A3). Sometimes the cone like JXPs tended to fuse 
from the apposing ends and loose their characteristic punctate structure in the treated group 
(Figure   45B2, B3). It was worth noting that these features lead to merging of adjoining 
JXPs. This could be further highlighted on an intensity profile, where the distance between 
the two peak intensities of the apposing JXPs varied (Figure   45C). This parameter was 
analyzed in Kv1.2 labeled JXPs. The frequency distribution of these inter-JXP length 
distributions indicated a shift towards the longer length in the treated group, indicating an 
increasing trend in the nodal gap after CZ treatment (Figure   45D).  
 
5.10. Co-localization of Kv1.1/1.2 within unaffected surviving axons exhibit a relative 
decrease of Kv1.2 intense JXPs  
 
It was interesting to note that these surviving axons exhibit varied morphological features; 
so the possibility of differential role that could be acquired by two α-subunits on these 
axons was examined on the basis of their levels of expression. The extent of Kv1.1/1.2 
labeling on these surviving JXP showed dissimilarity (Figure   40, Figure   42, Figure   
46C, D). Kv1.1 fluorescence extended much longer on the JXP in the internode relative to 
Kv1.2 in the treated group (Figure   42C, D, Figure   46A). The collective mean 
intensity/area (µm2) of the defined JXPs (ROI, as described in earlier section), for both 
Kv1.1 and 1.2 showed a non-significant decrease in the treated group (Figure   46B), 
indicating a spreading of the signal away from the JXP. The number of Kv1.1+ve and 
Kv1.2+ve JXPs and their corresponding intensity plots provided a trend for the two. 
Prediction based on extended linear regression (R2) co-efficient for Kv1.1 was ascending 
whereas Kv1.2 showed a marked descends in the treated group. Taken together, it reflects a 
change in the pattern of expression of these two α-subunit on the surviving JXP of treated 
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group, where Kv1.2 appears to be down-regulated mostly extending towards the nodal end 
of JXP in majority of these axons. This observation further supports the feature noted by 
the area and length measurements.    
 
Since Kv1.1 and 1.2 exhibited a differential labelling on the JXPs (Figure   47 Fig. 35, 
41A, C, D), the extent of their overlap was further examined, by analysing the correlation 
coefficient (Pearson’s). This allowed information regarding intensity distribution within the 
co-localising region (LSM 710/ConfoCor3 user manual, page 4-170, 10/2008). R2 for 
untreated was 0.145 and 0.176 for the treated group indicating a tighter co-relation in the 
experimental group (Figure   46F). The average co-relation co-efficient (Rr) for these JXPs 
showed an increase in the treated group (p > 0.001, n = 92, 96) (Figure   46D). This was 
further reflected by the average overlap co-efficiency of these two channels, namely Kv1.1 
and 1.2 (Figure   46E) which showed a significant increase (p > 0.001, n = 93,115). 
 
5.11. Minor nodal disruption is accompanied by changes in JXP  
 
The nodes are complementary structures required for efficient action potential propagation 
besides the JXPs. Herein labeling of focal nodes using pan-Nav antibody exhibited multiple 
effects due to CZ induced demeylination. In the micrographs of Nav labeled ON axons from 
both groups these appeared to be of varied shapes and sizes (Figure   48A).  Briefly, the 
normal or intact nodes could be described as compact and focal spots with a visible 
delimiting boundary. The nodes that were affected appeared as smeared or elongated. Some 
of them also appeared as doublets (Figure   48. 43B). Whether, these doublets were an 
induced feature or a mere co-incidence of two closely apposed nodes was a question. 
However, these doublets were less frequent in the untreated nerves. So, it was assumed as 
an induced effect for analysis here, considering the fact that such nodal proximity will 
create interference with the trains action potentials propagation (Waxman, 2005). Even 
though most of the nodes remained intact, small proportions were affected as per these 
morphological parameters (Figure   48 C, D). It was interesting to note that a minority of 
the nodes exhibited elongated shape in the untreated group as well, which could be referred 
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as oblong shape rather than an absolute spherical or rounded shape. Taking that into 
consideration and accounting them as normal revealed that 21 ± 3.04 % (p > 0.001, n = 
712, 635) of the nodes are affected due to CZ-treatment. This observation indicated that 
Nav is dislocated from its focal node following CZ-treatment. These collectively indicate an 
induced effect on the nodal Nav.  
 
Analysis of these features of the node in affiliation with the JXPs was anticipated to be 
revealing as they collectively form the structural units for maintenance of effective action 
potential propagation along an axon. Herein a composite morphological element 
comprising of two intact and apposing JXPs flanking a focal node was considered as a 
structural unit for impulse conduction. These units in control samples are being referred as 
“intact JXP” for the sake of description here. They were assessed on the basis of double 
immuno- labeling for Nav/Kv1.2. Those which maintained such a feature in the treated 
nerve was categorized as “spared” or “surviving” units (Figure   49). It was interesting to 
note that there is a significant decrease in such units after CZ-treatment (Figure   49D, F). 
The effects were multifarious and they were indicated by a) absence of adjoining JXP 
which would normally flank the other side of the node, b) disparate JXPs flanking a node c) 
the JXP appears fragmented as two or more interlinked segments (Figure   49C). All these 
structural changes are bound to produce a designated effect on the propagation of action 
potential and summon an impact on the safety factor of these axons, resulting in impedance 
mismatch. One would expect that the hemi-nodes are present in a normal condition as well, 
but the described alterations were very frequent in the treated group, so it is accepted as a 
CZ induced effect here. The treated group exhibit 60.53 ± 9.62% average decrease, (p = 
0.02, n = 157, 102) of such functional units. Subsequently, an analysis of the signal 
intensity of these nodes, indicated a significant increase in the average absolute intensity 
relative to the controls (253.28 ± 24.23 vs. 353.65 ± 34.44 AU) in the treated group (p > 
0.001, n = 40, 46). Collectively, these indicate an accompanied displacement of nodal Nav 
channels.  
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5.12. Cellular profiles exhibit Kv1.1, 1.2 and Nav signals after CZ treatment 
 
CZ-treatment induced expression of these ion channels in some cellular profiles which 
remain intercalated in between the axons. Nav, Kv1.1 and 1.2 all were found in such type of 
cells. Nav expressed was most prominent (Figure   50A, B). Since these were located on 
the cells, it was expected that they will not have a direct impact on the electrophysiological 
property of an axon; hence it was not considered in this study. Even though the precise 
identity of these cells expressing Kv1.1 and 1.2 was not established here, it is anticipated 
that these are proliferating microglial cells induced by CZ treatment (Pott et al., 2009, 
Groebe et al., 2009, Hiremath et al., 1998) which express Kv1.1 and 1.2 (Li et al., 2008, Wu 
et al., 2009) (Figure   50C, D).   
 
5.13. Kv1.4 is of glial origin 
 
Kv1.4 had a limited expression on the JXPs, but the microscopic signal obtained appeared 
fuzzier and a co-labelling of axons with CNPase, indicated their presence of cells. These 
clusters of spotty signal surrounded a nucleus (Figure   51). The cells were further 
identified as oligodendrocytes which surround the axons, employing staining for 
Adenomatous polyposis coli a marker of oligodendrocyte and propidium iodide to label the 
nuclei. This allowed confirmation of their identity.  Thus, it is concluded that majority of 
Kv1.4 signal obtained from ON homogenate is of glial origin.  
 
 
5.14. Abnormal electro-responsiveness and conductivity of ON from CZ-treated mice  
 
The functional impacts of these changes in ON were assessed by CAP recordings from the 
central stump of semi-dissected ON at physiological temperature (Figure 52A). In controls, 
stimulation of the distal end of the nerve evoked synchronous CAPs, whose amplitude 
could be graded by varying the stimulus strength (Figure 52C); the threshold stimulus 
ranged between 0.36 and 0.44 mA (0.39  0.2; n = 6) with responses saturating at 
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intensities between 0.9 and 1.2 mA (0.96  0.4, n = 6) (Figure 52C1, C2). Uniform 
conduction of normal axons was evident from synchronous monophasic CAPs, evoked by a 
single or paired pulse stimuli, with absolute refractory phases of control nerve ranging 
between 2.0 and 2.6 ms (2.38  0.2 ms, n=6) (Figure 52B, D1, D2). Analysis of the effects 
of TEA (10mM) or 4-AP (1mM) on sub-maximal CAPs in the control nerves showed an 
increase in their amplitude with stabilization of their blocking effect 15-20 min after 
application. Figure 52 (E, F) illustrates representative CAPs before and in the presence of 
TEA or 4-AP. The effect of TEA in controls was subtle and slow, but failed to reach 
statistical significance (n=4, P=0.061). In contrast, 4-AP that caused a more prominent 
increase of CAP amplitude (67.2  5.2%; n=5; p<0.005), which declined during the 10 min 
washout (not shown). Notably, neither TEA nor 4-AP affected the 50% refractory phase of 
CAPs (5.3  0.3ms and 5.4  0.2ms; p=0.21 and p=0.48) in controls, with only 4-AP 
reducing the threshold stimulus intensity (3.3  0.4; p=0.038) for eliciting CAPs. Unlike the 
controls, CAPs of ON from CZ-treated mice revealed a complex shape, with an early 
synchronized fast phase followed by a protracted late component (Figure 52C1), reflecting 
altered excitability and conductive properties of the demyelinated axons. Furthermore, the 
minimal stimulus intensity required for eliciting CAPs in the demyelinated ON was 
elevated (range: 0.42 and 0.62mA, mean: 0.58  0.3; n=5) with the absolute refractory 
phase prolonged (range: 2.8 and 3.6 ms; mean: 3.0  0.2, n=5) (Figure 52D). Similar to 
controls, blockade of K+ channels with TEA (10mM) or 4-AP (1mM) in demyelinated 
nerves increased CAP amplitude, with the effects of both blockers reaching statistical 
significant (58.4  21.2% and 114.2  21.7%, respectively, n=5 in each group; p<0.005) 
(Figure 52E, F). As observed with the controls, refractory time for 50% recovery of CAPs 
(7.7  0.3ms and 7.5  0.2ms) remained unaltered under both treatments while the 
threshold stimulus intensity was significantly reduced (0.47  0.1mA and 0.46  0.1mA; 
n=5 in each group; p<0.05) (not shown).      
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5.15. Differential contribution of Kv1.1 and Kv1.2 to CAP in demyelinated ON  
 
The relative contributions of Kv1.1- and 1.2-containing channels in ON to tuning the 
electrogenic properties of these axons were evaluated. Blockade of Kv1.1 and 1.2 subunits 
of normal ON with DTXK (100nM) or TsTX-K (100nM) revealed little change in the 
characteristics of CAPs, with both amplitude and activation threshold remaining relatively 
unaltered (amplitude increase: 15  7.2%, n=5; 10.3  5.8%, p>0.05; n=6, respectively) 
(Figure 53A, B, C, D). At the specified concentrations, DTXK is known to block 
completely Kv1.1-containing channels (IC50 of 2.5nM) (Robertson et al., 1996, Wang et al., 
1999) while TsTX-K abolishes K+ currents mediated by Kv1.2 channels (IC50 of 0.55nM) 
(Hopkins, 1998). Because of the presence of both subunits in mouse ON JXPs, 
ineffectiveness of such toxin blockers in myelinated axons is likely to be due to poor 
accessibility of K+ channels. Such an interpretation also accords with the toxins’ failure to 
change the refractory time in control ON (n=5; p>0.05) (Figure 53E). In stark contrast, in 
demyelinated nerves, the same concentrations of DTXK and TsTX-K caused significant 
augmentation of the CAP amplitude (74.3  5.4%, n=5; 32.2  4.2%, n=5; respectively, 
P<0.05) with the late asynchronous component being especially sensitive (Figure 53A, B). 
Concurrently, both current thresholds (72.5% decrease with DTXK; or TsTX-K 22.8%; 
P<0.05) and 50% refractory time period were notably reduced, albeit the latter reached 
statistical significance only in DTXK-treated samples (61.3  7.1%, n=4 vs. 13.2  3.1%) 
(Figure 53C-E). Of note, blockade of KV1.2 subunits with TsTX-K after the effect of 
DTXK reached a plateau did not produce additional changes in the threshold or the peak 
amplitude of CAPs (n=4; P=0.11 and P=0.091, respectively). The quantitatively different 
effects of these blockers were unexpected given that the presence of one toxin-sensitive 
subunit renders the hetero-tetrameric channels susceptible to toxins (Akhtar et al., 2002, 
Hopkins, 1998), and suggests that enhanced K+ conductance in demyelinated axons could 
be mediated largely through JXP tetrameric Kv1 channels possessing higher numbers of 
Kv1.1 than 1.2, or even an unusual homo-tetrameric form Kv(1.1)4.  
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5.16. Conclusion 
 
Thus, this chapter demonstrates evidences for dysregulation of JXP Kv1 channels. 
Preferential and ectopic emergence of Kv1.1 channels on the axons following CZ treatment 
is indicated by fluorescence microscopy studies. This has been further supported by the 
higher blocking effect obtained by DTXK in CAP recordings. The fluorescence signal for 
Kv1 and Nav channels obtained in the cells of unidentified origin following CZ feeding 
remains an interesting and intriguing observation, which might be of relevance in the 
progression of demyelination.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 201 
 
 
 
 
 
 
 
 202 
 
 
 
 
Figure   38: Expression of Kv1 α-subunits in ON. 
 
A. Identification of Kv1 α-subunits in detergent-solubilised nerve membrane extract of ON, 
using Western blot analysis. Lanes: 1, 3, 5, 7, 9 and 11 untreated control; 2, 4, 6, 8, 10 and 
12, CZ-treated samples. Mouse monoclonal IgGs for Kv1.1-1.6 were used for probing as 
indicated on top. Lane: 1, 2, Kv1.1; 3, 4, KV1.2; 5, 6, Kv1.3; 7, 8, KV1.4; 9, 10 KV1.5 and 11, 
12, KV1.6. The positions of markers shown on the left side are marked as Mr ~ 50 and ~75. 
These indicate the presence of KV1.1, 1.2 and 1.4 but absence of KV1.3, 1.5 and 1.6 α-
subunits in the ON of both groups (15µg membrane protein). B. The right hand panel 
shows resolution of Kv1.2 band into three bands corresponding to sizes ~68, 71 and 77kD, 
when freshly prepared, non-frozen ON protein, maintained with protease inhibitors at 4ºC 
was used. C. Co-IP of ON Kv1.2 α-subunit from detergent solubilized nerve homogenate 
(25µg of nerve protein); indicate its association with Kv1.1. They were precipitated using 
polyclonal IgG and probed with mAb antibody for each subunit. This was confirmed by 
reciprocal co-IP of both subunits. The polyclonal antibody is indicated on top and mAb at 
the bottom of each band in this panel.  
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Figure   39: Dysregulation of Kv1 channels following CZ treatment. 
 
ELISA based quantification of Kv1 channels show a significant increase in Kv1.1 (A) and 
1.4 (C) (n=6, p>0.001 and>0.001), and a decrease in Kv1.2 (B) (n=6, p>0.001). The 
signal has been quantified as RLU (Relative luminescence intensity) and the relative values 
of untreated control and treated sample against the known standard has been presented 
here as histogram, □ untreated, ■ treated.    
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Figure   40: Altered expression of JXP Kv1 channels after CZ treatment. 
 
A. Normally JXP Kv1 channels are expressed as paired punctate structure on the axon axis 
(red box). Both Kv1.1 (A1, green) and 1.2 (A2 red) normally co-localise (A3, yellow). The 
extents of red labelling appear to be more in untreated axons (A3). B. After CZ-treatment 
apart from normal appearing punctate JXP structure (red box), these channels gain 
internodal prominence (white box, white arrow). The levels of green labelling (Kv1.1) also 
seem to increase after treatment. D. A confocal Z-stack image represented in gray scale 
shows elongated internodal expression of Kv1.1α-subunits after CZ treatment. E. Same 
axon shows the labelling for Kv1.2 α-subunit. Note a more extended internodal distribution 
of Kv1.1 (left) relative to Kv1.2 (right), indicating gain of axonal expression by this 
particular subunit. Scale bar 10µm, □ untreated, ■ treated.    
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Figure   41: Kv1.1 homo-oligomers identified in ON homogenate of both groups. 
 
 A.  Generalized scheme of multi-stage immunoprecipitation of Kv1.1 homo-oligomer in a 
detergent solubilized crude extract of ON. IP-1, IP-2 and IP-3 indicate the three 
immunoprecipitation steps involved. The blue boxes show the elimination of all possible 
combination of Kv1.x oligomers at that particular step. B. An aliquot (45µg protein 
suspended in 750µl) of solubilized extract was precipitated with different polyclonal anti 
Kv1.x antibodies (5µg/ml) in the sequence illustrated (A). The resultant pellets (ppt) from 
each step (IP-1, IP-2 and IP-3) were subjected to SDS-PAGE and blotted with the anti-
Kv1.x (mAb) as indicated in A. The supernatant (supt) obtained at each step was also 
subjected to the same probing step in order to ensure that the supernatant is devoid of any  
associated oligomer (indicated as blue box in A) in that particular  step. The marker 
position is indicated on the left of each panel.  UT and T indicate the untreated and treated 
ON samples used for these experiments.  
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Figure   42: Demonstration of in situ interaction of Kv1.1-1.2 α-subunits in JXPs after 
CZ treatment unveils their disparate patterns. 
 
A. Schematic diagram to show the use of two antibodies directed against different epitopes 
of the same Kv1.1 (A1) of different proteins like Kv1.1 and 1.2 (A2) in generation of PLA 
fluorescent signals. The black and red antibodies are directed against two different 
epitopes. Grey symbolizes the secondary antibody and the red flocculent structure is 
amplified signal after ligation of the PLA probes. B. First panel shows the elongated JXP 
feature of an axon following CZ treatment and prevalence of Kv1.1 in such axons. Next 
panel (B2) demonstrates two different shapes of JXP after CZ treatment. Note the 
aggregated Kv1.1/1.2 cluster near the nodal gap, whereas channels lacking Kv1.2a-subunit 
in them tend to extend much longer into the internode, Scale bar 5µm.  
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Figure   43: JXPs expressing Kv1.4 is not as prominent as Kv1.2. 
 
A. Broad view of Kv1.2 (red)/1.4(green) labeled axons from control group (left panel). 
There is an evident reduction in Kv1.2/1.4 co-labeled JXPs after CZ treatment (right panel), 
Scale bar 10µm. B. A Kv1.2+ve JXP overlaps with Kv1.4+ve signals in control. This is shown 
as an inset (bottom left) using co-labeling for both a-subunits in untreated and treated 
samples. C. Histogram representing different levels of overlap in the JXPs of both groups. 
Kv1.2/1.4 overlap decreases following CZ treatment (p>0.001, n=1161, 892), □ untreated, 
■ treated.    
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Figure   44: CZ treatment induces variation in JXP length and area 
 
A. Frequency distribution of area occupied by Kv1.1/1.2 co-labeled JXPs. B. Average JXP 
area of treated group increases relative to control (p>0.001, n=46, 42). C. Frequency 
distribution of JXP length of surviving axons. D. Increase in average JXP length is eminent 
following CZ treatment, (p>0.001, n=46, 42), □ untreated, ■ treated.    
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Figure   45: Inter-JXP length increases in the treated group. 
 
A. Representative images of Kv1.2 labeled (red) JXPs from control group showing different 
shapes (A1-A3). B. Similar images of Kv1.2 labeled (red) JXPs from treated group show the 
deviation from normal pattern. Note the disparity of two apposing JXP (B1), fusion of such 
JXPs along the nodal gap (B2) and emergence of extended JXP protruding towards the 
node. The white arrows indicate the position of node in between the two adjoining JXPs. 
(Scale bar 5µm). C. Intensity profiles have been shown in the bottom panel to highlight 
such digression. D. Representative frequency distribution showing the difference between 
both samples. There is an increase in inter-JXP length after CZ treatment, (n = 120, 109), 
□ untreated, ■ treated.    
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Figure   46: Differential expression intensities of Kv1.1 and 1.2 in the surviving JXPs 
exhibit discordant effect induced on these α-subunits by CZ. 
 
A. Intact JXPs of untreated control and treated ON axons exhibit differential intensity of 
Kv1.1 (green) and 1.2(red) labelling proximal to the node. Kv1.1 tends to spread out into 
the internode after CZ treatment relative to the control group.  Scale bar 5µm.  B. Both of 
these a-subunits represent decreased levels of mean intensity (arbitrary units) (MI)/µm2 on 
these types of JXPs.(p=0.02 for Kv1.1, p=0.07 for Kv1.2, n=99, 123) C. Representative 
scatter plot shows  the ascending intensity pattern of Kv1.1+ve JXP in control  relative to the 
treated  nerve (n=99, 123). D. Representative scatter plot showing the descending intensity 
pattern of Kv1.2+ve in JXPs of treated nerve (n=99, 123).  The block and empty squares on 
these plots represent treated and untreated JXPs. Dashed and solid lines represent the 
untreated and treated trend-lines, □ untreated, ■ treated. Scale bar5µm.     
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Figure   47: Co- localization efficiency of Kv1.1/1.2 is high in the intact JXPs. 
 
A. Z-stack representation of Kv1.1 and 1.2 co-labeled JXP of control and experimental 
group axons, showing intense labeling close to the nodal gap, but it extends into the 
internode to a greater extent indicating that these channels occupy larger area after CZ 
treatment. White arrows point towards the nodal end. Scale bar 2µm. B. Co-label intensity 
profiles of these axons show the higher levels of these channels proximal to the nodal gap 
in treated condition (black top panel). C. The bottom profile shows segregated levels of 
Kv1.1 (green) and 1.2 (red) which contribute to the overlapped signal intensity. Note the 
intensity is higher proximal to the node and is more extended in the treated group(right) 
relative to the controls (left)  D. Pearson’s co-relation co-efficient (Rr) of surviving JXPs 
represented as an average indicate an increase of signal in these surviving JXPs following 
CZ treatment (p>0.001, n=92, 96). E. Similarly there is an average increase in overlap co-
efficiency of Kv1.1/1.2 signals following CZ treatment (p>0.001, n=93, 115). F. Scatter 
plot of overlap co-efficiency indicate a higher co-relation in the treated samples. Dashed 
and solid lines represent the treated and untreated trend-lines, □ untreated, ■ treated.    
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Figure   48: Nav channels are dislocated from the node in treated group. 
 
A. pan Nav labeled nodes of the experimental group (bottom panel) show a deviation from 
the normal compact and intense labeling in untreated control (top panel) sample (scale bar 
2µm). B. Collectively, on the basis of morphology the nodes were grouped to represent 
three eminent patterns, smeared or oblong (B3), doublet (B3), and elongated (B4) in the 
treated group, whereas the untreated group has an intact delimited node (B1). C. These 
impaired nodes were accounted herein and it exhibits an increase in treated group of axons 
(n = 712, 635). D. Smearing is the most common effect and it is represented as a significant 
increase following CZ treatment, (p > 0.001, n = 712, 635), □ untreated, ■ treated.    
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Figure   49: Surviving JXPs show unique labelling of nodal Nav and Kv1.2. 
 
A. The intact JXPs from control group show uniform labeling of Kv1.2 (green) adjoining 
the nodes (pan-Nav, red) which are equidistantly placed. B. The non-affected axons show a 
similar pattern in the treated groups as well. C. The impaired axons exhibit an array of 
pattern (C1-C7).  They might appear heminodal (C1, C5), display disparate JXPs adjacent 
to the node (C3, C6), appear fragmented JXP (C4, C6) or be elongated (C7) following CZ 
treatment. D. Broad view of such untreated ON labeled with Nav/Kv1.2. E. Broad view of 
treated ON showing Nav/Kv1.2 labeling. F. Such intact JXP show a decrease in frequency 
of occurrence (p=0.02, n= 157, 102). G. Overall there is an increase in the peak intensity 
of Nav labeling in the axons of treated samples, (p>0.001, n=40, 46), □ untreated, ■ 
treated.    
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Figure   50: Ion channel expression in cells after CZ treatment. 
 
A. Broad view of Kv1.2 (green, A2) and Nav (red, A3) colabeled axons from untreated 
control. B.  Broad view of Kv1.2 (green, B2) and Nav (red, B3) colabeled axons from 
treated group. C. The treated group nerve cells expressing Kv1.2 also co-localize with 
Kv1.1 (white box) in addition to their usual JXP location (yellow arrow). F. The boxed cells 
in C have been expanded to show all these three cells which have co-localised Kv1.1 and 
1.2. White arrows point the junction of these cells, which are distinct from typical JXP of 
an axon, Scale bar10µm. 
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Figure   51: Kv1.4 is expressed in APC positive cells. 
 
A. Cell bodies enwrapping CNPase positive axons (green) express Kv1.4 (red) indicating 
glial origin of Kv1.4 channels in ON.  The white arrows point to the processes of these cell 
bodies which is CNPase positive. Panel on the right represents that the axon intercalating 
cells are APC positive oligodendrocyte. B. Merged image showing a APC positive cell 
(green) with prominent nuclear localisation (red) of propidium iodide (PI) and its 
processes in gray (bright field, BF). Black arrows point towards the processes of 
oligodendrocytes.  C. APC positive cell (white arrow points to the emerging process of this 
cell).  D.   Corresponding nuclei of those cells confirmed using nuclear PI stain. E. APC 
and PI stains overlap, this indicates the cellular origin of APC signals. Scale bar 5µm. 
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Figure 52: Demyelination lowers the excitability and disrupts conductive 
synchronicity of ON axons. 
A. Low magnification view of ON showing attached stimulation and recording electrodes. 
Inset illustrates the experimental set-up for CAPs recordings. Rec. - recording electrode; 
Suc. - suction pipette used for stimulation;  OX – optic chiasm. B. Typical CAPs evoked in 
control ON by paired-pulse stimulation (PPS) at varying inter-pulse intervals. Note the 
time dependent recovery of the second CAP from the refractory phase following the first 
CAP. C. Graded synchronous CAPs recorded from control animals (C1, left) contrasting 
with bi-component CAPs derived from experimental ON (C1, right) activated from higher 
stimulus threshold (1-4). (C2) Stimulus-response relation of CAPs in controls and 
experimental ON showing higher activation threshold and lower amplitude of evoked CAPs 
in demyelinated ON. Inset illustrates the differences in the stimulus threshold for eliciting 
CAPs: controls (white bar, n=6) and experimental (grey bar, n=5). D1.  Representative 
sub-maximal single pulse (in-boxed) induced CAP (top, 2) and CAP pre-conditioned by a 
stimulus (bottom, 1-2) from control and experimental ON; inter-pulse interval - 3 ms 
(above schematics illustrate stimulation paradigms). D2.  A summary plot of the relation of 
inter-stimulus interval with refractory phase (50% recovery); inset is a summary histogram 
of ½ of refractory time of sub-maximal CAPs (A2-A1). Note faster recovery of the second 
response from the refractory phase in controls than that in demyelinated axons (white bar 
vs. grey bar). (E1 and E2) Representative recordings of the effect of TEA and 4-AP on 
CAPs: control (left) and demyelinated (right) ON. Note the enhancement of the CAP 
amplitude in demyelinated ON caused by TEA and 4-AP that is also reflected in summary 
plots (F). NS – not significant, □ untreated, ■ treated.    
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Figure 53: Kv1.1 and 1.2 subunits exhibit differential role in K+ channels for 
regulating excitation and conduction in demyelinated ON. 
 
Representative CAP recordings (A, B upper) demonstrating the effects of DTXK and TsTX-
K in control (A) and demyelinated (B) ON: before (1) and 40 min after presentation of the 
toxins to the nerves. (A, B lower) Time course of the effects of DTXK and TsTX-K on evoked 
CAPs (sub-maximal) of control (white circles, n=5; n=6) and experimental (black circles, 
n=5; n=5) ON. Arrows point to the start of the application of toxins. Note a slight increase 
of the CAPs by these toxin blockers in controls (A, B lower, white circles) compared to 
much stronger enhancement of CAPs in demyelinated ON by TsTX-K (B) and especially 
DTXK (A). (C, D and E) Summary plots demonstrating the effects of DTXK and TsTX-K on 
the relation of the threshold stimulus and CAP amplitude (sub-maximal) (C and D, 
respectively) and 50% CAP recovery from refractory phase (E). Note the more potent 
effects of DTXK on CAP stimulus threshold, amplitude and recovery from refractory phase 
(E).  
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CHAPTER 6 
 
DISCUSSION AND FUTURE WORK 
 
Demyelination can be induced for several reasons, but studying MS-associated chronic 
CNS demeylination (Compston and Coles, 2002) has remained a major challenge for the 
development of therapeutics. Most of the basic information available in this field has 
entailed studies based on PNS nerve with acute demeylination (Brismar and Schwarz, 
1985), hypomyelination (Wang et al., 1995, Rasband et al., 1999b, Westenbroek et al., 
1992, Peretz et al., 2000) or transgenic animal models (Smart et al., 1998, Chiu et al., 1999, 
Ogawa et al., 2010). 4-AP, a broad-spectrum Kv channel blocker produces beneficial effects 
in MS, but with epileptogenic side-effects. Altered expression and of these channels in 
spinal cord axon injury (Nashmi and Fehlings, 2001), are less responsive to the benefits of 
this type of drug (Smith et al., 2000, Judge and Bever, 2006). Whereas ON, a CNS tissue of 
clinical interest remains susceptible to 4-AP benefits (Kocsis et al., 1986, Foster et al., 
1982). This indicates an apparent dissimilarity in axon Kv1 channels present in different 
types of systems. In vitro studies show that this kind of differential sensitivity to 
pharmacology could be rendered due to variation in α-subunit composition of tetrameric 
Kv1 channels in JXPs (Akhtar et al., 2002, Al-Sabi et al., 2011, Al-Sabi et al., 2010) . This 
thesis here presents data pertaining Kv1 associated features in CZ-induced sub-chronic 
demyelinating ON which provides a better insight into the structure and function of CNS 
axons.   
6.1. Development of animal model for studying MS like demyelination 
 
MS is a demyelinating disease which involves factors triggering cascade of events. This 
results in engagement of the immune system, acute injury of axons and glia, recovery of 
function and structural repair, post-inflammatory gliosis, and neuro-degeneration. The 
sequential involvement of these processes underlies the clinical course characterized by 
episodes with recovery, persistent deficits, and secondary progression. It is almost 
impossible to replicate such diversified complicating disease features in an animal model 
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(Hartmut and Kurschus, 2006, Schmandt et al., 2006, Ransohoff, 2012). Herein use of 8 
week CZ- induced demyelination model, which can be considered as a time point at the 
confluence of acute (Crawford et al., 2009, Kipp et al., 2009) and chronic demyelination 
(Ludwin, 1980, Matsushima and Morell, 2001, Hoffmann et al., 2008) has provided us with 
a preliminary view of several phenomenon of neurotherapeutic relevance involving axon 
and glia. The observations presented here may not be a direct co-relate for RRPMS (a 
clinical complicating factor), even though elements for remyelination cannot be ruled out 
for the said time point in this study. An inclusion of extended and detailed time course 
would further elaborate these facts and establish the importance. Specific seizure induction 
upon anesthetization was indicative of features associated to demyelination, which was of 
extraneous interest here. Investigation of this response in view of changes induced in 
hippocampus might prove advantageous. Even though it is widely accepted that MS is a 
complex neurodegenerative disease and thought to arise through autoimmunity against 
antigens of the CNS. Interestingly, this hypothesis fails to explain why genetic and 
environmental risk factors linked to the disease in one population tend to be unimportant in 
others. Several such pertinent questions are indicative of the fact that despite great advances 
in documenting the cellular and molecular mechanisms underlying MS pathophysiology, 
the autoimmunity framework has been unable to develop a comprehensive explanation of 
the etiology of the disease. Last decade has witnessed several new frameworks for 
understanding MS (Fischer et al., 2013, Lassmann et al., 2007, Nair et al., 2008, Trapp and 
Stys, 2009, Corthals, 2011) as a dysfunction of the homeostasis of lipids which collapses 
during acute-phase inflammatory response and triggers, trauma, or stress, starting a 
feedback loop of increased oxidative stress (Dutta et al., 2006, Waxman, 2006, Mahad et 
al., 2008). Inflammatory response, and proliferation of cyto-toxic cells that cross the blood 
brain barrier and both catabolize myelin and prevent remyelination (Huterer et al., 1995, 
Corthals, 2011) are parts of the entire process. So, unlike other popular immune models for 
studying MS CZ-induced demyelination used herein allowed a better understanding of this 
disease as a chronic metabolic disorder (Ransohoff, 2012), with several neurotherapeutic 
implications. This will further permit exploration of axon associated changes in view of, 
astrocytosis (Groebe et al., 2009, Norkute et al., 2009, Pott et al., 2009), activation of 
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microglia (Pott et al., 2009, Groebe et al., 2009, Howell et al., 2010), oxidative stress, axon-
oligodendrocyte association (Fischer et al., 2013), and seizure (Hoffmann et al., 2008).   
6.2. Peripheral vs. Central nerve, relevance to MS like demyelination 
 
Even though a lot is known about demyelination from studies involving peripheral nerves 
(Brismar and Schwarz, 1985, Zhou et al., 1998, Shields et al., 2000), an extrapolation from 
PNS to CNS cannot be made (Chomiak and Hu, 2009, Waxman, 2005) hence, these are of 
lesser relevance to MS due to the CNS nature of this disease (Compston and Coles, 2002). 
There could be various reasons for it (Susuki and Rasband, 2008). For instance, response to 
energy deficiency (hypoxia) has differential effect on these two systems, a) PNS can remain 
unaffected till 30 min of hypoxia exposure, CNS cannot, b) PNS recovers after 
reoxygenation, but CNS fails due to continued increase in Ca2+ load. c) CNS axons like ON 
are devoid of synaptic machinery, hence the interpretation is easier, d) CNS is critically 
dependent on energy supply, and oxidative metabolism for  maintenance of excitability 
(Stys, 1998). These might render profound symptomatic effect, because partially 
demyelinated axons conduct impulses at reduced velocity—explaining the characteristic 
delays in conduction of evoked potentials. Demyelinated axons can discharge 
spontaneously and show increased mechanical sensitivity—accounting for the flashes of 
light on eye movement (phosphenes) and electrical sensation running down the spine or 
limbs on neck flexion (Lhermitte’s symptom and sign) (Compston and Coles, 2002). Thus, 
the use of ON here brings forth a better picture of the happenings in CNS axon which is of 
an impinging concurrence to MS associated features.  
6.3. Nature of myelin loss from WM tracts of CNS due to CZ-treatment implications 
for MS axonopathy  
The exact nature of demyelination in MS is complex and heterogeneous in nature (Gilmore 
et al., 2009, Lassmann et al., 2001, Lucchinetti et al., 2000). Even though no animal model 
can ever produce all the characteristics, herein use of a moderate dose of CZ to induce 
demyelination (Hiremath et al., 1998, Matsushima and Morell, 2001) has prompted 
multiple features similar to MS, but with a lower immune-response (Matsushima and 
Morell, 2001) and associated implications. Based on the increased body wt. variation 
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induced it was assumed that if severe systemic effects were present, it would be mild here. 
This was evident due to continued weight gain in both groups denoted absence of any 
prominent adverse effect (Franco-Pons et al., 2007). Even though 5-6 weeks CZ-treatment 
induces demeylination (Matsushima and Morell, 2001), and continued feeding for 12 week 
(Hoffmann et al., 2008, Sun et al., 2006), is sufficient to advance it to a chronic level, 
present protocol was expected to yield an intermediate effect between the two phases. 
Possible, mild seizure was indicative of such events (Hoffmann et al., 2008). Early 
therapeutic intervention (Jagust, 2013) i.e., before the onset of chronic phase is anticipated 
to be of great significance in MS. Hence, the observations, pertaining  to myelin disruption, 
changes in surrounding glial cells, neurofilament, JXP Kv1 and nodal Nav channels in ON 
are of special interest as it represents a phase of demyelination, which emphasizes the 
interdependence of all these facets. Even though these aspects have been studied in 
different systems earlier, this study has provided a global approach to MS axonopathy. 
Higher susceptibility of WM rich forebrain tracts like CC, and CM are indicative of 
repugnant effect on axons. Thus CZ-induced demyelination was considered suitable to 
analyze axon features in view of preferential and robust CNS demyelination and 
distinguished WM pattern similar to Type III lesions (Kipp et al., 2009).  
6.4. Featured changes induced were disruption of myelin periodicity and increase in 
dp-NF  
CNS demyelination of ON herein was characterized by the demonstration of reduction in 
myelin sheaths, its compactness and periodicity.  For the first time, this type of pattern has 
been described for ON which establishes an early diagnostic clinical relevance employing 
non-invasive methods (Sun et al., 2006) for this model. Electron microscopic analysis 
highlighted a reduction in the myelin thickness and a corresponding increase in “g” ratio 
(Chomiak and Hu, 2009) indicating radial loss of myelin and possible paranodal 
demyelination. Even though no pronounced phenotypic effect was observed in this nerve, 
ultrastructural analysis revealed several changes in axo-myelin structure and surrounding 
cells. Collapse of IPL and subsequent localized aggregation of MDL was evident, which 
was suggestive of interrupted radial insulation of the nerve. Does this relate to an 
experimental evidence for potassium-accumulation and a subsequent decrease in myelin 
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resistance that might lead to functional excitation block with varying patterns of altered 
spike trains (Brazhe et al., 2011) would be of great clinical relevance for ON. Proteomic 
ally myelin proteins like CNPase, MBP also exhibited disruption. Relative levels of 
lipophilins like PLP and DM20 (Griffiths et al., 1998) are one of the complicating factors 
involved in maintenance of myelin periodicity and surprisingly this was found to be altered 
due to an increase in DM20 level in their total pool. Why is it so, remains to be deciphered? 
All these support the observed axial loss of myelin following CZ feeding. So, it is 
understood that there is no or very less amount of denuded axons. This type of myelin 
thinning is anticipated to result in decreased insulation and, thus, interrupt the propagation 
of action potentials.  
 
Neurofilament has been variously implicated in MS associated demyelination (Salzer et al., 
2010, Lunn et al., 2002, Schirmer et al., 2011). Herein NF cytoskeleton was found to be 
disorganized, which corresponded to its reduced phosphorylation. This imparted an induced 
change in the proportions of the two forms (p-NF and dp-NF) in axons, with larger 
diameter axons accumulating more dp-NF. Thus, an imbalance could be noted within the 
pool of axons in ON. The small diameter axons exhibit resilience to such changes. This is 
possibly due to the excessive energy demand levied on thick axons relative to the thinner 
one (Perge et al., 2009) hence rendered more susceptible. A lower impact on small diameter 
axon highlights their importance in reducing the capacitative load, and favoring more 
effective propagation of action potentials in demyelination (Smith and McDonald, 1999, 
Shrager, 1993). The fore mentioned changes in axons can be attributed to metabolic 
challenge induced in oligodendrocytes due to CZ-treatment resulting in the loss of myelin 
integrity and glial trophic support. Thus, it differs from immune models where 
demyelination is due to T cell attack on myelin specific proteins (Schmandt et al., 2006).  
 
Additionally, mitochondrial injury also a recognized major effector mechanism for 
demyelination (Khan et al., 2010, Dutta et al., 2006, Mahad et al., 2009, Mahad et al., 2008, 
Stys, 2004, Trapp and Nave, 2008), was noticed in this study. Interestingly, none of the 
animal models employed has ever been reported to have such induced changes. Even 
though this was not the main focus of this study, it further strengthens the relevance with 
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MS related mechanisms which are of great scientific interest. Changes in nuclear 
morphology might also be of alternative significance associated with impaired 
mitochondrial transport in damaged axons  (Kim et al., 2010). 
6.5. Ectopic axonal Kv1 channels and over expression of Kv1.1 is accompanied with 
loss  functional units of JXP (Kv-Na-Kv)  
 
Myelin integrity appears to be mandatory for targeting K+ channels to JXPs (Rasband and 
Shrager, 2000, Rasband et al., 1999a). On the other hand, nodal clustering of Na+ channels 
does not require myelination but their more widespread appearance along the axon during 
demyelination suggests a stabilizing influence of axo-glial signaling on nodal Na+ channel 
clusters (Coman et al., 2006, Poliak et al., 2001). Unlike Na+ channel aggregation, the 
formation of compact myelin is required for initiation and maintenance of K+ channel 
clusters in ON irrespective of oligodendrocyte presence (Baba et al., 1999). Here, 
microscopic examination of JXPs displayed varied distribution patterns of Kv1 channels. 
Most of them exhibited elongation with the expression of ectopic K+ channels in the nodal 
and inter-nodal segments.  Notably, the treated group showed proteomic increase of Kv1.1 
and 1.4 but reduced Kv1.2. Kv1.1 and 1.2 were the major JXP channels, whereas Kv1.4 was 
mostly of glial origin, which localized with some Kv1.2+ve JXPs. Kv1.4 was not considered 
for functional analysis, even though its elevated levels reaffirmed a feature similar to 
chronic spinal cord injury (Edwards et al., 2002). Elongated internodal expression of Kv1.1 
was noted, in PLA and IHC signals.  Normally Kv1.1 in higher quantities in the 
residual/spared JXP decreased relative to controls, which was at par in both groups. The 
number of Kv1.1+ve JXPs exhibited an increasing trend, whereas Kv1.2+ve JXPs showed a 
decrease in treated nerve. These spared JXPs exhibited higher co-efficiency of Kv1.1/1.2. 
Thus, indicating an unexpected pliancy of Kv1.1 in maintenance of a normal JXP feature. 
The unaffected axons were confirmed on the basis of a defined functional unit for action 
potential propagation, which was marked by the presence of two intact JXPs flanking a 
node. Such functional units were found to be decreased in the treated group. What leads to 
such a change remains unknown here, even though several in vitro studies have attributed 
varying causes (Connors et al., 2008, Allen et al., 1998). The basis for such a preferential 
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increase of localized Kv1.1 expression in CZ-treated axon remains to be deciphered, but 
this observation is suggestive of some deviant mechanism triggered by demyelination.  
6.6. Augmented K+ conductance susceptible to Kv1.1 selective DTXk warrants a more  
in-depth study  
 
Altered Kv1 expression accords with the physiological data highlighting an augmented K+ 
conductance susceptible to DTXK (Kv1.1-selective) that proved more effective in restoring 
CAPs in demyelinated ON than TsTX-K (Kv1.2-selective). The electrophysiological data 
demonstrated that Kv1 channel blockers partially restored the CAPs and shortened the 
refractive phase in demyelinated ON. Unlike control which were responsive to 4-AP only 
CZ-treated axons were pliable to the effects of both TEA and 4-AP.  Interestingly, this is in 
contrast to sciatic nerve where CAPs are insensitive to these blockers prior to and after their 
demyelination (Bostock et al., 1981). While improved conductivity of ON by 4-AP accords 
with its beneficial effects in MS clinical trials (Judge and Bever, 2006, Stefoski et al., 
1987), the broad spectrum action with pro-convulsive effects hinder its widespread use for 
MS therapy. Similar electrophysiological experiments with DTXK as a Kv1 channel blocker 
in demyelinated nerves proved it more effective in restoring CAPs than TsTX-K. Because 
the relative strengths of K+ and Na+ currents in axons is a primary determinant of successful 
propagation of action potentials (Bostock et al., 1981), the enhanced impact of DTXK-
sensitive K+ currents on CAPs and enrichment of demyelinated axons with Kv1.1 suggests 
appearance of channels containing heteromers or homo-tetrameric Kv1.1 channels.  Unlike 
other studies (Allen et al., 2006, Velumian et al., 2010, Devaux et al., 2002, Alberts et al., 
2002) where the whole nerve CAP has three peaks, here, in this study single peak was 
obtained. This is possible because of the insertion of sharp recording electrode very close to 
the stimulating electrode. Such a method is expected to lead to variation owing to the depth 
of electrode insertion. Herein the electrode was allowed to penetrate till 1/3rd deep into the 
nerve, so that a comparable account has been achieved from both groups. A detailed 
account on the basis of ultrastructural analysis and whole nerve recording is warranted for 
revealing the consolidated effect.   
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Further on, electrophysiological assessment of a suspected role of Kv1.1 α-subunit in Kv1 
channels, appearing on the axolemma of JXPs following demeylination, using recombinant 
expression of Kv(1.1)4 channels reveals a lower activation threshold and faster kinetics than 
Kv(1.2)4 or Kv1.1/1.2-containing hetero-tetramers (unpublished lab observation). Even 
though there has been a study which explains the emergence of Kv1 channels on membrane 
surface (Zhu et al., 2007). What leads to such change during disease progression remains 
unknown. The noted presence of Kv1.1 homomer in both experiment and control ON here, 
directs to the question that do these isoforms alter their micro domains (O'Connell and 
Tamkun, 2005) during demyelination, so that a functional effect can be noted. If yes, what 
kicks in this change?  Kv1.1 otherwise has a strong ER retention sequence (Zhu et al., 
2003), due to which it is not easily expressed as a homomeric surface protein. Is there any 
chaperone like protein (Schulte et al., 2006) which plays a vital role in their ectopic 
presence? These collectively provide an additional and important insight into 
demyelination-associated changes in the locations and subunit compositions of Kv1 
channels of ON.   
6.7. Expression of ion-channel proteins on cells of unknown identity  
 
Axon injury and subsequent dysfunction is an integral component of MS associated 
neurological disability (Schirmer et al., 2011, Howell et al., 2010, Trapp et al., 1998) . 
Interestingly, this is an induced effect and various types of cells can be involved with 
mechanisms for demyelination. Herein observed emergence of Kv1 and Nav channels in 
some cell of unestablished identity remained an intriguing feature. Possible identity as an 
oligodendrocyte, astrocyte or microglia (Butt et al., 2004) will be indicative of features 
relevant to the stage of disease progression (Nair et al., 2008). Little is known on these lines 
and whether these can be of any therapeutic relevance are questions of interest which 
remains to be exploited for regenerative stem cell therapy (Franklin and Ffrench-Constant, 
2008). Very few studies (Jukkola et al., 2012, Edwards et al., 2002), have explored these 
options. Even though the present study establishes ameliorative effect of Kv1.1 on axon 
conduction, their presence on other type of cells might have an important bearing of disease 
progression or regeneration.  This study shows the presence of Kv1.4 on oligodendroglia 
cells here. Previous studies have noted their up regulation in astrocytes (Jukkola et al., 
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2012), or both astrocyte and oligodendrocyte (Edwards et al., 2002) suggesting possible 
neuroprotective role of these cells. Glial cells express all transcripts of the six Kv1 genes 
(Kv1.1-1.6), but do not express all proteins (Schmidt et al., 1999). So what leads to the 
emergence of such proteins in the cells in a disease state? Are these cells proliferative in 
nature (Chittajallu et al., 2002)? What is the origin of these cells? Do they signify 
neurodengeneration (Koeberle et al., 2010) or neuroprotection (Jukkola et al., 2012)? 
Astrocytes are the major intercalating cells found in ON (Perge et al., 2009). Such 
questions are very pertinent and even though not covered under this study an answer to 
them in view of the existing Kv channel blocking therapy would prove to be a step ahead in 
the direction of holistic approach towards the development of MS therapeutics. 
 
Their role in regulation of de- and remyelination in MS have been suggested and this 
proposition has entailed several roles contemplating to be either beneficial or detrimental 
for disease progression. A recent study (Skripuletz et al., 2013) on this model showed that 
their ablation was associated with failure of damaged myelin removal and a consecutive 
delay in remyelination. It is important to note that similar to Skripultz et al an 
ultrastructural change in myelin structure has been noted in the present study. The noted 
changes in the morphology of astrocyte in this study is supportive of the fact that these cells 
have an important role in the surrounding environment of the axons, which is of great 
importance to understanding regenerative processes in MS (Skripuletz et al., 2013). So, 
employing this model with the said effect would prove beneficial in further strengthening 
the role of axonal Kv1 channels in view of de- and re-myelination both. 
 
6.8. Present scenario for treatment of MS and issues 
 
Clinicians treating MS aim to reduce the frequency of demyelinating attacks, and limit the 
lasting effects, of relapses, relieve symptoms, prevent disability arising from disease 
progression, and promote tissue repair (Compston and Coles, 2002, Trapp and Nave, 2008). 
The present course of treatment for patients include strategies like,  
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a) Interferons for reduction of relapse rates:  Since permanent disability can be caused 
by incomplete recovery from episodes, relapse frequency is bound to correlate with 
accumulation of disability during the RRPMS. Successful use of the beta interferons: beta-
1a (Avonex, Biogen, and Rebif, Ares-Serono), and beta-1b (Betaferon and Betaseron, 
Schering) reduce such relapses and accumulation of disability. But such reductions fail to 
have any impact on continuing secondary progression.  
b) Corticosteroids for prevention of disability attributable to relapse: Corticosteroids, 
is used to inhibit transcription of proinflammatory cytokines, such as interleukin-1, 
interleukin-2, tumour necrosis factor-α and proinflammatory enzymes, including 
collagenase, elastase, and plasminogen activator. These anti-inflammatory effects have long 
been used for acute treatment of MS. All trials to date have indicated reduction of relapses 
and hence short-term morbidity, but not the ensuing permanent deficits. 
c) Symptomatic management of fixed neurological deficits:  
 The spasticity and sphincter dysfunction is treated by baclofen, which acts on spinal 
cord GABA-B receptors to suppress reflex arcs released from higher inhibitory 
control; or tizanidine, which acts through spinal cord α2 receptors to modulate 
presynaptic release of excitatory amino acids.  
 Bladder symptoms are most easily inhibited by anti-cholinergics.  
 Paroxysmal attacks respond well to membrane-stabilizing drugs—typically 
carbamazepine. None of the pharmacological treatment show beneficial effect on 
the tremor of MS.  
 Fatigue cannot be satisfactorily treated (Compston and Coles, 2002).  
Two non-specific potassium K+ channel blocking drugs, 4-aminopyridine (4-AP) and 3,4-
diaminopyridine (3,4-DAP), have been tested as a symptomatic treatment in patients with 
MS based on the clinical rationale that neurologic function could be improved by 
overcoming conduction block in demyelinated axons present in MS lesions. Although 4-
AP, in particular, produces clear neurologic benefits in some. Dalfampridine/fampridine (4-
AP) is in phase II and III placebo- controlled clinical trials. These trials, with extended-
release dalfampridine show an average 25% increase in the walking speed in more than 
one-third of the patients who received the drug and met the prescribed criteria for consistent 
responders. The safety profile of dalfampridine is also being reviewed, with a focus on the 
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risk for epileptic seizures as an adverse effect (Goodman and Hyland, 2010, Judge and 
Bever, 2006).  
d) Immunotherapeutic strategies for improved treatment of disease activity:  
Two approaches are adopted to reduce the activation and proliferation of auto reactive T 
cells. One is to suppress immune activity non-specifically and has acceptable safety 
profiles. Past attempts (with cyclophosphamide, cyclosporin, lymphoid irradiation, 
cladribine) have shown evidence for efficacy but with major side-effects; examples of this 
legacy are paclitaxel, teriflunomide, and autologous bone marrow transplantation. The 
second strategy is to assume that the specific interaction between MBP, T cells, and antigen 
presenting cells is the pivotal event driving MS. Several drugs have been designed to 
manipulate this interaction (Compston and Coles, 2002).  
6.9. Indicated axonopathy and prevention of disability acquired through progression 
 
The relationship between progression and relapse has been emphasized by a small, 
uncontrolled study of patients with secondary progressive MS. They were treated with a 
short pulse of Campath-1H (a monoclonal antibody that depletes T cells and modulates 
their activity). Half of the patients continued to have progression of disability; displayed 
continued cerebral atrophy, and loss of spectroscopic markers of axons, despite the absence 
of cerebral inflammatory activity. A similar dissociation between effective suppression of 
new lesions and continued cerebral atrophy in progressive patients was seen in a trial of the 
lympho cytotoxic drug cladribine, a purine nucleoside analogue resistant to the action of 
adenosine deaminase (Coles et al., 1999).  
 
Thus, there are a lot of compelling evidences which has led to the conclusion that 
immunomodulatory drugs are of little use once axonal degeneration has reached a critical 
threshold and clinical progression is established. It follows that there might be an 
opportunity, early in the disease course; to suppress those components of the inflammatory 
processes that initiate the cascade leading to delayed progression. The immunotherapies 
prove inadequate in reducing relapse frequency, and also to prevent transition to the 
secondary progressive phase of the illness. Thus, the essential question involving current 
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immunotherapies therapies for MS is —whether an early anti-inflammatory therapy reduce 
the proportion of patients who ever enter the secondary progressive phase, or usefully affect 
the slope of that progression? These are being addressed in trial designs. However, time 
seems to have been lost, and possibly several years will pass before an answer is available. 
But, since the result cannot be prejudged, parallel strategies for limiting the effect of 
progression are needed. All these indicate our limited understanding of the pathogenesis of 
MS and the usefulness of existing therapies (Compston and Coles, 2002) 
 
This thesis in view of the given therapeutic approach (es) for MS has sought out to explore 
the option of employing Kv1 blocking strategy for amelioration of disability. Even though it 
is considered for symptomatic treatment, with the provided background of how the diseases 
progresses and axon-glia and all accompanying features gradually get affected advancing 
towards the later phase and neurological disability acquires prominence. It is imperative 
that containing neurological disability should be the prime approach, but in lack of the 
appropriate intervention, it is worthwhile to establish specific blocking of Kv1 channels and 
get rid of the epileptogenic effect, which arises due to the presently available blcokers. 
Even though it would be premature to judge whether the strategy is right or wrong, 
development of blockers for Kv1.1 homomer will prove fruitful in providing relief to the 
patients with minimal side effects, specifically when the most used immunotherapeutic 
results are disappointing.  Further continuation on the directions obtained in this pilot study 
would be rewarding. 
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